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Microcirculation is the part of the circulation where nutrients, water, gases (such as oxygen), 
hormones, and waste products are exchanged between the blood and cells.(1) The microcircu-
lation consists of a network of blood vessels less than 100 µm in diameter (arterioles, capillaries 
and venules, respectively). An adequate blood flow within these microvessels is a prerequisite 
for normal organ perfusion. The microcirculation also functions as a volume reservoir for blood, 
so that the microcirculation plays an important role in regulating preload and thus cardiac 
output.(2) Another major function of the microcirculation is to regulate vascular resistance to 
maintain adequate mean arterial pressure. Regulation of vascular resistance to preserve arterial 
pressure (by constriction of the resistance vessels) and allowing each tissue to receive sufficient 
blood flow to sustain metabolism may be in conflict. Often the temporary compromise is to 
preserve the mean arterial pressure by increasing arterial resistance at the expense of reduced 
blood flow to most organs; ultimately, however, the tissue exchange function must be restored.
In patients with circulatory failure, including cardiogenic shock, blood flow is diverted from 
less important tissues (skin, subcutaneous, muscle, gastrointestinal tract) to vital organs (heart, 
brain, kidneys). Multiple organ failure is common in these patients, often despite correction of 
heart rate, mean arterial pressure and cardiac output. It has been reported that redistribution of 
blood flow away from the splanchnic area may result in translocation of microorganisms from 
the gut into the blood and that may be one of the factors contributing to the development of 
multiple organ failure.(3, 4) Microcirculatory blood flow alterations may play an important role 
in this process. Hypoperfusion of microcirculation may be an etiologic factor in the pathogen-
esis of multiple organ failure and may contribute to mortality in a considerable proportion of 
patients with circulatory shock.(5, 6)
In patients admitted to an intensive care unit, assessment of sublingual microcirculation is the 
easiest way to study the microcirculation. However, it was largely unknown whether micro-
circulatory changes in the sublingual area are representative of hypoperfusion elsewhere, 
most importantly in the splanchnic region. Several arguments suggest that this is indeed the 
case. First, the tongue shares a common embryogenic origin with the gut.(7) Second, indirect 
evidence comes from studies of sublingual tonometry which demonstrated a good correla-
tion between PCO2 measurements obtained in the sublingual region and in the stomach.
(8, 9) Finally, De Backer et al. demonstrated in a small study that the proportion of perfused 
sublingual capillaries correlated with survival.(6)
The aim of this thesis was to investigate whether sublingual microcirculation, measured with 
Sidestream Dark Field imaging and regarded as a surrogate marker for splanchnic perfu-
sion, is a determinant of organ failure and outcome in patients with cardiogenic shock. We 
hypothesized that impaired sublingual perfusion correlated to organ failure and short-term 
mortality and that this parameter could be improved using pharmacological (i.e., vasodilators 
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or inotropic agents) or mechanical therapy (i.e., intra-aortic balloon pump counterpulsation 
or more sophisticated devices that produce flow on their own). The results from these pioneer 
studies are described in this thesis.
Part A presents two review articles, which comprehensively highlight the importance of the 
microcirculation in critical diseases. In Part B, we present the results of circulatory support by 
intra-aortic balloon pump counterpulsation and percutaneous left ventricular assist devices on 
short- and long-term prognosis of patients with acute cardiac diseases. In Part C, we describe the 
microcirculation in pathological conditions, during cardiopulmonary bypass and in cardiogenic 
shock, and we propose to focus on tissue perfusion in the management of cardiogenic shock. 
Part D reports a series of observational studies, which present the effects of pharmacologic and 
mechanical interventions on sublingual microcirculation. In Part E, we summarize the main 
findings and reflect on these from a broader perspective and we tentatively give directions for 
future research.
Aim of the thesis 15
rEfErENCES
 1. Bohlen HG. The microcirculation and the lymphatic system. In: Rhoades RA, Tanner GA, eds. Medical 
Phsyiology. Boston (Mass): Little, Brown and Company; 1995.
 2. Peters J, Mack GW, Lister G. The importance of the peripheral circulation in critical illnesses. Intensive 
Care Med 2001; 27(9): 1146-1158.
 3. Fiddian-Green RG. Associations between intramucosal acidosis in the gut and organ failure. Crit Care 
Med 1993; 21(2 Suppl):S103-107.
 4. Baue AE. The role of the gut in the development of multiple organ dysfunction in cardiothoracic 
patients. Ann Thorac Surg 1993; 55(4): 822-829.
 5. Lim N, Dubois MJ, De Backer D, Vincent JL. Do all nonsurvivors of cardiogenic shock die with a low 
cardiac index? Chest 2003; 124(5): 1885-1891.
 6. De Backer D, Creteur J, Dubois MJ, Sakr Y, Vincent JL. Microvascular alterations in patients with acute 
severe heart failure and cardiogenic shock. Am Heart J 2004; 147(1): 91-99.
 7. Chierego M, Verdant C, De Backer D. Microcirculatory alterations in critically ill patients. Minerva 
Anestesiol 2006; 72: 119-205.
 8. Creteur J, De Backer D, Sakr Y, Koch M, Vincent JL. Sublingual capnometry tracks microcirculatory 
changes in septic patients. Intensive Care Med 2006; 32(4): 516-523.
 9. Marik PE. Sublingual capnography: a clinical validation study. Chest 2001; 120(3): 923-927.

Chapter 2
The microcirculation in health 
and critical disease
Corstiaan A. den Uil, Eva Klijn, Wim K. Lagrand, J. Jasper Brugts, 
Can Ince, Peter E. Spronk, Maarten L. Simoons
Progress in Cardiovascular Diseases 2008; 51(2):161-70
Ch
ap
te
r 2
18
ABSTrACT
The microcirculation is a complex system, which regulates the balance between oxygen demand 
and supply of parenchymal cells. In addition, the peripheral microcirculation has an important 
role in regulating the hemodynamics of the human body, because it warrants arterial blood 
pressure as well as venous return to the heart. Novel techniques have made it possible that the 
microcirculation can be observed directly at the bedside in patients. Currently, research using 
these new techniques is focusing at the central role of the microcirculation in critical diseases. 
Experimental studies have demonstrated differences in microvascular alterations between 
models of septic and hypovolemic shock. In human studies, the microcirculation has most 
extensively been investigated in septic syndromes and has revealed highly heterogeneous 
alterations with clear evidence of arteriolar-venular shunting. Until now, the microcirculation 
in acute heart failure syndromes such as cardiogenic shock has scarcely been investigated. 
This review concerns the physiologic properties of the microcirculation as well as its role in 
pathophysiologic states such as sepsis, hypovolemic shock, and acute heart failure.
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iNTrODUCTiON
The microcirculation is that part of the circulation where oxygen, nutrients, hormones, and 
waste products are exchanged between circulating blood and parenchymal cells.(1) The micro-
circulation consists of a network of blood vessels less than 100 µm in diameter. According to 
anatomical features and the direction of the blood flow, these microvessels are subdivided into 
arterioles, capillaries, and venules. Adequate blood flow in capillaries is a prerequisite for nor-
mal organ perfusion and function. In critically ill patients, capillary blood flow in tissues may be 
impaired. In this article, we systematically review morphology and physiologic function of the 
microcirculation in tissues outside the heart, such as the splanchnic region, skin, muscles and 
the sublingual area, because these microcirculatory beds have been studied most extensively. 
We also comprehensively discuss the current literature on the role of the microcirculation in the 
pathogenesis of critical illnesses.
NOrMAL fUNCTiON Of ThE MiCrOCirCULATiON
Capillaries consist of a single layer of epithelium and a basement membrane. The main function 
of capillaries is to allow exchange of molecules between blood and tissues. Capillary blood flow 
(a product of driving pressure, arteriolar tone, and hemorheology) and capillary patency are 
the main determinants of capillary perfusion.(2) Blood flow in one single capillary is not a good 
indicator of oxygen delivery to the tissue under evaluation due to the temporal and spatial 
heterogeneity of capillary blood flow.(3, 4) Capillary patency is reflected by functional capillary 
density (FCD), defined as the number of functional capillaries in a given area where functional 
is defined as capillaries filled with flowing red blood cells. Because oxygen has to diffuse from 
capillaries to tissue cells, every organ has a rich abundance of microvessels.(5) Density and 
anatomy of this local microvasculature depend on the metabolic requirement of each specific 
tissue. Although oxygen transport from the blood in the capillaries to the tissue cells is the key 
function of the microcirculation, the arteriolar and venular parts of the microcirculation have 
important functions in maintaining adequate tissue perfusion and hemodynamics. Arterioles 
are tiny branches of arteries that lead to capillaries and form the major resistive component 
of the microcirculation. The walls of arterioles are surrounded by circular smooth muscle cells, 
which are under the control of the sympathetic nervous system. Vascular endothelial cells can 
respond to alterations in local shear stress and give local stimulatory signals to arterioles via 
cell-to-cell communication.(6, 7) These central and local control mechanisms regulate constric-
tion and dilatation of the arterioles depending on the metabolic requirements of the tissue 
cells. Under abnormal conditions, such as shock or heart failure, the balance between vascular 
resistance to preserve arterial pressure (by constriction of the resistance vessels) and peripheral 
tissue flow may be lost, causing insufficient blood flow to sustain metabolism in specific organs. 
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For instance, the temporary compromise as a response to a sudden decline in blood pressure 
(eg, in shock states) is an increase in arterial resistance, which can result in a reduced blood 
flow to the less vital organs such as the skin and the splanchnic system. The venular part of the 
microcirculation serves as a large low-pressure reservoir through which blood is returned to the 
heart. It may contain as much as 75% of total blood volume.(8) Active and passive changes of 
venous vascular tone alter the quantity of venous blood, which thereby change cardiac preload 
and cardiac output and guarantee maintenance of the circulating blood pool.(9)
In addition, intravascular content is important for local regulation of microvascular blood 
flow. There is increasing evidence that red blood cells (RBCs) not only carry oxygen to the tis-
sues, but are also able to locally sense and regulate oxygen delivery in the microcirculation.
(10) RBCs, when exposed to hypoxia, can release nitric oxide (NO) and adenosine triphosphate 
(ATP), which are potent vasodilators, thus improving oxygen delivery.(11-14)
METhODS TO ASSESS MiCrOvASCULAr BLOOD fLOW
Gastric tonometry has been introduced as a technique to assess splanchnic perfusion.(15) Using 
a special gastric tonometry catheter, CO2 tension (pCO2) can be measured in the stomach, ileum 
and sigmoid lumen. The pCO2 values can be used to estimate, for example, the pH of the gastric 
mucosa (pHi) or can be related to the value of the arterial pCO2 (by calculating the so-called 
pCO2 gap).(16) Despite substantial initial enthusiasm, this technique has never been widely 
implemented due to technical problems and difficulties in demonstrating the use of gastric 
tonometry-derived variables as therapeutic guides.(17) Recently, it became also possible to 
monitor tissue pCO2 in other sites. Sublingual capnometry is a promising noninvasive example, 
although the value of this new technique in critically ill patients still has to be determined.
Intravital microscopy (IVM) is considered the gold standard for in vivo investigation of the 
microcirculation and has been widely used in animal studies to examine the microcirculation 
in situ. This technique can be used for investigation of thin tissues that allow transillumination, 
whereas fluorescent dyes have to be used to allow epiillumination of thicker organ surfaces. 
Unfortunately, the use of dyes in humans is hindered by safety concerns and IVM studies in 
humans have therefore been limited to observation of nail fold capillaries that can be observed 
without using dyes.(18) However, one can question the clinical significance of the nail fold 
microcirculation due to its high sensitivity to external temperature, which hinders reproduc-
ibility of measurements. The large size of an IVM microscope is also a reason why this technique 
is not extensively used in clinical research and practice.
The recently developed laser-Doppler flowmetry is a technique that is based on frequency 
shifts in laser light by moving erythrocytes. The technique measures red cell flux in small-volume 
samples (0.5 mm3) of organ surfaces, thus providing averages of velocities in all microvessels in 
the tissue volume that is under investigation. However, this feature of laser-Doppler flowmetry 
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is also an important limitation of the technique because averaged numbers for microvascular 
blood flow do not provide information about heterogeneity of blood flow, which actually 
is a major characteristic of the microcirculation. Modifications of this methodology, called 
laser-Doppler perfusion imaging and laser-speckle imaging, allow construction of real-time 
2-dimensional perfusion maps of a larger area. Hence it has become possible to perform 
successive measurements in exactly the same area of interest. These techniques, however, are 
still limited by the fact that individual blood vessels cannot be visualized. Moreover, the laser-
Doppler-derived signal is expressed in arbitrary units (flux or perfusion units), which implies 
that results can only be reported in percentage of change rather than in absolute terms.
Near-infrared spectroscopy (NIRS) is a technique that can be used to noninvasively moni-
tor regional and microcirculatory oxygenation at the bedside. In short, this technique uses 
near-infrared light that can easily penetrate biological tissues. Hemoglobin has a well-defined 
absorption spectrum that is influenced by O2-binding. It is the analysis of the attenuation 
spectra of such pigments (spectroscopy) that is used to monitor tissue oxygenation (StO2) in 
vivo. The technique has been validated and has been applied extensively to evaluate cerebral 
perfusion and to perform peripheral ischemia/reperfusion experiments.(19, 20) NIRS is a prom-
ising method to assess tissue perfusion, although the variety of NIRS devices currently com-
mercially available and the different values generated by these devices, hinder comparison of 
results from different NIRS studies. Careful calibration of each device and standardization of the 
method are required to completely use the opportunities provided by the NIRS technique.(21)
Modern clinically applicable microscopic approaches to investigate the microcirculation are 
orthogonal polarization spectral imaging (OPS) and its successor Sidestream Dark Field (SDF) 
imaging. Orthogonal polarization spectral imaging as well as SDF imaging are both validated 
techniques to investigate the microcirculation of tissues covered by a thin epithelial layer (Table 
1). Currently, most studies are performed of the well-accessible sublingual microcirculation, 
and most investigators report the use of OPS imaging to study this particular micro-vascular 
bed. In OPS imaging, the tissue embedding the microcirculation is illuminated by polarized 
green light.(22) Back-scattered, depolarized, light is projected onto a charged coupled device 
video camera after it passes an analyzer, that is, a second polarizer that is orthogonally oriented 
with respect to the first polarizer. In this way, surface reflections are filtered out and images 
can be observed of the microcirculation below the surface under investigation. In OPS imag-
ing, the hemoglobin is actually used as contrast agent, so that red blood cells are imaged as 
dark moving globules against a white/grayish background. The obtained video clips can be 
analyzed to quantify various parameters such as flow and morphology via precise semiquan-
titative methods or by using dedicated software packages.(23-26) Recently, SDF imaging was 
introduced as the successor of OPS imaging. The SDF imaging device consists of a central light 
guide, surrounded by concentrically placed light emitting diodes that emit stroboscopic green 
light. The center of the probe is optically isolated from the light emitting diodes so that hinder-
ing surface reflections are avoided. This results in similar images compared to OPS-derived 
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video clips (Figure 1), although SDF imaging results in better visualization of capillaries due to 
complete avoidance of surface reflections and the short, stroboscopic illumination intervals 
that prevent smearing of flowing RBCs.(27)
Table 1. Validation studies for OPS and SDF imaging.
reference Compared 
techniques
Subjects Tissue investigated 
conditions
Analysis 
method
Conclusions
Harris (76) IVM vs. OPS 
imaging
10 hamsters Dorsal 
skinfold
Ischemia/
reperfusion
Cap-Image 
Software
Good agreement for 
RBC velocity and vessel 
diameters
Mathura (77) IVM vs. OPS 
imaging
10 healthy 
volunteers
Nailfold Baseline and 
after venous 
occlusion
Cap-Image 
Software
Good agreement 
for RBC velocity and 
capillary diameter.
Better capillary contrast 
with OPS
Langer (78) IVM vs. OPS 
imaging
9 rats Liver Ischemia/
reperfusion
Cap-Image 
Software
Good agreement for 
RBC velocity and vessel 
diameters
Harris (79) IVM vs. OPS 
imaging
9 hamsters Dorsal 
skinfold
Standardized 
hemodilution
Cap-Image 
Software
Good agreement for 
vessel diameter and 
FCD at various levels of 
hematocrit
Goedhart (27) OPS vs. SDF 
imaging
10 healthy 
volunteers
Nailfold Baseline, venous 
and arterial 
occlusion
Microscan 
Analysis 
Software
Good agreement for 
capillary diameter and 
RBC velocity
2 healthy 
volunteers
Sublingual - Image quality 
analysis
Higher capillary contrast 
and quality with SDF
Figure 1. Sidestream Dark Field video frame of the sublingual microcirculation. The image represents a tissue area of 0.98 × 0.73 mm.
2
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Figure 1. Sidestream dark field image of the sublingual microcirculation.
Figure 2. The effects of cardiogenic shock on the microcirculation.
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ThE MiCrOCirCULATiON iN SEPSiS
Sepsis is defined as the clinical syndrome characterized by the presence of both infection 
and a systemic inflammatory response of the body. The term severe sepsis is often used in the 
literature and refers to sepsis complicated by organ dysfunction. Septic shock refers to a state of 
acute circulatory failure characterized by persistent arterial hypotension unexplained by other 
causes.(28) Although major progress has been made in the treatment of sepsis, a substantial 
number of patients will not survive despite early, aggressive correction by volume resuscita-
tion and administration of vaso-active agents and antibiotics.(29-32) Indeed, severe sepsis 
is the most common cause of death in general (non-cardiac) critical care units.(33) Current 
guidelines for resuscitation of patients with severe sepsis and septic shock aim at normalizing 
global hemodynamic and metabolic parameters (ie, central venous pressure, mean arterial 
pressure, urine output, central venous oxygen saturation and lactate level).(34) Although these 
parameters are indicative for global tissue perfusion, information about regional perfusion, 
hypoperfusion and hypoxia in a septic patient is often lacking. Yet, regional hypoxia and associ-
ated organ dysfunction is one of the major features of septic shock. This is the reason why 
microcirculation research has gained so much interest in the last years. One of the key features 
of the microcirculation in sepsis is a heterogeneous distribution of blood flow. It has been shown 
that certain vascular beds, or microcirculatory units, become underperfused, whereas others 
show a normal or even abnormally high blood flow.(24, 35-37) It has been suggested that this 
phenomenon is explained by autoregulatory dysfunction through heterogeneous expression 
of inducible nitric oxide synthase, an important system responsible for autoregulatory vasodila-
tion of the microcirculation.(38, 39) Several other phenomena play a role in the pathogenesis 
of sepsis. Smooth muscle cells that line arterioles and regulate perfusion lose their adrenergic 
sensitivity and tone in sepsis.(40) Erythrocyte deformability decreases, whereas their ability to 
aggregate increases.(41, 42) In addition, leukocytes activated by septic inflammation generate 
reactive oxygen species that may impair glycocalyx function and coagulatory function.(43-45) 
These defects may further impede microcirculatory perfusion, which can finally result in an 
oxygen extraction deficit, severe functional shunting, and (multiple) organ failure.(2, 35, 46, 47) 
Although the microcirculation seems to play an important role in the pathogenesis of severe 
septic shock, others have argued that mitochondrial dysfunction is the driving mechanism 
underlying multiorgan dysfunction in sepsis.(48) However, whether mitochondrial failure is 
indeed a primary cause of oxygen extraction deficit in sepsis is still a source of debate. De Backer 
et al. used OPS imaging to demonstrate that total vascular density and capillary perfusion are 
impaired in patients with sepsis, and these micro-vascular alterations have been associated 
with in-hospital mortality.(24, 31) Subsequent studies showed that micro-vascular alterations 
could be improved with nitroglycerin(36), dobutamine(49), and red blood cell transfusion.(50, 
51) Nevertheless, it remains unknown whether a microcirculation-guided therapy, monitored 
by OPS or SDF imaging, improves outcome in patients with septic shock.
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SEPTiC ShOCK vErSUS hyPOvOLEMiC ShOCK
Kerger et al(52) have demonstrated that functional capillary density can deteriorate in experi-
mental severe hemorrhagic shock with an induced mean arterial pressure (MAP) of 40 mm 
Hg. These changes were related to mortality. To our knowledge, 3 experimental studies have 
been performed to investigate whether there is a difference between microcirculatory dysfunc-
tion in septic shock relative to mild hypovolemic shock. First, Boczkowski et al(53) used a rat 
diaphragmatic microcirculation model in which they investigated capillary perfusion using 
transillumination in experimental sepsis and during controlled hemorrhage. Blood pressure 
decreased similarly in rats with sepsis vs rats with hemorrhage, but the percentage of nonper-
fused capillaries was significantly higher in the septic group, whereas it remained at normal 
values in the group rats with hemorrhage. Second, Nakajima et al.(54) used intravital micros-
copy to investigate the effects of hemorrhagic shock, normotensive sepsis, and septic shock on 
the microcirculation of mouse small intestine. Significant decreases in red blood cell velocity 
were observed in the groups with sepsis and septic shock, whereas it remained preserved in 
mice with hemorrhage-induced hypotension. Although mean FCD also decreased in mice with 
hemorrhagic shock, this decrease was much worse in mice with septic shock. Finally, Fang et 
al.(55) used OPS imaging to estimate buccal micro-vascular blood flow in rats with septic shock 
vs rats with MAP-matched hemorrhagic shock. These investigators demonstrated that micro-
vascular blood flow was worse in the septic group compared to the MAP-matched hemorrhagic 
shock group. Additionally, saline infusion resulted in complete restoration of microvascular 
blood flow in the MAP-matched hemorrhagic shock group whereas saline infusion could not 
improve microvascular blood flow in the septic shock group. Taken together, these studies 
have demonstrated that the microcirculation in mild hemorrhagic shock is not affected to such 
an extent as compared to septic shock. In addition, the results presented by Fang et al.(55) 
suggested that micro-vascular alterations in hypovolemic shock (conversely to septic shock) at 
least in part depend on global hemodynamics. These findings have to be confirmed in human 
studies and it should be realized that administration of allogeneic red blood cell transfusions 
after hypovolemic shock rather than hypovolemic shock itself may have deleterious effects on 
the microcirculation in humans.(50, 51)
CArDiOGENiC ShOCK
Cardiogenic shock is one of the acute heart failure syndromes and is defined as evidence of 
tissue hypoperfusion induced by heart failure after correction of preload. Cardiogenic shock 
is characterized by a reduced arterial blood pressure (systolic <90 mm Hg or a drop of MAP 
>30 mm Hg) and/or low urine output (<0.5 mL/kg per hour), with a heart rate more than 60 
beats per minute.(56) In most cases, cardiogenic shock develops after an acute myocardial 
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infarction. In patients admitted with acute myocardial infarction, cardiogenic shock is the 
leading cause of death.(57) Other causes of cardiogenic shock include cardiomyopathy, val-
vular heart disease, myocarditis, myocardial contusion and previous cardiac surgery. Despite 
advances in treatment, in-hospital mortality of cardiogenic shock patients remains about 50%.
(58) For years, it has been accepted that when cardiac output, and thus systemic blood flow, 
decreases, compensatory redistribution of blood volume (partly by active venoconstriction) 
results in a decrease in peripheral vascular capacitance with a compensatory increase in cardiac 
filling pressures and cardiac output. In this classic paradigm of cardiogenic shock, depression 
of cardiac output also causes arteriolar vasoconstriction and an elevation of systemic vascular 
resistance. Studies that investigated the peripheral circulation in patients with chronic, severe 
heart failure (New York Heart Association class III-IV) and cardiogenic shock have supported this 
hypothesis.(59-61) However, data on the state of the peripheral microcirculation in acute heart 
failure is scarce and did not consistently confirm the classic notion of systemic vasoconstriction 
in all patients with cardiogenic shock. For example, Lim et al.(62) reported that 40% of patients 
admitted with cardiogenic shock due to myocardial infarction died with a cardiac index more 
than 2.2 L/min per square meter. In line with these data, post hoc analysis of data from the 
SHOCK-trial demonstrated that a considerable number of patients, admitted with cardiogenic 
shock, developed a systemic inflammatory response syndrome (SIRS) during hospital stay. In 
these patients, systemic vascular resistance (SVR) at shock onset was significantly lower com-
pared to patients who did not develop SIRS, although a wide variation of SVR among patients 
was observed. A low SVR, suggesting peripheral vasodilation, was a predictor for later develop-
ment of sepsis.(63) The latter data suggested once again that not all cardiogenic shock patients 
develop diffuse vasoconstriction as a compensatory response to cardiac pump failure. Figure 
2 shows the current theory on the effects of cardiogenic shock on the microcirculation. In fact, 
inappropriate vasodilation due to SIRS might further impair perfusion at the microvascular 
level, which might be important in the pathogenesis of multiple organ failure and the persis-
tence of shock.(64) This process may be due to an increased production of nitric oxide by nitric 
oxide synthase (NOS). Accordingly, strategies were developed to inhibit NOS in patients with 
cardiogenic shock. Small studies suggested that NOS-inhibition could improve blood pressure.
(65-67) The Tilarginine acetate injection in a Randomized International study in Unstable MI 
Patients with cardiogenic sHock (TRIUMPH)-trial was designed to test whether administration 
of tilarginine, a NOS-inhibitor, would result in an improved 30-day survival in patients with 
myocardial infarction complicated by cardiogenic shock. Unfortunately, enrolment of patients 
was recently terminated at 398 patients because of lack of efficacy. There was no difference in 
favor of NOS-inhibition in 30-day all-cause mortality between patients who received tilarginine 
(48% died) relative to placebo (42% died, risk ratio 1.14: 95% confidence interval 0.92-1.41).(68)
This negative study underlines that microcirculatory alterations in cardiogenic shock are still 
not fully understood. The aforementioned sophisticated 2-dimensional imaging techniques 
may give better insight in the nature of these alterations. De Backer et al(69) used OPS imaging 
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to investigate the sublingual microcirculation in 40 patients with acute heart failure, most 
of them having cardiogenic shock, who were investigated within 48 hours after the onset of 
acute heart failure. These investigators reported similar alterations to those observed in sepsis, 
including a lower proportion of perfused capillaries in patients with heart failure compared 
to control patients. Moreover, these alterations were related to in-hospital mortality. However, 
these investigators performed only one measurement per patient, and it remained unclear 
whether the microcirculation could be improved by pharmacologic therapy and whether such 
interventions could be beneficial in reducing the high mortality rate in cardiogenic shock 
patients.
MACrOCirCULATiON vErSUS MiCrOCirCULATiON iN SEPTiC AND 
CArDiOGENiC ShOCK
An important finding in several studies in SIRS and sepsis was that the alterations in micro-
vascular flow occurred independently of systemic hemodynamic variables.(24, 49, 70) De 
Backer et al(69) have argued that probably the same principle holds for cardiogenic shock. 
Conversely, several studies have shown that there is a close correlation between macrocircula-
tion and microcirculation in animals and patients with left ventricular systolic dysfunction. This 
Figure 2. The effects of cardiogenic shock on the microcirculation. A decrease in cardiac output, caused by systolic myocardial dysfunction, 
results in a decrease in mean arterial blood pressure. These phenomena cause compensatory vasoconstriction of the resistance vessels, 
which decreases microvascular perfusion. The degree of SIRS and the administration of vasoactive pharmacologic agents can both modulate 
microcirculatory responses and influence perfusion at the microvascular level. In case of severe hypoperfusion of the microcirculation, lactate 
levels will increase whereas venous oxygen saturation will decrease. Abbreviations: MAP, mean arterial pressure; SIRS, systemic inflammatory 
response syndrome; SvO2, venous oxygen saturation; SVR, systemic vascular resistance.
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Figure 1. Sidestream dark field image of the sublingual microcirculation.
Figure 2. The effects of cardiogenic shock on the microcirculation.
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was recently confirmed with OPS imaging in pigs subjected to ventricular fibrillation followed 
by advanced life support.(71, 72) Measured by OPS imaging, Erol-Yilmaz et al(73) recently 
reported a better sublingual functional capillary density during biventricular pacing relative to 
either only right ventricular pacing or no pacing. Although cardiac output was not measured in 
this study, these data suggest a relation between cardiac output and sublingual microcircula-
tory perfusion. Further well-designed studies in cardiogenic shock patients, preferably using 
SDF imaging, are needed to completely explain these results. The exact extent of peripheral 
vasoconstriction may in fact be dependent of the degree of SIRS present in a patient with 
cardiogenic shock (Figure 2).
fUTUrE PErSPECTivES iN MiCrOCirCULATiON rESEArCh
There is overwhelming evidence that sepsis is a disease of the microcirculation.(2, 74) However, 
the exact role in the pathogenesis is still incompletely understood. Ongoing animal studies 
and 3-dimensional computer models, simulating micro-vascular blood flow and gradients of 
hypoxia, will improve our understanding of microvascular alterations and will result in new 
approaches to monitor and treat patients with sepsis.(75) Furthermore, randomized studies are 
currently underway to test whether microcirculatory flow-guided therapy might be beneficial 
for patients with severe sepsis and septic shock. The microcirculation does not seem to play 
a completely independent role in hypovolemic shock, although this has to be confirmed in 
human studies. Research focusing on the exact role of the microcirculation in cardiogenic shock 
is still in its premature stages. We have to learn more on nature, severity and duration of periph-
eral microcirculatory changes in acute heart failure syndromes in order to comprehensively 
investigate whether these changes can be improved by pharmacologic and mechanical treat-
ment strategies. It is to be hoped that these future studies may in the end result in improved 
treatment and survival of heart failure patients.
CONCLUSiONS
An adequate function of the peripheral microcirculation in the different organ systems is 
necessary to maintain adequate tissue perfusion and to preserve normal hemodynamics. 
Recent technical developments have enabled investigation of the microcirculation at the 
bedside and confirmed that the microcirculation is impaired in severe sepsis and septic shock. 
Heterogeneous microvascular alterations in sepsis occur independently of changes in global 
hemodynamic parameters. Several recent experimental studies have demonstrated that the 
microcirculation in hypovolemic shock is not affected to such an extent as in septic shock, 
although it should be realized that allogeneic RBC transfusions following hypovolemic shock 
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might impair the microcirculation. The role of the peripheral microcirculation in cardiogenic 
shock is still incompletely understood, although there is growing evidence that systemic 
inflammation of the body is an important aspect in the pathogenesis. In addition, there is still 
debate whether microcirculatory alterations in acute heart failure syndromes occur completely 
independent of changes in the macrocirculation. Novel bedside technology to image the 
peripheral microcirculation may be helpful to understand the pathogenesis of cardiogenic 
shock more comprehensively and to learn whether intervention strategies, aimed at improving 
peripheral microvascular flow, are beneficial for patient outcome.
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ABSTrACT
Microcirculation, a complex and specialized facet of organ architecture, has characteristics that 
vary according to the function of the tissue it supplies. Bedside technology that can directly 
observe microcirculation in patients, such as orthogonal polarization spectral imaging and 
sidestream dark field imaging, has opened the way to investigating this network and its com-
ponents, especially in critical illness and surgery. These investigations have underscored the 
central role of microcirculation in perioperative disease states. They have also highlighted varia-
tions in the nature of microcirculation, both among organ systems and within specific organs. 
Supported by experimental studies, current investigations are better defining the nature of 
microcirculatory alterations in critical illness and how these alterations respond to therapy. 
This review focuses on studies conducted to date on the microcirculatory beds of critically ill 
patients. The functional anatomy of microcirculation networks and the role of these networks 
in the pathogenesis of critical illness are discussed. The morphology of microvascular beds 
that have been visualized during surgery and intensive care at the bedside are also described, 
including those of the brain, sublingual region, skin, intestine, and eyes.
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iNTrODUCTiON
In recent years, interest in the role of microcirculation in critical illness has grown. This seems 
logical because microcirculation is ultimately responsible for providing oxygen to the tissues. 
Microcirculation is a complex network, with special morphologic features tailored for the spe-
cific function of the tissues it supplies. Recently, new imaging techniques and clinical investiga-
tions have identified microcirculation as a pivotal element in the pathogenesis of sepsis.
Although major progress has been made in the treatment of sepsis, morbidity and mortality 
rates associated with sepsis remain high.(1, 2) Hemodynamic treatment is primarily aimed at 
correcting global hemodynamic and oxygen-derived variables.(2) Despite aggressive correction 
of global parameters with volume resuscitation and vasoactive agents, some patients progress 
into multiorgan failure and die.(3, 4) The ultimate aim of resuscitation is to correct and avoid 
tissue hypoxia. However, the end points used to evaluate the achievements of resuscitation 
therapy (eg, lactate levels, venous oxygen saturation, and mean arterial pressure) are not sensi-
tive enough to detect regional hypoxia. This lack of sensitivity is primarily due to the distributive 
defect associated with septic shock, in which a defect in the distribution of normal cardiac 
output (or even increased cardiac output) results in regional hypoxia that is not detected by 
conventional hemodynamic monitoring of systemic circulation. This occult hypoxia highlights 
the necessity of finding new end points for the treatment of severe sepsis and septic shock.
This review first explores the characteristic features of several microvascular beds that can 
be visualized at the bedside. Second, the distinctive abnormalities occurring during sepsis are 
discussed in relation to different types of shock. In addition, we review the response of micro-
circulation to available therapeutic modalities frequently used to treat septic shock patients. 
Although many methods exist to study microcirculation, either directly or indirectly, this 
review mainly focuses on the use of either orthogonal polarization spectral (OPS) imaging or 
sidestream dark field (SDF) imaging(5, 6) for direct clinical visualization of microcirculation with 
bedside vital microscopy. Because the heterogeneity of microcirculatory alterations among 
different organs and within individual organs is a key characteristic of the pathophysiology of 
hemodynamic dysfunction in sepsis, the preferred technique for identifying these alterations 
is direct visualization.
ThE ANATOMy AND fUNCTiON Of DiffErENT MiCrOCirCULATOry BEDS
Microcirculation has evolved from being a hypothesized necessary link between the arteries 
and veins, in Harvey’s theory of circulation, to a possible end point of resuscitation in critical 
illness. In 1661, Malpighi demonstrated, for the first time in vivo, long, thin-walled tubes, which 
he termed capillaries. Technical advances made in recent years have made it possible to directly 
or indirectly study microcirculation in different pathologic states. Most of the information 
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concerning the functional morphology of microcirculation has been obtained from extensive 
studies involving experimental animals.
Microvasculature consists of arterioles, capillaries, and postcapillary venules, of which the 
arterioles are the major determinant of vascular resistance. Blood flow depends on a pressure 
gradient along the vascular tree, as well on the amount and distribution of resistance across the 
microvasculature. Circular smooth muscle cells surround the arteriolar walls. By alternately con-
tracting and relaxing, these muscle cells control microvascular flow. In specific microcirculatory 
beds, such as those of the brain pericytes, surrounding arterioles can also cause constriction 
and regulate blood flow.(7) This vascular tone controls the diameter of the vessels because, as 
described by the law of Poiseuille, the resistance to flow is primarily determined by the radius 
of the vessel. The proximal arteriole determines the total blood flow to the capillaries, whereas 
the terminal arterioles and precapillary sphincters control the distribution of blood within 
the capillaries. Capillary walls, which consist of a single layer of endothelium and basement 
membranes, represent the principal site of oxygen and nutrient exchange between blood and 
tissue. Changes in systemic blood pressure lead to a corresponding change in microcirculatory 
flow, which is then compensated for by local readjustments. These changes ensure that the 
microcirculatory blood flow is adequate to meet the oxygen requirements of the parenchymal 
cells, a mechanism called autoregulation.
The microvasculature characteristics of each organ system are closely related to the func-
tional role played by the organ as a whole. The number of capillaries per unit mass of organ 
or tissue (capillary density) may be related to the organ’s metabolic requirements (muscles, 
heart, brain) or to other functional requirements (skin, intestinal mucosa, kidney).(8) Oxygen 
transport to the tissues occurs via passive diffusion from the capillaries, as was first described 
by Krogh early in the 20th century. The diffusion of oxygen in this manner is considered to be 
the main rate-limiting process in oxygen transport to tissue. Besides diffusion from the capil-
laries, diffusion of oxygen to the parenchymal cells also occurs from the larger vessels, such as 
the arterioles and venules. Although the microvascular beds of most organs and tissues clearly 
have both metabolic and functional components, one or the other usually predominates. In 
this way, the morphology of each microcirculatory bed is designed to fit the function and 
oxygen requirements of each organ.
Regarding critical illness, skeletal muscle has been the most extensively studied tissue in 
experimental studies. This is due to its easy accessibility and to the technical limitations of 
intravital microscopes, the main instruments used in such studies. Interest later shifted to other 
microvascular beds, such as in the intestine and brain. Upon the introduction of OPS and SDF 
imaging, microcirculation could be observed in humans, and the location most often studied 
with these techniques has, to date, been the sublingual microcirculation. This is because this 
region is easily accessible and its vascularization is close to the brain and heart. The extent 
to which studies of this region can be extrapolated to other microvascular beds is uncertain. 
However, sublingual microcirculatory alterations do have clinical significance. The superior 
The heterogeneity of the microcirculation in critical illness 37
sensitivity of sublingual microcirculation as an indicator of the severity of disease over systemic 
hemodynamic and oxygen-derived variables (demonstrated in several clinical studies) makes 
sublingual tissue clinically relevant for detecting microcirculatory alterations.
OrThOGONAL POLArizATiON SPECTrAL AND SiDESTrEAM DArK fiELD 
iMAGiNG fOr CLiNiCAL MONiTOriNG Of MiCrOCirCULATiON
The intravital microscope has provided much insight into the physiology and pathophysiology 
of microcirculation in several models of disease. However, the microscope’s technical limitations 
have limited its impact. The main limitation of this technique is the need for transillumination of 
the microcirculatory bed from below for visualization. Observing the microcirculation of organ 
surfaces using epi-illumination causes surface reflection of the incident light, resulting in poor 
visualization of the underlying microcirculatory bed. Therefore, the intravital microscope has 
been used mainly for the study of organs that permit transillumination, such as the mesen-
teric, cremaster, and hind limb muscles. Fluorescence microscopy (illumination from above), 
has facilitated the study of other organs. Not being able to apply these types of techniques 
to large animal models has limited the clinical relevance in studying the microcirculation. 
In small animal studies the relation between macro- and microcirculation, an essential link 
needed to understand the role of the microcirculation in functional hemodynamics, has not 
been sufficiently elucidated. This limited their translational applicability to clinical scenarios. 
The technical limitations of transillumination were finally overcome with the introduction of 
the OPS imaging technique.
OPS imaging illuminates tissues with polarized green light and measures the reflected light 
from the tissue surface after filtering out the polarized portion of the reflected light.(6) OPS 
imaging thus makes it possible to visualize microcirculation without transillumination. This 
modality filters out the surface reflection and permits visualization of subsurface structures. 
Green light is absorbed by hemoglobin in red blood cells, thereby tracking the movement of 
red blood cells, which appear in microcirculation as moving dark globules. However, the OPS 
technique has only limited sensitivity for studying capillary kinetics and morphology in detail. 
An improved optical modality to address this shortcoming was introduced with SDF imaging 
(5). Covered by a disposable cap, the SDF probe is placed directly on tissue surfaces. The light 
from the concentrically positioned light-emitting diodes (530 nm wavelength) penetrates 1 mm 
into the tissue, thus illuminating the microcirculation and its components. Because hemoglobin 
absorbs this wavelength, erythrocytes can be clearly observed as flowing cells. Also, because 
there is no direct optical contact with the sensing central core of the probe, surface reflections do 
not interfere with image collection. Therefore, remarkably clear images of the microcirculation 
can be captured. The resulting improved image quality allows for better automatic analysis of the 
images, and the low energy requirement of SDF imaging further enhances its utility by allowing 
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battery and portable computer operation. Using these techniques, brain, sublingual, cutaneous, 
and conjunctival microcirculation have been studied during surgery and intensive care.
CLiNiCAL EvALUATiON Of MiCrOCirCULATiON DUriNG SUrGEry AND 
iNTENSivE CArE
Both OPS and SDF imaging can be used to investigate the microcirculation of organ surfaces. 
OPS imaging has been used to visualize human brain microcirculation during neurosurgery.
(6) Given its embryologic association with the gastrointestinal tract and its easy accessibility, 
Figure 1. (A) Vascularization of the eye, including microcirculation. (B) SDF image of conjunctival microcirculation.
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Figure 1. (A) Vascularization of the eye, including microcirculation. (B) SDF image of 
conjunctival microcirculation.
Figure 2. (A) Vascularization of the sublingual area, including microcirculation. (B) OPS 
image of sublingual microcirculation.
Figure 2. (A) Vascularization of the sublingual area, including microcirculation. (B) OPS image of sublingual microcirculation.
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Figure 1. (A) Vascularization of the eye, including microcirculation. (B) SDF image of 
conjunctival microcirculation.
Figure 2. (A) Vascularization of the sublingual area, including microcirculation. (B) OPS 
image of sublingual microcirculation.
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sublingual microcirculation has been extensively studied, especially in intensive care medicine. 
In addition, these techniques have been applied to the study of microcirculation in the nail fold.
(9, 10) From a historic perspective, however, the study of the human brain during surgery repre-
sents a new, uncharted area of clinical research.(6) Figures 1-4 illustrate several microcirculatory 
beds described below, as well as their corresponding microcirculatory images, acquired using 
OPS or SDF imaging.
Brain microcirculation
The microvascular bed of the cerebral cortex consists of a dense, highly interconnected net-
work that arises from pial arteries. Irregular tortuous capillaries characterize this cerebrocortical 
Figure 3. (A) Vascularization of the gut, including microcirculation. (B) OPS image of villus microcirculation.
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Figure 3. (A) Vascularization of the gut, including microcirculation. (B) OPS image of villus 
microcirculation.
Figure 4. (A) Vascularization of the skin, including microcirculation. (B) SDF image of nail 
fold microcirculation.
Figure 4. (A) Vascularization of the skin, including microcirculation. (B) SDF image of nail fold microcirculation.
4
Figure 3. (A) Vascularization of the gut, including microcirculation. (B) OPS image of villus 
microcirculation.
Figure 4. (A) Vascularization of the skin, including microcirculation. (B) SDF image of nail 
fold microcirculation.
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capillary bed, and these capillaries are supplied by branches of cortical penetrating arteries, 
which cannot be visualized in vivo.(11) The arteriolar system is composed of three main vas-
culature zones: the pial, cortical, and subcortical vascular networks. When the brain surface is 
examined with intra-vital microscopy, the capillaries appear to have no preferential orientation 
or characteristic length, and the capillaries cannot usually be traced back to their pial arter-
ies. On the brain surface, the arterial microanastomoses characterize the pial microarterial 
network.(12) The capillaries drain into postcapillary venules that give rise to the pial veins. It is 
still unclear whether arteriovenous anastomoses are present in the cerebral microvasculature. 
Capillary density in the brain is related to the average metabolic rate at steady state.(13) In addi-
tion to the classical factors that control microcirculatory blood flow (myogenic, metabolic, and 
neurohumoral mechanisms), evidence suggests that pericytes located around the capillaries 
regulate cerebral blood flow in both normal and pathological states.(7)
The initial observation of normal brain microcirculation using OPS imaging was followed by 
several other reports on the structure of cerebral cortical microcirculation in different disease 
states. First, it was shown that, during surgery for subarachnoid hemorrhage, the cortical micro-
vasculature response to hypocapnia was different between patients prone to vasospasm and 
patients who did not develop vasospasm.(14) In addition, excision of arteriovenous malforma-
tions in the brain resulted in increased microcirculatory flow and functional capillary density in 
the perinidal brain tissue.(15)
Conjunctival microcirculation
Direct access to brain microvasculature is impossible outside the operating room. However, 
a recent study suggests that the microcirculation of the eye conjunctiva might function as an 
indicator of the cerebral microcirculation.(16) At the bedside, the most accessible part of the 
eye for evaluating microcirculation is the bulbar conjunctiva, which offers a complete vascular 
bed with arterioles, capillaries, and small collecting venules. Earlier studies using intravital 
microscopy have reported on the behavior of the conjunctival microcirculation in sickle cell 
patients.(17, 18) The anterior segment of the human eye is supplied by the anterior ciliary 
arteries, which supply the anterior conjunctival, anterior episcleral, and limbal circulation. The 
episcleral arterial circle broadly resolves into superficial and deep components.(19) With intra-
vital microscopy or OPS and SDF imaging, collecting venules are visualized as heavy, prominent 
dark vessels situated parallel to narrower, straighter vessels, which comprise the accompanying 
terminal arterioles.(20) Capillaries arise at intervals from the end arterioles and form an irregular 
network of vessels that come together to form the venular system. The arterioles frequently 
terminate in main arteriovenous channels that communicate directly to the venular tree. This is 
most notable near the corneo-scleral junction.(21)
The bulbar conjunctiva has been most extensively studied in diabetes and hypertensive 
patients. In these patient groups, several alterations in microcirculatory morphology and flow 
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have been demonstrated. Microcirculatory alterations in the conjunctiva, however, have not 
yet been investigated in sepsis.
Sublingual microcirculation
The sublingual area is one of the most accessible human mucosal surfaces, which is why it has 
been extensively investigated. Blood is supplied to the sublingual area via the external carotid 
artery, the lingual artery, and the sublingual artery, subsequently. Only a limited number of 
sublingual arterioles are present, whereas numerous capillaries (diameter <20 μm) and venules 
(diameter 20-100 μm) are present in the sublingual area. Because perfusion of the sublingual 
mucosa is related to blood flow in the external carotid artery, sublingual perfusion may, in part, 
reflect cerebral blood flow. However, only a few studies have investigated the cerebral and 
sublingual perfusion simultaneously. Perfusion of the sublingual area could represent blood 
flow in the splanchnic region for two major reasons. First, this is suspected because the tongue 
shares a common embryogenic origin with the gut. Second, studies in critically ill patients 
reported good correlations between sublingual and gastric mucosal carbon dioxide pressures, 
as measured with sublingual capnometry and gastric tonometry, respectively, further strength-
ening the hypothesis.(22, 23)
intestinal microcirculation
Branches from a common submucosal vasculature supply blood to the muscle, submucosal 
layer, and mucosal layer of the gut. Small arteries that branch extensively in the submucosal 
layer penetrate the muscularis layer of the intestinal wall. The branches all lead to capillary 
beds, and though diffusive shunting is thought to occur at the base of the villi, there is no 
evidence for arteriovenous shunts in the intestinal circulation.(24) Several submucosal arteries 
that transport blood back to the muscularis layer form a network of arterioles and capillar-
ies around the intestinal smooth muscle cells. Other submucosal arteries supply blood to the 
mucosa and to each intestinal villus, where dense capillary networks exist. Veins leaving the villi 
join veins from the mucosal and muscularis layers, and they exit the intestinal wall alongside 
the mesenteric arteries that supply blood. Because absorption of water and solutes is one of 
the primary functions of the villi, the capillaries in the mucosal villi are very dense. A critical 
feature that may facilitate reabsorption of water is that the vessels carrying blood into and out 
of the villus lie close together, in parallel paths. Because the afferent and efferent blood vessels 
in the villi are close together, oxygen could diffuse from the arterioles to the venules at the 
base of the villus.(25) It is probably this organization that makes the tip of the villus the part 
most vulnerable to shock. The integrity of the intestinal mucosa is important to preventing 
the translocation of bacteria and toxins into the systemic circulation. Hypoperfusion of the gut 
mucosa may contribute to mucosal injury.(26, 27) In this context, experimental studies have 
evaluated the effect of sepsis and also hemorrhagic shock on the intestinal microcirculatory 
blood flow.(28-30) A recent study by Dubin and colleagues(30) demonstrated that endotoxic 
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shock in sheep rapidly induced alterations in intestinal and sublingual microcirculation. Fluid 
resuscitation normalized the systemic and intestinal hemodynamics, while also restoring the 
microvascular flow at the sublingual and intestinal serosal levels. However, the microvascular 
flow and percentage of perfused vessels in the intestinal mucosa were not effectively restored 
after fluid resuscitation. Human data are scarce, and they are limited to the observations in sto-
mas of patients with abdominal sepsis. Boerma and colleagues(31), after comparing the micro-
circulatory alterations between the sublingual region and stomas in patients admitted with 
abdominal sepsis, reported no correlation between sublingual and intenstinal microcirculatory 
alterations on day 1 of sepsis. After 3 days, however, these regional alterations became more 
systemic and correlations were found between the sublingual and intenstinal microcirculatory 
alterations The alterations in one microcirculatory bed, therefore, do not necessarily reflect 
alterations in other microvascular beds. However, although microcirculatory beds may differ 
substantially in different organs, studies have clearly demonstrated the clinical significance 
of sublingual microcirculatory alterations in sepsis. These alterations indicate the response to 
treatment and resuscitation and serve as sensitive and specific indicators of bad outcome.
Dermal microcirculation
The study of the cutaneous microvascularization with IVM, OPS, and SDF has been limited to 
the nail fold area because of the distinctive construction of the skin, which includes a thick 
epidermal layer. Other techniques have also been used to study skin microcirculatory blood 
flow in illness. Using laser Doppler flowmetry, Young and Cameron(32) demonstrated an 
impaired microcirculatory blood flow response of the forearm after transient ischemia. Using 
intra-vital microscopy, the blood flow velocity in the capillary bed of the nail fold was found to 
be decreased in normotensive febrile patients.(33) In investigating cutaneous microcirculation, 
the question remains: To what extent is microcirculatory flow of the skin important in critical 
illness? This question arises mainly because of the role thermoregulatory properties play in 
governing and interfering with the skin microvasculature. Because the major role of cutaneous 
circulation is thermoregulation, blood flow to the skin typically exceeds metabolic require-
ments. In the deep dermis, branches from subcutaneous arteries that penetrate the dermis 
form an arterial plexus.(34) The vessels within this plexus generally run parallel to the surface. 
Arterioles penetrating from the dermal plexus to the subpapillary region form a subpapillary 
plexus. Capillaries connect to the subpapillary venous plexus, and single capillary loops ascend 
to each papilla. The descending portion of the capillary joins the subpapillary venous plexus, 
which drains into the deeper cutaneous venous plexus. Due to the numerous arteriovenous 
shunts (only in apical regions) and because many cutaneous veins run close to parallel arteries, 
the resulting counter-current heat exchange conserves heat. The combination of rich sympa-
thetic innervation of the cutaneous arterioles and a high microvascular blood flow relative to 
oxygen demand allows a primary control of reflexes.
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Other microcirculatory beds
In addition to these areas, other microcirculatory beds have been studied using OPS and SDF 
imaging. While these applications have been limited to single studies, such studies have dem-
onstrated the applicability of these techniques to other organ surfaces if they can be exposed 
for investigation. For instance, rectal microcirculation was studied in patients with malaria.(35) 
During maxillofacial surgery and especially for assessing wound healing, these techniques 
have also been used to explore additional areas of the oral cavity (36). Finally, during surgery 
in which several organ surfaces are exposed, investigations have examined microcirculation in 
the liver, pancreas, and kidney.(37-39)
MiCrOCirCULATiON iN SEPSiS
Observational studies of sublingual microcirculation in sepsis have contributed to the under-
standing of the pathophysiology of acute circulatory failure and multiple organ dysfunction.
(40) Both clinical and experimental studies have previously indicated that sepsis and septic 
shock are disorders of microcirculation. In the early phases of sepsis, a persistent deficit in 
microcirculatory perfusion is associated with poor outcome, as was demonstrated by De Backer 
and colleagues.(41) These investigators compared the sublingual microcirculation in septic 
patients versus that of healthy volunteers and detected a significant decrease in the propor-
tion and density of small perfused vessels during sepsis. In addition, the alterations were more 
severe in nonsurvivors than in survivors. Meanwhile, Sakr and colleagues(3) observed that the 
recovery of microcirculatory alterations within the first 24 hours indicated good outcome. In 
this study, the persistent loss of capillary perfusion was one of the most sensitive and specific 
hemodynamic predictors of survival from septic shock. Trzeciak and colleagues(4) studied 
the effects of an early goal-directed protocol on indices of microcirculatory perfusion in early 
sepsis. They demonstrated that, even in the context of early goal-directed therapy, microcir-
culatory flow was more markedly impaired and more heterogeneous in septic nonsurvivors 
than in survivors. Interestingly, the investigators found a correlation between microcirculatory 
and macrocirculatory parameters in early sepsis, but this correlation was weaker in later sepsis. 
This finding emphasizes the importance of early resuscitation, since time is one of the most 
important factors affecting therapeutic strategies for improving microcirculation.(42)
Many pathogenic mechanisms contribute to the microcirculatory abnormalities that occur 
during sepsis. In this context, microcirculation can be regarded as the integrative compartment 
in which all of these factors come together. Left uncorrected, microcirculatory abnormalilties 
can lead to multiorgan failure and death. The most challenging septic patients are those who 
have received treatment but do not improve. Here, the initial hit, in combination with therapy, 
time, comorbidity, and genetic background, all contribute to the complex pathogenesis of 
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sepsis that leads to organ failure. Together, these are referred to as the microcirculatory and 
mitochondrial distress syndrome.(40)
Significant increases in leukocyte rigidity are observed during sepsis. The rigidity sub-
sequently decreases with an improvement in the clinical condition.(43) A significant role 
has also been attributed to the mechanical behavior of white blood cells in microcirculatory 
alterations.(44) During sepsis, red blood cells are less likely to become deformed and more 
likely to aggregate.(45-47) The vasodilatory effects of several mediators released during sepsis, 
in combination with the excessive amounts of fluids given (which reduce viscosity), result in a 
low systemic resistance and low arterial pressure. The capillary leakage caused by endothelial 
injury of the capillaries results in hypovolemia and tissue edema, both of which result in larger 
diffusion distances between oxygen-carrying red blood cells and parenchymal cells. A pos-
sible initial contributing factor to the disruption of the barrier function of the microcirculatory 
milieu could lie in the disruption of the glycocalyx, which covers the endothelium and forms an 
important barrier and transduction system.(48) As was previously observed, the glycocalyx can 
be disrupted during inflammation and cardiovascular disease and this was made visible with 
OPS or SDF imaging.(49, 50) Recently, in a volunteer study, administration of endotoxin resulted 
in a shedding of the glycocalyx detected sublingually using OPS imaging. The shedding could 
be partially prevented by administration of a tumor necrosis factor scavenger.(51) In addition to 
metabolic, myogenic, and neurohumoral regulatory mechanisms that control microcirculatory 
blood flow, other regulatory factors can alter vascular tone and affect blood flow. Over the last 
decade, it has been demonstrated that red blood cells play an important role in the regulation 
of vascular tone through their ability to sense hypoxia and respond by releasing vasodilatory 
substances, such as nitric oxide (NO) and ATP.(52) It has been suggested that excessive NO 
production plays a key role in the pathology of the microcirculatory abnormalities in sepsis. 
Excessive NO induced by inducible NO synthase (iNOS) has deleterious effects on red blood cell 
function because it overrides the naturally-occurring regulatory mechanisms of vasodilation 
and vasoconstriction associated with autoregulation. The iNOS induction caused by cytokine 
release during bacteremia results in excessive NO formation during inflammation and infec-
tion,(53) resulting in the loss of vascular tone and a reduced responsiveness to vasoconstrictors.
(54) The inhomogeneous expression of iNOS between different organ compartments could 
represent the underlying cause of the shunting of the microcirculation in various organ seg-
ments.(55) The heterogeneity caused by shunting results in local areas of hypoxia and impairs 
oxygen extraction. The shunting theory of sepsis could explain why resuscitation strategies 
based on the correction of upstream hemodynamic variables do not correct the downstream 
indicators of hypoxia because they are unable to recruit shunted microcirculatory units.(56) The 
functionally vulnerable microcirculatory units are bypassed, and oxygen is shunted from the 
arteriole to the venous compartment. As described above, various mechanisms in sepsis could 
contribute to microcirculatory dysfunction and promote shunting. In sepsis, the perfusion in 
the capillaries is more severely altered, even while the flow in larger microvessels is preserved 
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in septic shock patients, which represents direct evidence of shunting pathways in resuscitated 
sepsis.(57) Direct evidence of functional shunting pathways is derived from microcirculatory 
pO2 measurements using palladium porphyrin phosphorescence. During various conditions of 
shock and resuscitation, microcirculatory pO2 levels become lower than the pO2 of the venous 
effluent of an organ, demonstrating the action of functional shunting.(56)
Several experimental studies have been performed to elucidate the differences in microcir-
culatory response to different types of shock. Particular focus has been placed on differentiating 
between the effects that distributive (eg, sepsis) and hypovolemic (eg, hemorrhage) types of 
shock have on microcirculation.(58) Collectively, these studies have shown that the microcir-
culatory abnormalities in sepsis can occur in the presence of normal (or even supranormal) 
systemic hemodynamics. In contrast, in hypovolemic shock, the microcirculation and systemic 
hemodynamics seem to follow each other more closely.
This difference is probably due to the fact that autoregulatory mechanisms still function 
in hypovolemic shock, whereas these mechanisms are severely impaired in septic shock. In 
addition, the differing courses of shock could be the result of differing responses from vari-
ous microvascular beds. At the arteriolar level, the cremaster muscle and diaphragm respond 
differently from the small intestine.(59-61) In the intestine, arteriolar constriction occurs at all 
levels of the arteriolar network. In contrast, in the cremaster muscle and diaphragm, larger arte-
rioles constrict and smaller ones dilate. Therefore, there appears to be heterogeneity not only 
between organs but also within a single organ. Experimental studies have thus demonstrated 
that an increase in heterogeneity is associated with a decrease in functional capillary density 
and diminished red blood cell velocity in models of sepsis.(62).
Several studies have reported that global hemodynamics do not necessarily reflect regional 
blood flow during sepsis and septic shock.(4, 63) Farquhar and colleagues(28), using a subacute 
model of sepsis, found that capillary density in the distal small bowel mucosa decreases dur-
ing normotension. Lam and colleagues(62) used a skeletal muscle preparation in the same 
subacute sepsis model to observe the distributions of perfused capillaries and red blood cell 
flow. They demonstrated an increase in capillaries with stopped flow and a decrease in the total 
number of capillaries. In addition, they demonstrated an increase in the spatial heterogeneity 
of red blood cell-perfused capillaries, similar to what later was demonstrated in clinical sepsis.
(4) To underscore the dissociation of the presence of shock and microcirculatory abnormali-
ties in sepsis, Nakajima and colleages(29) compared the effects of hemorrhage and endotoxin 
shock at the microvascular level in a rat model. They found that, in the intestinal villi, the 
capillary density, red blood cell velocity, and flux all decreased. Yet, at the same level of hypo-
tension, only moderate changes were detected during hemorrhagic shock. Boczkowski and 
colleagues(59) showed similar results in the microvascular bed of the diaphragm by comparing 
an acute model of sepsis with hypotensive hypovolemic controls. Fang and colleagues(64) 
demonstrated similar findings for buccal microcirculation in a subacute model of septic shock 
compared with hemorrhagic shock. Additionally, they demonstrated that when both models 
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where matched according to the cardiac index, the microcirculatory alterations were similarly 
altered. After resuscitation, the improved global hemodynamics were not effective in improv-
ing the buccal capillary blood flow in septic shock, in contrast to hemorrhagic shock, where 
improved global hemodynamics was found to be bneficial on microcirculation.
Thus, in shock profiles other than distributive shock, microcirculatory alteration seems to 
be effectively corrected by resuscitating global hemodynamical variables. In septic shock, 
however, therapeutic modalities aimed at recruiting systemic variables do not always seem to 
be effective in recruiting microcirculation. Therefore, more specific therapies may be required.
(55) All these experimental studies have contributed to the view that sepsis is a disease of 
microcirculation.
rESUSCiTATiNG ThE MiCrOCirCULATiON
Clinical investigations are currently being conducted to determine whether treatment modali-
ties aimed at recruiting microcirculation provide a beneficial therapeutic target. Several agents 
and resuscitation strategies have been studied in experimental models and in single center 
intensive care unit populations. Various animal studies have demonstrated that, under condi-
tions in which autoregulatory mechanisms have not been affected, fluid resuscitation success-
fully improves the microcirculatory abnormalities and oxygen transport to baseline values.
(29, 64) In septic shock, however, fluid resuscitation alone is ineffective in improving microcir-
culatory function. Even when the systemic variables have been normalized, microcirculatory 
alterations can persist.(3, 41) Nevertheless, in a fraction of preload-dependent intensive care 
patients, a fluid loading of 500 mL within a 15 min period was found to significantly improve 
microcirculatory parameters,(65) although the inclusion criteria were not clear in this study.
In the clinical setting, several therapeutic agents have been demonstrated to effectively 
improve microcirculatory abnormalities in septic shock patients. One of the important findings 
from these studies is that the microvasculature, specifically endothelial function, is still respon-
sive in sepsis. This was demonstrated elegantly by De Backer and colleagues,(41) who found 
that sublingual topical application of acetylcholine was able to recruit microcirculatory units 
in resuscitated septic patients. The topical sublingual application of acetylcholine reversed the 
local microcirculation in septic shock patients to normal values. Spronk and colleagues(57) 
demonstrated that intravenous infusion of an NO donor (nitroglycerin) improved sublingual 
microcirculation in normovolemic, pressure-resuscitated patients. Whether such therapeutic 
approaches will improve outcome has yet to be determined. De Backer and colleagues(63) 
also tested the effect of dobutamine, used at a fixed dosage, on microcirculation of the sub-
lingual region of septic patients. Dobutamine improved sublingual microcirculatory flow, with 
acetylcholine-induced reserve being preserved. They also found that lactate levels correlated 
with the degree of microcirculatory improvement, but that microcirculatory alterations did not 
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correlate to changes in systemic hemodynamic parameters, such as cardiac output and MAP. 
These studies demonstrate that, in sepsis, microcirculatory alterations can persist, independent 
of resolving systemic hemodynamic variables, and that these alterations predict poor outcome.
Since the heterogeneous expression of iNOS is one of the factors contributing to the 
inflammation-induced autoregulatory dysfunction of microcirculatory flow, iNOS inhibition 
was hypothesized to improve microcirculatory function in sepsis. It has been demonstrated 
in several animal studies that a combined therapy of fluid and iNOS inhibitors was able to 
resuscitate weak microcirculatory units.(66) Interestingly, in a clinical study, although MAP 
improved, mortality in the group treated with non-selective iNOS inhibitors was significantly 
higher, resulting in early termination of the trial.(67) Clearly, inhibition of the harmful effects of 
nitric oxide requires a more specific approach.
Although several questions remain concerning the mode of action of activated protein C 
(APC), there is evidence that it improves the microcirculatory flow indices in experimental mod-
els.(68, 69) In humans, improvement in the microcirculatory flow observed with OPS imaging 
was reported during treatment with activated protein C (APC), which decreased after cessation 
of the APC treatment.(70) The latter finding may suggest that the timing and length of treat-
ment with APC may be an essential component in its application.
CONCLUSiONS
One of the key features of both experimental and human sepsis is the distributive alteration 
of microvascular blood flow. These distributive alterations have been demonstrated by a 
heterogeneous microvascular blood flow between different vascular beds, as has been clearly 
visualized through the use of imaging techniques as OPS and SDF. Using these techniques, 
microcirculatory alterations have been demonstrated to be associated with organ dysfunction 
and impaired outcome in sepsis. In light of the central role of microcirculatory alterations in the 
pathogenesis of sepsis, it seems logical to hypothesize that restoring microcirculatory func-
tion contributes to the treatment of sepsis. However, several questions remain unanswered. 
First, what is the clinical impact of the sublingual monitoring of microcirculation in terms of 
response to conventional therapy and clinical benefit? Second, what are the best therapeutic 
interventions to recruit microcirculation, and how do these differ from conventional therapeu-
tic modalities? Finally, will the outcome of patients with sepsis improve when microcircula-
tion is effectively resuscitated? To answer these questions, more evidence must be gathered. 
Routine investigation of microcirculation might become a key component in the functional 
hemodynamic monitoring of critically ill patients.
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ABSTrACT
The aim of this study was to evaluate short- and long-term outcome in patients undergoing 
coronary artery bypass grafting (CABG), who received an intra-aortic balloon pump (IABP) prior 
to surgery. Between January 1990 and June 2004, all patients (N=154) who received an IABP 
prior to on-pump CABG in our center were included. Patients received the IABP for vital indica-
tions (i.e. either unstable angina refractory to medical therapy or cardiogenic shock; group 1: 
n=99) or for prophylactic reasons (group 2: n=55). A Cox proportional hazards model was used 
to identify predictors of long-term all-cause mortality. Compared with the EuroSCORE predic-
tive model, observed 30-day mortality in group 1 (15.2%) was slightly higher than predicted 
(10.3%). A decrease in 30-day mortality occurred in group 2 (median predicted mortality was 
7.2% and observed was 0%). Cumulative 1-, 5-, and 6-year survival was 82.8 ± 3.8%, 70.1 ± 4.9%, 
and 67.3 ± 5.1% for group 1 versus 98.2 ± 1.8%, 84.0 ± 5.6% and 84.0 ± 5.6% for group 2 (Log-
rank: p=0.02). Logistic EuroSCORE (HR 1.03 [1.01-1.05], p=0.007) was an independent predictor 
of long-term all-cause mortality.
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iNTrODUCTiON
The main effects of intra-aortic balloon pump (IABP) counterpulsation are reduction of ven-
tricular afterload, improvement in coronary perfusion, and enhancement of subendocardial 
perfusion.(1) Several studies have supported insertion of an IABP prior to high-risk cardiac 
surgery.(2-4) In addition, preoperative insertion has been associated with lower in-hospital 
mortality rates compared to intra-operative or postoperative insertion.(5) However, data are 
lacking on long-term prognosis of patients undergoing high-risk coronary artery bypass graft-
ing (CABG), who were treated with IABP assist preoperatively. We performed a cohort study to 
address short- and long-term mortality in these patients.
MATEriALS AND METhODS
Patient inclusion and data collection
Between January 1990 and June 2004, all patients (N=154) who received an IABP prior to CABG 
in our center were included. Data were acquired from patient medical records and from the 
local hospital database. Retrospectively, the logistic European system for cardiac operative risk 
evaluation (EuroSCORE) was calculated for each patient.(6) A priori, we made the decision to 
analyze the data separately dependent on the indication for IABP counterpulsation. Ninety-
nine patients (64%) received an IABP for vital indications (cardiogenic shock or unstable angina 
refractory to pharmacological therapy; group 1). The remaining 55 patients (36%) received the 
IABP for prophylactic reasons (left ventricular ejection fraction below 40%, redo surgery, or 
complex coronary artery lesions; group 2).
intra-aortic balloon pump
All IABPs were inserted at the catheterization laboratory or intensive cardiac care unit. In all 
patients, the IABP was introduced using the Seldinger technique. Between 1990 and 1995, 
Datascope (Datascope Corp, Fairfield, NJ, USA) 10.5 and 9.5 French catheters were used. From 
1995 through 2000, Arrow (Arrow Corp, Reading, PA, USA) 9 French catheters, and between 
2000 and 2004, Arrow (Arrow Corp, Reading, PA, USA) 8 French catheters were used.
Study definitions
Left ventricular function was estimated with echocardiography performed by trained 
cardiologists. Impaired left ventricular function was defined as an ejection fraction <40% 
measured by echocardiography. Cardiogenic shock was defined as systolic blood pressure 
below 90 mmHg with clinical signs of hypoperfusion, i.e. cold extremities, oliguria or altered 
mental state. Inotropic agents used were catecholamines (dobutamine, dopamine, and/or 
norepinephrine) and phosphodiesterase inhibitors (enoximone). The following complications 
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of IABP counterpulsation were registered: leg ischemia requiring IABP removal, IABP-related 
femoral artery thrombosis, need for vascular surgery, infection, and access site bleeding requir-
ing blood transfusion. Leg ischemia was defined as a novel absence of peripheral pulsations 
together with a white coloration of the leg.
Management of surgery
In all patients, nonpulsatile cardiopulmonary bypass was established through standard median 
sternotomy with aortic root and right atrial cannulation. Surgery was performed under mild 
hypothermia (32 °C).
follow-up
Follow-up started at the day of surgery (baseline). In 2005, vital status of all patients was 
acquired from the Registry of Deaths. Median follow-up duration in the database was 5.7 years 
(range: 0-6 years). Follow-up duration was cut off at 6 years, because, after 6 years, the number 
of patients at risk decreased significantly and the risk estimates became unstable.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation. Non-normally distributed 
variables were presented as median and interquartile range. Discrete variables were noted as 
numbers and proportions. Differences between groups were tested with one-way analysis of 
variance (ANOVA), Mann-Whitney, or chi-square test, when appropriate. Cumulative incidence 
of survival was determined by Kaplan-Meier analysis with survival expressed as calculated 
probability ± standard error. Kaplan-Meier survival curves were compared by the log-rank test. 
The Cox proportional hazards model was used to identify predictors of long-term all-cause 
mortality. Multivariate Cox proportional hazards model analysis was done by entering the 
clinical characteristics that were significantly different between both groups and that showed 
the best correlation with long-term mortality in univariate analysis. Hazard ratios (HR) were 
presented together with their 95% confidence intervals. A two-tailed p-value <0.05 was con-
sidered statistically significant.
rESULTS
Clinical characteristics of the study population
Between January 1990 and June 2004, 154 consecutive patients were included in this study. 
Table 1 demonstrates the clinical characteristics of the patients, divided into indication for IABP 
therapy (group 1: “vital indication”; group 2: “prophylactic” reasons). Mean age of the patients 
was 64 ± 9 years in group 1 and 66 ± 8 years in group 2. Seventy-six percent of them were male. 
In 26 cases (17%), CABG was combined with surgery for other sequelae of coronary obstruction. 
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Logistic EuroSCORE was significantly higher in group 1 relative to group 2 (10.3 [4.7-18.8] % vs. 
7.2 [3.8-10.3] % in group 2, p=0.002).
ThirTy-DAy OUTCOME
Fifteen patients (15.2%) in group 1 and no patients (0.0%) in group 2 died in the 30 days follow-
ing surgery (group 1 vs. group 2: p=0.001). Observed mortality in group 1 was slightly higher 
Table 1. Clinical characteristics of the study population (N=154)
Group 1
“vital indication”
N=99
Group 2
“Prophylactic”
N=55 P-value
Age, yrs (mean ± SD) 64 ± 9 66 ± 8 0.18
Gender, male 75 (76%) 42 (76%) 0.99
Logistic EuroSCORE, % (median and IQR) 10.3 [4.7-18.8] 7.2 [3.8-10.3] 0.002
Preoperative CV risk factors
 Hypertension
 Current smoking
 Dyslipidemia
 Diabetes mellitus
37 (37%)
36 (36%)
42 (42%)
27 (27%)
29 (53%)
13 (24%)
26 (47%)
13 (24%)
0.09
0.15
0.61
0.70
History
 Previous MI
 Prior CABG
 Impaired LV function (EF<40%)
67 (68%)
17 (17%)
39 (39%)
36 (69%)
8 (15%)
16 (29%)
0.99
0.82
0.22
Clinical parameters
 Body mass index, kg/m2 (mean ± SD)
 Heart rate, bpm (mean ± SD)
26 ± 3
84 ± 22
26 ± 3
78 ± 15
0.75
0.08
Diagnosis
 Acute myocardial infarction
 Mechanical complication of AMI
55 (56%)
12 (12%)
19 (35%)
0 (0%)
0.02
0.005
Coronary angiography
 Three-vessel coronary disease or left main stem 
stenosis >70%
65 (66%) 46 (84%) 0.02
Preoperative treatment
 Inotropic agents for cardiogenic shock 20 (20%) 0 (0%) <0.001
Type of surgery
 Isolated CABG procedure
 CABG plus mitral valve surgery
 CABG plus LV reconstruction
 CABG plus VSR repair
76 (77%)
17 (18%)
2 (2%)
5 (5%)
52 (95%)
2 (4%)
2 (4%)
0 (0%)
0.006
0.01
0.62
0.16
Anastomoses
 >3 anastomoses 50 (53%) 42 (79%) 0.001
Complications from IABP counterpulsation
 Leg ischemia requiring IABP removal
 Arterial thrombosis requiring vascular surgery
 Thrombocytopenia
2 (2%)
1 (1%)
1 (1%)
3 (6%)
2 (4%)
0 (0%)
0.35
0.29
0.99
Data represent numbers (%) unless otherwise indicated. Abbreviations: SD, standard deviation; EuroSCORE, European system for cardiac 
operative risk evaluation; IQR, interquartile range; CV, cardiovascular; (A)MI, (acute) myocardial infarction; CABG, coronary artery bypass 
grafting; LV, left ventricular; EF, ejection fraction; VSR, ventricular septal rupture.
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than predicted by EuroSCORE (Figure 1). However, a decrease in mortality occurred in group 2: 
median predicted mortality was 7.2% and observed was 0% (Figure 1).
LONG-TErM OUTCOME
After six years of follow-up, 3% of the patients were lost. The endpoint (all-cause mortality) 
occurred in 29 (29%) patients in group 1 and in 7 (13%) patients in group 2. Kaplan-Meier esti-
mated 6-year survival was 67.3 ± 5.1% for group 1 and 84.0 ± 5.6% for group 2, p=0.02 (Figure 
2). Logistic EuroSCORE (HR 1.03 [1.01-1.05], p=0.007) was the best independent predictor of 
long-term all-cause mortality (Table 2).
Figure 1. Short-term prognosis. Observed mortality (light gray) compared with mortality predicted by the European System for Cardiac 
Operative Risk Evaluation (EuroSCORE; black). Group 1: ‘vital indication’, group 2: ‘prophylactic indication’ for intra-aortic balloon pump 
counterpulsation.
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Figure 1. Short-term prognosis.
Figure 2. Kaplan-Meier plot of long-term survival.
Figure 2. Kaplan-Meier plot of long-term survival. Long-term survival of the study population stratified to the indication for intra-aortic 
balloon pump counterpulsation (group 1: ‘vital indication’, group 2: ‘prophylactic indication’).
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Figure 1. Short-term prognosis.
Figure 2. Kaplan-Meier plot of long-term survival.
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COMPLiCATiONS Of iNTrA-AOrTiC BALLOON PUMP COUNTErPULSATiON
Overall, six patients (3.9%) developed IABP-related complications. Complications occurred in 
both groups of patients (Table 1). Five patients (3%) had symptoms of leg ischemia at the side 
where the IABP was inserted. In two of these cases, IABP removal before initiation of surgery 
was necessary. The other three patients (2%) developed signs of leg ischemia after postop-
erative removal of the IABP. This was due to common femoral artery thrombosis, requiring 
vascular surgery. In two patients, embolectomy was performed and in the third patient a iliaco-
femoro-popliteal Goretex bypass was made. These three cases of arterial thrombosis following 
IABP occurred in the time period 1991-1994. Finally, one patient experienced an episode of 
thrombocytopenia (lowest thrombocyte count 43*109/L) without signs of hemorrhage. There 
were no IABP-related access site bleedings requiring red blood cell transfusion. If performed, 
IABP tip cultures were all negative. All six patients with complications survived the first 30 days 
following surgery.
DiSCUSSiON
This is the first study reporting long-term outcome of a unique group of patients who underwent 
CABG with the use of preoperative IABP, reflecting a 15-year experience in our center. Compared 
with the EuroSCORE predictive model, we demonstrated that prophylactic intra-aortic balloon 
pump counterpulsation allowed a reduction in 30-day mortality. In both groups, a considerable 
number of patients survived until 6 years of follow-up following surgery. Logistic EuroSCORE, 
used as a continuous variable, was an independent predictor of long-term outcome.
Several studies suggested that preoperative introduction of an intra-aortic balloon pump 
may have beneficial effects on mortality in specific patient groups undergoing CABG.(4, 7) 
The low short-term event rate in our subgroup of patients treated prophylactically with IABP, 
suggests a beneficial effect of counterpulsation as well. Data on long-term survival of patients 
treated with preoperative IABP is still lacking in the current literature. In our study, consisting of 
Table 2. Correlates with long-term mortality found with Cox regression analyses (N=154).
Univariate
hr [95%Ci] P-value
Multivariate
hr [95%Ci] P-value
Age, years 0.99 [0.96-1.03] 0.65 1.00 [0.96-1.04] 0.98
Gender, male 1.47 [0.64-3.36] 0.36 1.51 [0.62-3.66] 0.37
Logistic EuroSCORE, % 1.05 [1.03-1.06] <0.001 1.03 [1.01-1.05] 0.007
Inotropic agents for cardiogenic shock 3.46 [1.66-7.18] 0.001 1.17 [0.46-2.97] 0.74
CABG plus other type of surgery 3.55 [1.80-7.02] <0.001 2.30 [0.97-5.49] 0.06
Indication of IABP (“prophylactic” relative to 
“vital indication”)
0.38 [0.17-0.87] 0.02 0.58 [0.24-1.41] 0.23
Abbreviations: HR, hazard ratio; EuroSCORE, European system for cardiac operative risk evaluation; CABG, coronary artery bypass grafting.
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a considerable number of high-risk patiens, we found that 5-year survival was 70% in unstable 
patients and 84% in patients treated prophylactically with IABP. Based on large databases of 
isolated, mainly low risk, CABG patients, recent studies have reported a 5-year probability of 
survival of about 80-90%(8, 9), which suggests that long-term survival in our study population 
was relatively favorable. Notably, the difference in long-term survival rates between group 1 
and group 2 was determined by the high 30-day mortality rate in group 1, since the Kaplan-
Meier curves ran parallel after 30 days of follow-up. Interestingly, Singh et al. reported recently 
that among survivors of STEMI complicated by cardiogenic shock, annual long-term mortality 
rates approximate those of STEMI patients without shock.(10) Our findings point out a similar 
principle in a different cohort of patients.
We used the logistic EuroSCORE, which is known to be more accurate in relatively high risk 
patients than the simple additive EuroSCORE model.(11) Other investigators have demon-
strated the predictive value of the additive EuroSCORE model as well as the logistic EuroSCORE 
model for long term all-cause mortality.(12, 13) We confirmed the independent association of 
logistic EuroSCORE and long-term outcome in patients treated with preoperative IABP.
Overall IABP-related complication rate was 3.9%, which is in line with other reports.(4, 14) 
The complications included arterial thrombosis, occurring in the years that larger catheters 
were used than nowadays. No IABP-related deaths occurred, indicating a specific area of indica-
tion for these devices before moving on to more powerful left ventricular assist devices with a 
higher complication rate.(15)
Our study has its limitations. First, we investigated a relatively small number of heteroge-
neous patients. However, we divided our population into two groups of unstable patients, who 
had a vital indication for IABP therapy and patients who were treated prophylactically. A second 
limitation is the retrospective nature of our study. However, main data could be retrieved from 
surgeon’s reports and discharge letters in our local computer database. The remaining missing 
data were all acquired from patient medical records. Third, we compared short-term mortality 
with logistic EuroSCORE, which may actually overestimate the operative risk.
In conclusion, a considerable number of patients undergoing on-pump cardiac surgery with 
preoperative IABP, survived at the long-term. Logistic EuroSCORE was an independent predic-
tor of long-term outcome. Further improving outcome in those patients who are hemodynami-
cally compromised prior to surgery remains a challenge for the future.
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ABSTrACT
Although intra-aortic balloon pump (IABP) counterpulsation is increasingly being used for the 
treatment of patients with cardiogenic shock from acute myocardial infarction, data on the 
long-term outcomes are lacking. The aim of the present study was to evaluate the 30-day and 
long-term mortality, and to identify predictors for 30-day and long-term all-cause mortality of 
patients with acute myocardial infarction complicated by cardiogenic shock who were treated 
with IABP. From January 1990 to June 2004, 300 consecutive patients treated with IABP were 
included. The mean age of the study population was 61±11 years and 79% of the patients 
were men. The survival rate until IABP removal after successful hemodynamic stabilization was 
70% (n=211). The overall cumulative 30-day survival rate was 58%. The 30-day mortality rate 
decreased over time from 52% in 1990 to 1994 to 36% in 2000 to 2004 (p for trend <0.05). Fol-
low-up ranged from 0 to 15 years. In patients who survived until IABP removal, the cumulative 
1-, 5-, and 10-year survival rate was 69%, 58% and 36%, respectively. The adjusted predictors of 
long-term mortality were arrhythmias during the intensive cardiac care unit stay (hazard ratio 
[HR] 1.8, 95% confidence interval [CI] 1.2 to 2.9) and renal failure during the intensive cardiac 
care unit stay (HR 2.5, 95% CI 1.3 to 5.1). After adjustment, treatment with primary percutane-
ous coronary intervention (HR 0.5, 95% CI 0.3-0.9) and coronary artery bypass grafting (HR 0.4, 
95% CI 0.2-0.8) were associated with lower long-term mortality. In conclusion, in patients with 
AMI complicated by cardiogenic shock treated with IABP, the 30-day survival improved with 
time and an encouraging number of patients survived in the long term.
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iNTrODUCTiON
Cardiogenic shock is a state of inadequate tissue perfusion due to cardiac dysfunction.(1) The 
incidence of cardiogenic shock complicating acute myocardial infarction (AMI) ranges from 
5% to 10%.(2) Even though the prognosis of patients with cardiogenic shock has improved 
over time because of aggressive reperfusion strategies, the in-hospital mortality rate from 
cardiogenic shock remains very high (i.e. 50%).(2, 3) Use of intra-aortic balloon pump (IABP) 
counterpulsation is associated with improved survival in patients with cardiogenic shock 
treated with thrombolysis.(4-7) Although IABP use in cardiogenic shock adjunctive to primary 
percutaneous coronary intervention (PCI) was recently questioned,(8) IABP is the method of 
first choice for mechanical assistance in patients with cardiogenic shock who do not respond 
adequately to standard pharmacologic treatment.(9) Also, long-term follow-up data of these 
patients are lacking. Therefore, the aim of the present study was to evaluate the 30-day and 
long-term outcomes and to identify predictors of 30-day mortality for patients with cardio-
genic shock treated with IABP. In addition, we evaluated the predictors of long-term mortality 
in patients who survived until IABP removal after successful hemodynamic stabilization.
METhODS
From January 1990 to June 2004, all consecutive patients (n=300) with cardiogenic shock from 
AMI who were treated with IABP at Erasmus Medical Center in Rotterdam, the Netherlands, were 
included. Our center is a tertiary referral center for PCI, mechanical treatment of cardiogenic 
shock and heart transplantation. From 1990 to 2000, about 175 patients with AMI were admit-
ted to our center annually. From 2001 to 2004, the number of admitted AMI patients increased 
to 350 annually, because primary PCI was implemented as a standard treatment of AMI, and 
our center was a referral center for primary PCI. The indication for IABP counterpulsation was 
cardiogenic shock in all cases. IABP insertion was withheld only when it was technically not 
feasible (e.g. because of severe atherosclerotic peripheral artery disease or aortic disease), or 
in patients judged to have a definite fatal prognosis because of concomitant disease, which 
concerned 21 patients during the inclusion period. The data were acquired retrospectively 
from the patient medical records and hospital database, for which a missing rate of <5% was 
considered acceptable. We performed a sub-analysis of those patients who survived until IABP 
removal after successful hemodynamic stabilization.
The IABP was inserted either at the catheterization laboratory or at the intensive cardiac 
care unit. From 1990 to 1995, Datascope (Datascope, Fairfield, NJ, USA) 9.5F and 10.5F catheters 
were used. From 1995 through 2000, Arrow (Arrow, Reading, PA, USA) 9F catheters were used, 
and from 2000 to 2004, Arrow 8F catheters were used.
Recent AMI was defined as AMI at hospital admission. In addition to clinical suspicion of AMI 
(i.e. typical chest pain and electrocardiographic abnormalities), all patients had a diagnostic 
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increase in cardiac markers during the hospitalization period. Cardiogenic shock was defined 
as low systolic blood pressure (<90 mm Hg) owing to cardiac insufficiency, with clinical signs 
of hypoperfusion (e.g., cold extremities, oliguria, altered mental state) not responsive to fluid 
resuscitation. Most patients had already received inotropic agents before the collection of 
baseline data. Blood pressure was measured just before IABP insertion (baseline). Left ventricu-
lar function (LVF) was assessed with echocardiography by trained cardiologists and categorized 
into normal (ejection fraction >40%) or impaired (ejection fraction <40%). The inotropic agents 
used in our hospital were catecholamines (dobutamine, dopamine, and/or norepinephrine) 
and phosphodiesterase inhibitors (enoximone). The anti-arrhythmic agents used in our hos-
pital were lidocaine, amiodarone, sotalol and digoxin. The following complications of IABP 
counterpulsation were registered: limb ischemia requiring IABP removal, bleeding, embolic 
and thrombotic events, need for vascular surgery, and IABP-related infection. Limb ischemia 
was defined as diminished or absent peripheral pulsation with a white coloration of the leg 
at the side of IABP catheter introduction. Major bleeding was defined as a bleeding requiring 
red blood cell transfusion. Minor bleeding was defined as any access site bleeding not requir-
ing red cell transfusion. Infection was defined as fever, combined with leukocytosis, increased 
C-reactive protein level (>5 mg/L), and signs of inflammation at the IABP insertion site, with or 
without positive blood and/or IABP-tip cultures.
Follow-up started at the day of IABP insertion (baseline). In March 2006, vital status of all 
patients was acquired from municipal civil registries with a response rate of 100%. Ten patients 
(3%) were lost during follow-up. Median follow-up duration was 6.1 years (range 0 to 15).
All data were analyzed using the Statistical Package for Social Sciences software, version 
15.0 (SPSS, Chicago, IL, USA). Continuous variables were compared using Student’s t test or 
1-way analysis of variance and are presented as the mean ± standard deviation. Nonparametric 
continuous variables were compared using the Mann-Whitney U test or Kruskal-Wallis test and 
are presented as median and range. Categorical variables were compared using the chi-square 
test or Fisher’s exact test, as appropriate, and are presented in percentages. Patients lost to 
follow-up were considered at risk until the date of last contact, at which point they were cen-
sored. Cumulative survival was estimated according to the Kaplan-Meier method. Kaplan-Meier 
survival curves were compared using the log-rank test. Univariate and multivariate logistic 
regression analyses were performed to identify predictors of 30-day all-cause mortality. Mul-
tivariate Cox proportional hazards regression analyses were performed to identify predictors 
of long-term all-cause mortality in patients who survived until IABP removal. On multivariate 
analyses, the variables of age, gender, diabetes mellitus, dyslipidemia, history, LVF, blood pres-
sure, heart rate, IABP running time, ST-elevation myocardial infarction, reperfusion therapy and 
complications during intensive cardiac care unit stay were entered into the model in a stepwise 
fashion. The final results are presented as unadjusted and adjusted odds ratios (OR), and as 
unadjusted and adjusted hazard ratios (HR), both with the associated 95% confidence intervals 
(CIs). Subanalyses were performed stratified to IABP running time (1, 2 to 5, and ≥6 days). All 
statistical tests were 2-tailed, and p <0.05 was considered statistically significant.
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rESULTS
The baseline characteristics are listed in Table 1. The mean age of the study population was 
61±11 years and 79% of the patients were male. Most patients had an ST-segment elevation 
myocardial infarction (92%). Reperfusion therapy was performed in 80% of the patients; 45% 
Table 1. Baseline and procedural characteristics (n=300).
Total (n=300)
Age (years) 61 ± 11
Gender (male) 79%
Risk factors
 Diabetes Mellitus
 Hypertension
 Smoking
 Dyslipidemia
 Peripheral arterial disease
 Renal insufficiency
20%
35%
55%
27%
9%
3%
History
 Prior cerebro-vascular accident
 Prior myocardial infarction
 Prior coronary artery bypass grafting
 Prior percutaneous coronary intervention
6%
45%
9%
7%
Systolic blood pressure (mm Hg)* 102±31
Diastolic blood pressure (mm Hg)* 63±19
Heart rate (bpm) 99±26
Impaired left ventricular function 76%
Three vessel / left main stem coronary artery disease 42%
Location of myocardial infarction
 Anterior/septal ST-elevation myocardial infarction
 Inferior/posterior ST-elevation myocardial infarction
 Non-ST-elevation myocardial infarction
57%
35%
8%
Mechanical complication of myocardial infarction 12%
Reperfusion therapy
 Primary percutaneous coronary intervention 45%
 Thrombolysis 27%
 Coronary artery bypass grafting 12%
 No reperfusion therapy 20%
Complications during stay at intensive cardiac care unit
 Cardiopulmonary resuscitation 33%
 Mechanical ventilation 56%
 Arrhythmias requiring anti-arrhythmic agents 44%
 Renal failure requiring renal replacement therapy 6%
Intra-aortic balloon pump running time
 1 day 31%
 2-5 days 49%
 ≥6 days 20%
Data are presented as mean ± SD or percentages.
* Blood pressure measured just before insertion of IABP.
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were treated with primary PCI, 27% were treated with thrombolysis, and 12% were treated 
with emergency coronary artery bypass grafting (CABG). Most patients had already received 
inotropic agents before IABP insertion (82%). Mechanical ventilation and cardiopulmonary 
Table 2. Baseline and procedural characteristics of patients who survived until removal of intra-aortic balloon pump (IABP) after successful 
hemodynamic stabilization
Total
(n=211)
iABP running 
time 1 day
(n=37)
iABP running 
time 2-5 days
(n=123)
iABP running 
time ≥6 days
(n=51)
P-value
Age (years) 60±11 61±12 60±11 59±12 0.7
Gender (male) 81% 84% 81% 80% 0.9
Risk factors
  Diabetes Mellitus
  Hypertension
  Smoking
  Dyslipidemia
  Peripheral arterial disease
  Renal insufficiency
20%
35%
56%
28%
8%
4%
16%
44%
53%
35%
9%
3%
21%
33%
56%
25%
8%
2%
22%
34%
59%
31%
7%
8%
0.8
0.5
0.9
0.4
0.9
0.1
History
  Prior cerebro-vascular accident
  Prior myocardial infarction
  Prior coronary artery bypass grafting
  Prior percutaneous coronary 
intervention
6%
43%
10%
8%
5%
41%
16%
14%
7%
38%
5%
7%
4%
55%
18%
6%
0.8
0.1
<0.05
0.4
Systolic blood pressure (mm Hg)* 105±30 114±28 104±32 100±25 0.1
Diastolic blood pressure (mm Hg)* 64±17 69±16 63±18 62±16 0.2
Heart rate (bpm) 96±27 95±28 94±28 101±22 0.3
Impaired left ventricular function 73% 50% 74% 85% <0.01
Three-vessel / left main stem coronary 
artery disease 38% 41% 38% 35% 0.9
Location of myocardial infarction
  Anterior/septal STEMI
  Inferior/posterior STEMI
  Non-STEMI
57%
36%
7%
43%
46%
11%
59%
37%
4%
63%
27%
10%
0.2
Mechanical complication of myocardial 
infarction 11% 11% 13% 8% 0.7
Reperfusion therapy
  Primary percutaneous coronary 
intervention
  Thrombolysis
  Coronary artery bypass grafting
  No reperfusion therapy
47%
30%
15%
13%
63%
23%
11%
6%
49%
30%
14%
11%
31%
37%
20%
22%
<0.05
0.4
0.4
0.1
Complications during stay at ICCU
  Cardiopulmonary resuscitation
  Mechanical ventilation
  Arrhythmias requiring anti-
arrhythmic agents
  Renal failure requiring renal 
replacement therapy
26%
51%
48%
6%
24%
38%
19%
0%
24%
51%
46%
6%
29%
59%
73%
12%
0.8
0.1
<0.001
0.1
Data are represented as mean ± SD or percentages.
* Blood pressure measured just before insertion of IABP. Abbreviations: STEMI, ST-segment myocardial infarction; ICCU, intensive cardiac care unit.
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resuscitation during the intensive cardiac care unit stay were needed in 56% and 33% respec-
tively. Arrhythmias requiring the use of anti-arrhythmic agents and renal failure requiring renal 
replacement therapy occurred in 44% and 6% of patients, respectively.
The baseline characteristics of the patients who survived until IABP removal after successful 
hemodynamic stabilization (n=211) are listed in Table 2. The IABP running time in this subgroup 
was 1 day for 18%, 2 to 5 days for 58%, and ≥6 days in 24% with a median of 3 days (range 1 to 
27). A history of CABG (p<0.05), impaired LVF (p<0.01), and arrhythmias (p<0.001) were more 
frequent in patients with IABP running time ≥6 days than in patients with an IABP running time 
of 2 to 5 days. Fewer patients with an IABP running time ≥6 days were treated with primary PCI 
(p<0.05).
The cumulative survival rate untill IABP removal after successful hemodynamic stabilization 
was 70% (n=211) and the overall cumulative 30-day survival rate was 58%. Patients who had 
an IABP for only 1 day had greater 30-day mortality than patients with an IABP running time 
of >1 day. Mortality was greatest in the first days after IABP insertion. The cumulative long-
term survival rate was 48%, 41% and 25% at respectively 1, 5 and 10 years of follow-up. The 
10-year estimated cumulative survival in 30-day survivors was 41%. The cumulative long-term 
Figure 1. Cumulative long-term survival of patients with cardiogenic shock who survived until removal of IABP after successful hemodynamic 
stabilization, stratified by IABP running time. P-value was obtained by comparing IABP running time of ≥6 days with IABP running time of 2 to 
5 days.
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Figure 1. Cumulative long-term survival of patients with cardiogenic shock who survived 
until re o al of IABP after successful hemody a ic stabilization, stratified by IABP running 
time.
Figure 2. Adjusted predictors of 30-day mortality in patients with cardiogenic shock treated 
with IABP, presented as odds ratios with associated 95% confidence intervals.
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Kaplan-Meier survival estimates of patients who survived until IABP removal after successful 
hemodynamic stabilization are shown in Figure 1. In these patients, the cumulative long-term 
survival was 69%, 58% and 36% at 1, 5 and 10 years of follow-up, respectively. Patients with 
an IABP running time of ≥6 days had significantly greater long-term mortality compared with 
patients with an IABP running time of 2 to 5 days (p<0.05).
The unadjusted predictors of 30-day and long-term mortality are listed in Table 3. The 
adjusted predictors of 30-day mortality are presented in Figure 2. On multivariate analysis, the 
adjusted predictors of 30-day mortality were age (OR 1.04, 95% CI 1.01 to 1.07), impaired LVF 
(OR 2.5, 95% CI 1.1 to 5.5), need for cardiopulmonary resuscitation (OR 2.6, 95% CI 1.4 to 4.9), 
and need for mechanical ventilation (OR 2.4, 95% CI 1.3 to 4.5). After adjustment, treatment with 
primary PCI (OR 0.1, 95% CI 0.1 to 0.3), thrombolysis (OR 0.1, 95% CI 0.0 to 0.4), and emergency 
CABG (OR 0.1, 95% CI 0.0 to 0.4) were associated with improved 30-day survival. The adjusted 
predictors of long-term mortality in patients who survived until IABP removal after successful 
Figure 2. Adjusted predictors of 30-day mortality in patients with cardiogenic shock treated with IABP, presented as odds ratios with associated 
95% confidence intervals. Abbreviations: CABG, coronary artery bypass grafting; LVF, left ventricular function; PCI, percutaneous coronary 
intervention.
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Figure 1. Cumulative long-term survival of patients with cardiogenic shock who survived 
until removal of IABP after successful hemodynamic stabilization, stratified by IABP running 
time.
Figure 2. Adjusted predictors of 30-day mortality in patients with cardiogenic shock treated 
with IABP, pr sented as odds ratios with associated 95% confid nc  intervals.
Figure 3. Adjusted predictors of long-term mortality in patients with cardiogenic shock treated with IABP, presented as hazard ratios with 
associated 95% confidence intervals. Only patients who could be successfully weaned from IABP were included in long-term Cox regression 
analysis. Variables of age, gender, diabetes mellitus, dyslipidemia, history, LVF, blood pressure, heart rate, IABP running time, period of 
hospital admission, ST-elevation myocardial infarction, reperfusion therapy, and complications during ICCU stay were entered into the model 
in a stepwise fashion. Abbreviations: CABG, coronary artery bypass grafting; ICCU, intensive cardiac care unit; PCI, percutaneous coronary 
intervention.
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Figure 3. Adjusted predictors of long-term mortality in patients with cardiogenic shock 
treated with IABP, presented as hazard ratios with associated 95% confidence intervals.
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hemodynamic stabilization are presented in Figure 3. The adjusted predictors of long-term 
mortality were arrhythmias requiring the use of anti-arrhythmic agents (HR 1.8, 95% CI 1.2 to 
2.9) and renal failure requiring renal replacement therapy during the intensive cardiac care unit 
stay (HR 2.5, 95% CI 1.3 to 5.1). Treatment with primary PCI (HR 0.5, 95% CI 0.3-0.9) and CABG 
(HR 0.4, 95% CI 0.2 to 0.8) were associated with improved survival in the long term.
Temporal trends of IABP use from 1990 to 2004 are listed in Table 4. The frequency of IABP 
insertion increased during the study period from 69 patients with cardiogenic shock in 1990 
to 1994 to 132 patients in 2000 to 2004. The frequency of primary PCI increased from 22% in 
1990 to 1994 to 65% in 2000 to 2004 (p<0.001), and thrombolytic therapy was less frequently 
administered (p<0.01). The thirty-day mortality decreased from 52% in 1990 to 1994 to 36% in 
2000 to 2004 (p for trend <0.05).
Table 3. Unadjusted predictors of 30-day and long-term mortality.
30-day mortality
(Or [95%Ci])
Long-term mortalitya
(hr [95%Ci])
Age 1.03 [1.01-1.05] 1.02 [1.00-1.04]
Male 0.7 [0.4-1.2] 1.1 [0.7-1.7]
Risk factors
 Diabetes Mellitus
 Hypertension
 Smoking
 Dyslipidemia
1.1 [0.6-1.9]
1.0 [0.6-1.8]
0.7 [0.4-1.1]
0.7 [0.4-1.2]
1.2 [0.8-1.9]
1.1 [0.7-1.7]
0.7 [0.5-1.1]
0.9 [0.6-1.4]
History
 Prior cerebrovascular accident
 Prior myocardial infarction
 Prior coronary artery bypass grafting
 Prior percutaneous coronary intervention
1.3 [0.5-3.4]
1.5 [0.9-2.4
0.8 [0.4-1.8]
0.5 [0.2-1.4]
1.8 [0.9-3.5]
1.5 [1.0-2.2]
1.8 [1.0-3.1]
1.1 [0.5-2.3]
Impaired left ventricular function 2.8 [1.5-5.2] 1.8 [1.2-2.7]
Systolic blood pressure, units of 10 mm Hg 0.9 [0.8-1.0] 1.0 [1.0-1.1]
Diastolic blood pressure, units of 10 mm Hg 0.9 [0.8-1.0] 1.0 [0.9-1.1]
Heart rate, units of 10 bpm 1.1 [1.0-1.2] 1.0 [1.0-1.1]
Hospital admission in 1995-1999b 0.6 [0.3-1.2] 0.7 [0.4-1.1]
Hospital admission in 2000-2004b 0.5 [0.3-0.9] 0.7 [0.4-1.1]
IABP running time of 1 dayc 0.8 [0.5-1.5]
IABP running time of ≥6 daysc 1.6 [1.0-2.4]
ST-elevated myocardial infarction 2.7 [1.6-2.3] 1.3 [0.6-2.9]
Reperfusion therapy
 Primary percutaneous coronary intervention
 Thrombolysis
 Coronary artery bypass grafting
0.4 [0.2-0.7]
0.2 [0.1-1.0]
0.2 [0.1-0.5]
0.7 [0.4-1.2]
0.7 [0.3-2.2]
0.5 [0.2-0.9]
Cardiopulmonary resuscitation 2.5 [1.5-4.1] 1.2 [0.8-1.8]
Mechanical ventilation 2.0 [1.3-3.2] 1.4 [0.9-2.0]
Arrhythmias requiring anti-arrhythmic agents 0.9 [0.6-1.4] 1.7 [1.2-2.6]
Renal failure requiring renal replacement therapy 1.3 [0.5-3.4] 2.7 [1.5-5.1]
a Only patients who survived until removal of IABP after successful hemodynamic stabilization were included in long-term Cox regression 
analysis.
b Relative to hospital admission in 1990-1994.
c Relative to IABP running time of 2-5 days.
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The overall incidence of IABP-related complications was 20%. Infection (9%), bleeding (6%), 
and limb ischemia (5%) were the most frequently observed complications. Limb ischemia was 
mostly transient, with either spontaneous recovery or recovery after IABP removal. However, 
vascular surgery was needed in 2 patients. Five patients had a major bleeding (at the access 
site) requiring blood transfusion. Balloon rupture of the IABP occurred in 5 patients. The num-
ber of complications decreased from 32% in 1990 to 1994 to 10% in 2000 to 2004 (p<0.001).
DiSCUSSiON
To our knowledge, this is the first study presenting the long-term follow-up of a large cohort of 
patients with cardiogenic shock from AMI, all treated with IABP counterpulsation. Despite the 
high 30-day mortality, a considerable number of patients (36%) survived until 10 years after 
successful weaning of the IABP.
The 30-day mortality rate in our study (42%) was comparable to those reported from other 
studies of patients with cardiogenic shock.(2, 4, 10, 11). The Global Utilization of Streptokinase 
and t-PA [tissue plasminogen activator] for Occluded coronary arteries (GUSTO)-I investigators 
presented the long-term outcomes of a general group of patients with AMI, of whom some had 
cardiogenic shock.(12) That study found a 10-year survival rate of 54% in 30-day survivors of 
cardiogenic shock. In the present study, we found a lower 10-year survival rate (41%) in these 
patients. However, we have to consider that not all cardiogenic shock patients in the GUSTO-I 
study were treated with IABP. Therefore, our study population might have been a higher risk 
population compared with GUSTO-I patients.
The thirty-day mortality was greatest in patients who had an IABP inserted for <1 day. This 
group mainly consisted of severely compromised patients who could not be stabilized despite 
hemodynamic support from the IABP and other treatment modalities and who did not survive 
the first day after IABP insertion. The mortality rate with the IABP in place in this group was 
Table 4. Temporal trends of intra-aortic balloon pump (IABP) use between 1990 to 2004
1990-1994
(n=69)
1995-1999
(n=99)
2000-2004
(n=132)
P-value
Age (years) 61±10 58±12 63±11 <0.01
Gender (male) 81% 75% 81% 0.8
Reperfusion therapy
 Primary PCI
 Thrombolysis
 CABG
 No reperfusion therapy
22%
31%
19%
34%
34%
37%
13%
23%
65%
18%
7%
11%
<0.001
<0.01
<0.05
<0.001
Median IABP running time (days) 3 3 2 <0.01
Any IABP related complication 32% 26% 10% <0.001
30-day mortality 52% 41% 36% <0.05
Data are expressed as mean ± SD, median or percentage. Abbreviations: PCI, primary coronary intervention; CABG, coronary artery bypass 
grafting.
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61% on the first day. In contrast, the remaining patients (39%) were in a better hemodynamic 
condition compared with the patients with an IABP running time >1 day, explaining their bet-
ter 30-day outcome. Conversely, in patients who survived until IABP removal, those who were 
treated with an IABP for ≥6 days had greater long-term mortality than patients with an IABP 
running time of 2 to 5 days. However, the IABP running time was not an independent predictor 
of long-term mortality.
The adjusted predictors of 30-day mortality were age, impaired LVF, the need for cardiopul-
monary resuscitation and the need for mechanical ventilation. Various reperfusion therapies 
(i.e., PCI, thrombolysis and CABG) were associated with lower 30-day mortality after adjust-
ment. The US National Registry of Myocardial Infarction 2 (NRMI2) investigators reported older 
age, female gender, diabetes mellitus and a history of congestive heart failure as independent 
predictors of in-hospital mortality.(11) The predictors of long-term outcomes of patients with 
cardiogenic shock treated with IABP counterpulsation have not been previously presented. For 
patients who could be successfully weaned from IABP, we found a strong correlation of arrhyth-
mias and renal failure during the intensive cardiac care unit stay and long-term mortality. In 
addition, treatment with primary PCI and CABG was beneficial in the long term.
Although the admission period was not an independent predictor of outcome, the 30-day 
survival rate improved with time. This might have been related to the implementation of early 
revascularization with primary PCI in the routine treatment of AMI complicated by cardiogenic 
shock.(13-15) Improving outcomes over time in patients with cardiogenic shock were also 
found in a recent study.(2)
The incidence of major complications was in line with the incidence reported by the Bench-
mark registry.(16) In our study, severe bleeding, major limb ischemia, and balloon leak occurred 
in 2%, 1%, and 2% respectively, compared with 0.8%, 0.9% and 1.0%, respectively, as reported 
by the Benchmark registry. The number of vascular complications decreased during the study 
period, probably because of the use of improved IABP-devices (especially, the introduction of 
smaller size catheters), as well as increased physician’s skills and experience, which has also been 
demonstrated in previous studies.(17-19) We reported an IABP-related incidence of infection of 
9%. However, this relatively high rate of infection might have been overestimated because of 
the robust definition of infection used in our study. However, in most cases, IABP-tip and/or 
blood cultures to definitely prove IABP-related infections were not available in our study.
Additional limitations of our study included the retrospective nature and that we only 
included patients who were treated with IABP. Thus, caution is urged in extrapolating these 
results to patients ineligible for IABP or those in shock but not treated with IABP. The inclusion of 
a control group with cardiogenic shock without IABP treatment was not possible because IABP 
counterpulsation has been part of the routine treatment of patients with AMI complicated by 
shock for years in our center. Hence, benefit of IABP could not be proven by our study. Recently, 
a randomized controlled trial (clinicaltrials.gov identifier: NCT00491036) has been initiated that 
will address the potential benefit of IABP in patients with cardiogenic shock.
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ABSTrACT
Aims: Studies have compared safety and efficacy of percutaneous left ventricular assist devices 
(LVADs) with intra-aortic balloon pump (IABP) counterpulsation in patients with cardiogenic 
shock. We performed a meta-analysis of controlled trials to evaluate potential benefits of per-
cutaneous LVAD on haemodynamics and 30-day survival.
Methods and results: Two independent investigators searched Medline, Embase and 
Cochrane Central Register of Controlled Trials for all controlled trials using percutaneous LVAD 
in patients with cardiogenic shock, where after data was extracted using standardized forms. 
Weighted mean differences (MD) were calculated for cardiac index (CI), mean arterial pressure 
(MAP), and pulmonary capillary wedge pressure (PCWP). Relative risks (RRs) were calculated 
for 30-day mortality, leg ischemia, bleeding and sepsis. In main analysis, trials were combined 
using inverse-variance random-effects approach. Two trials evaluated the TandemHeart and a 
recent trial used the Impella device. After device implantation, percutaneous LVAD patients had 
higher CI (MD 0.35 l/min/m2, 95% CI 0.09;0.61), higher MAP (MD 12.8 mm Hg, 95% CI 3.6;22.0), 
and lower PCWP (MD -5.3 mm Hg, 95% CI -9.4;-1.2) compared to IABP patients. Similar 30-day 
mortality (RR 1.06, 95% CI 0.68;1.66) was observed using percutaneous LVAD compared with 
IABP. No significant difference was observed in incidence of leg ischemia (RR 2.59, 95% CI 
0.75;8.97) in percutaneous LVAD patients compared with IABP patients. Bleeding (RR 2.35, 95% 
CI 1.40;3.93) was significantly more observed in TandemHeart patients compared with patients 
treated with IABP.
Conclusion: Although percutaneous LVAD provides superior hemodynamic support in 
patients with cardiogenic shock compared to IABP, the use of these more powerful devices did 
not improve early survival. These results do not yet support percutaneous LVAD as first-choice 
approach in the mechanical management of cardiogenic shock.
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iNTrODUCTiON
Cardiogenic shock is a state of inadequate tissue perfusion due to cardiac dysfunction.(1) 
Despite the fact that prognosis of patients with cardiogenic shock has improved over time 
due to aggressive reperfusion strategies, in-hospital mortality from cardiogenic shock remains 
about 50%.(2-8)
Although recent guidelines supported the use of intra-aortic balloon pump (IABP) coun-
terpulsation as method of first choice for mechanical assistance in cardiogenic shock,(1, 9) 
the efficacy of routine IABP use adjunctive to primary percutaneous coronary intervention in 
cardiogenic shock was recently questioned.(10, 11) The recent introduction of percutaneous 
left ventricular assist devices (LVADs) is very promising since these more powerful devices have 
the potential to reverse cardiogenic shock and to lower the unacceptably high short-term 
mortality rates.(12, 13) These LVADs might be a better alternative as compared to IABP in the 
mechanical treatment of cardiogenic shock.(10, 14) The TandemHeart (TandemHeart, Cardiac 
Assist, Pittsburgh, PA, USA) is a percutaneous left atrial-to-femoral arterial LVAD, driven by a 
low-speed centrifugal continuous flow pump.(15) The Impella (Impella LP2.5, Abiomed Europe 
GmbH, Aachen, Germany) LVAD is a catheter-based, impeller-driven, axial flow pump which 
pumps blood directly from the left ventricle into the ascending aorta.(13)
Several controlled trials have compared safety and efficacy of these percutaneous LVADs 
with IABP.(16-18) However, the trials were underpowered to adequately evaluate potential 
benefit on 30-day outcome. We pooled data from these trials and compared (i) differences in 
hemodynamic parameters following device implantation, (ii) 30-day mortality, and (iii) adverse 
events in patients receiving percutaneous LVAD vs. those treated with IABP. Aim of the study 
was to present an overview on the current status of percutaneous assist devices in the manage-
ment of cardiogenic shock.
METhODS
Trial inclusion
All controlled trials using percutaneous LVAD in patients with cardiogenic shock were included. 
Follow-up duration had to be at least 30 days. Using Cochrane Central Register of Controlled Tri-
als, Embase and Medline (Pubmed U.S. National Library of Medicine), we performed a literature 
search from inception to April 2009 using the following MESH terms: “heart-assist device” OR 
“shock, cardiogenic”, as well as using the terms separately as text words.(19) A methodological 
filter was used to limit the results to clinical trials in humans.(19) No language restrictions were 
used. Two investigators (J.M.C. and C.A.U.) then independently retrieved potentially eligible 
reports for evaluation. Both investigators independently examined design, patient population, 
and interventions in the reports. In case of disagreement, this was resolved in consultation 
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with a third reviewer (R.T.D.). Trials without control group and trials using surgical LVADs were 
excluded. In addition, references of included trials were checked, www.clinicaltrials.gov was 
searched, conference proceedings were checked, and experts were contacted to ensure that 
no potentially eligible studies were missed. Quality of the reports was assessed in terms of 
randomization, adequateness of sequence generation, concealment of allocation, blinding, 
and handling of patient attrition.(20, 21) Data was extracted by two independent investigators 
(J.M.C. and C.A.U.) using standardized forms.
Study outcomes
Thirty-day all-cause mortality was a priori specified as our primary clinical outcome, as this is 
the most commonly used clinical endpoint in the literature on cardiogenic shock. Secondary 
outcomes were the following prespecified haemodynamic parameters: cardiac index (CI), mean 
arterial pressure (MAP), and pulmonary capillary wedge pressure (PCWP), all measured within 
2 h after device implantation. Safety outcomes were chosen a posteriori, and included the fol-
lowing reported device-related adverse events during support: leg ischemia, major bleeding, 
and fever and/or sepsis. Based on incomplete data reported in the studies, we also evaluated 
occurrence of thrombocytopenia and haemolysis when reported.
Statistical analysis
All data were analyzed with MIX (MIX 1.7, Kitasato Clinical Research Center, Sagamihara, 
Kanagawa, Japan)(22) and SPSS (SPSS 15.0, SPSS Inc., Chicago, IL, USA) software. Categorical 
variables were presented in numbers and in percentages. Continuous variables were presented 
as mean ± standard deviation. For continuous variables published as median and interquartile 
range, the mean and standard deviation were estimated. The mean was estimated by the 
formula x = (a+2m+b) / 4 using the values of the median (m), P25 and P75 (a and b, respec-
tively).(23) The estimator sd = IQR / 1.35 was used to estimate standard deviation (sd) from the 
interquartile range (IQR).(21) Weighted mean difference (MD) was used to compare continuous 
variables and was calculated for the pooled study population. The final results were presented 
as weighted MD with the associated 95% CI. Relative risk (RR) of unadjusted 30-day mortality 
and adverse events was calculated for each study and for the pooled study population. The final 
results were presented as unadjusted RR with the associated 95% CI. Heterogeneity between 
trials, defined as variation among the results of individual trials beyond that expected from 
chance, was assessed with Cochran’s Q statistic and I2 statistic. Both inverse variance weighted 
fixed effect model as well as a random effects model were used for comparison based on MD 
and RR. Conclusions were drawn based on the random effects models. All statistical tests were 
analyzed two-tailed and a p-value of <0.05 was considered statistically significant.
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rESULTS
Three trials met our inclusion criteria and were included in this study (Figure 1). Study char-
acteristics are presented in Table 1. All three trials randomly assigned patients to treatment 
with percutaneous LVAD or IABP counterpulsation. Two randomized controlled trials compared 
the TandemHeart device with IABP,(16, 17) and one randomized controlled trial compared the 
Impella with IABP counterpulsation.(18) One trial reported adequate sequence generation,(16) 
while the other two trials omitted description of methods for sequence generation.(17, 18) 
Methods for allocation concealment were not adequately reported. Complete follow-up was 
available in all included trials.
Figure 1. Identification of trials. Abbreviation: LVAD, left ventricular assist device.
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Figure 1. Identification of trials.
Potentially eligible reports identified 
  and retrieved for evaluation (n=697)
Reports included (n=3):
Trials of TandemHeart versus intra-aortic balloon pump (n=2)
Trials of Impella versus intra-aortic balloon pump (n=1)
Reports excluded (n=694):
Reviews or pooled analyses
Observational studies
Case reports
Animal studies
No percutaneous LVAD
No control group with cardiogenic shock
Controlled by other LVAD
Table 1. Study characteristics of included trials
Thiele et al.(16) Burkhoff et al.(17) Seyfarth et al.(18)
Percutaneous LVAD used TandemHeart TandemHeart Impella LP2.5
Control IABP IABP IABP
Total number of patients 41 33 26
Setting Single-center Multi-center Two-center
Inclusion period 2000-2003 2002-2004 2004-2007
Randomization Yes Yes Yes
Sequence generation Drawing envelopes Not reported Not reported
Concealment of allocation Sealed envelopes* Not reported Not reported
Blinding Not possible Not possible Not possible
Handling of patient attrition Complete follow-up Complete follow-up Complete follow-up
* Not reported whether the envelopes were opaque and sequentially numbered.
Abbreviations: IABP, intra-aortic balloon pump; LVAD, left ventricular assist device.
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Baseline characteristics
Baseline characteristics and baseline haemodynamic parameters of patients included in 
the randomized controlled trials are presented in Table 2. In the study by Thiele et al.(16) 41 
patients with revascularized acute myocardial infarction complicated by cardiogenic shock 
were included for randomization (21 patients assigned to LVAD and 20 patients assigned to 
IABP). Burkhoff et al.(17) randomized 33 patients with cardiogenic shock caused by acute myo-
cardial infarction or decompensated chronic heart failure (19 patients assigned to LVAD and 14 
patients assigned to IABP). Seyfarth at al. (18) randomized 26 patients with acute myocardial 
infarction complicated by cardiogenic shock (13 patients assigned to LVAD and 13 patients 
assigned to IABP). In total, 100 patients were included for meta-analysis, of whom 53 patients 
were treated with LVAD and 47 patients were treated with IABP. Almost all patients were treated 
with inotropes or vasopressors, mechanical ventilation, and percutaneous coronary interven-
tion.
Table 2. Baseline characteristics
Thiele et al.(16) Burkhoff et al.(17) Seyfarth et al. (18)
LVAD (n=21) IABP (n=20) LVAD (n=19) IABP (n=14) LVAD (n=13) IABP (n=13)
Age, years ± SD 63 ± 10 66 ± 10 66 ± 14 60 ± 11 65 ± 10 67 ± 19
Male, n (%) 16 (76) 15 (75) 14 (74) 9 (64) 8 (62) 11 (85)
Hypertension, n (%) 19 (90) 15 (75) 7 (54) 9 (69)
Diabetes mellitus, n (%) 11 (52) 11 (55) 5 (39) 3 (23)
Smoking, n (%) 9 (43) 6 (30) 8 (62) 7 (54)
Hypercholesterolemia, 
n (%)
11 (52) 9 (45) 8 (62) 7 (54)
Multivesseldisease, n (%) 13 (62) 14 (70) 9 (69) 10 (77)
LVEF, % ± SD 26 ± 9 27 ± 7 19 ± 14 22 ± 9 28 ± 14 31 ± 16
AMI, n (%) 21 (100) 20 (100) 11 (58) 10 (71) 13 (100) 13 (100)
Anterior MI, n (%) 18 (86) 13 (65) 7 (54) 8 (62)
Peak creatine kinase, 
U/L ± SD
5307 ± 4297 4395 ± 3987 4067 ± 6104 4971 ± 5211
Inotropes or 
vasopressors, n (%)
21 (100) 20 (100) 19 (100) 14 (100) 11 (84) 12 (92)
Mechanical ventilation, 
n (%)
20 (95) 20 (100) 12 (92) 12 (92)
Primary PCI, n (%) 20 (95) 19 (95) 12 (92) 12 (92)
Hemodynamics
CI, l/min/m2 ± SD 1.8 ± 0.4 1.6 ± 0.5 1.8 ± 0.4 1.8 ± 0.6 1.7 ± 0.5 1.7 ± 0.6
MAP, mm Hg ± SD 62 ± 14 65 ± 13 70 ± 16 67 ± 15 78 ± 16 72 ± 17
PCWP, mm Hg ± SD 20 ± 4 26 ± 7 25 ± 8 28 ± 6 22 ± 8 22 ± 7
Abbreviations: AMI, acute myocardial infarction; CI, cardiac index; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; LVEF, left 
ventricular ejection fraction; MAP, mean arterial pressure; PCI, percutaneous coronary intervention; PCWP, pulmonary capillary wedge pressure.
Percutaneous LVAD vs. IABP in cardiogenic shock: a meta-analysis 85
haemodynamic parameters following device implantation
Haemodynamic parameters measured after device implantation as well as results obtained 
from both fixed effect models and random effects models showing the pooled MDs between 
haemodynamic parameters of LVAD patients compared with IABP patients are presented in 
Table 3. In the random effects model, patients treated with a percutaneous LVAD had higher 
CI (MD 0.35 l/min/m2, 95% CI 0.09-0.61, p<0.01), higher MAP (MD 12.8 mm Hg, 95% CI 3.6-22.0, 
p<0.01), and lower PCWP (MD -5.3 mm Hg, 95% CI -9.4 to -1.2, p<0.05) compared with patients 
treated with IABP. (Figure 2)
Table 3. Meta-analysis of outcomes
Thiele et al. Burkhoff et al. Seyfarth et al. Pooled (fixed effect 
model)
Pooled (random 
effects model)
LVAD 
(n=21)
IABP 
(n=20)
LVAD 
(n=19)
IABP 
(n=14)
LVAD 
(n=13)
IABP 
(n=13)
Mean difference 
/ Relative Risk p
Mean difference 
/ Relative Risk p
hemodynamics
CI, l/min/m2 
± SD
2.3 ± 0.6 1.8 ± 0.4 2.2 ± 0.6 2.1 ± 0.2 2.2 ± 0.6 1.8 ± 0.7 0.35 (0.14 ; 0.55) <0.001 0.35 (0.09 ; 0.61) <0.01
MAP, mm Hg 
± SD
76 ± 10 70 ± 16 91 ± 16 72 ± 12 87 ± 18 71 ± 22 12.1 (6.3 ; 17.9) <0.001 12.8 (3.6 ; 22.0) <0.01
PCWP, mm Hg 
± SD
16 ± 5 22 ± 7 16 ± 4 25 ± 3 19 ± 5 20 ± 6 -6.2 (-8.0 ; -4.3) <0.001 -5.3 (-9.4 ; -1.2) <0.05
Clinical outcome
30-day mortality, 
n (%)
9 (43) 9 (45) 9 (47) 5 (36) 6 (46) 6 (46) 1.06 (0.68 ; 1.66) 0.80 1.06 (0.68 ; 1.66) 0.80
reported adverse events
Leg ischemia, 
n (%)
7 (33) 0 (0) 4 (21) 2 (14) 1 (8) 0 (0) 2.59 (0.75 ; 8.97) 0.13 2.59 (0.75 ; 8.97) 0.13
Bleeding, n (%) 19 (90) 8 (40) 8 (42) 2 (14) 2.35 (1.40 ; 3.93) <0.01 2.35 (1.40 ; 3.93) <0.01
Fever of sepsis, 
n (%)
17 (81) 10 (50) 4 (21) 5 (36) 1.38 (0.88 ; 2.15) 0.16 1.11 (0.43 ; 2.90) 0.83
Abbreviations: CI, cardiac index; IABP, intra-aortic balloon pump; LVAD, left ventricular assist device; MAP, mean arterial pressure; PCWP, 
pulmonary capillary wedge pressure.
30-day mortality
Reported absolute 30-day all-cause mortality as well as results obtained from both fixed effect 
model and random effects model showing the relative risk are presented in Table 3. In the 
pooled study population, 24 patients (45%) treated with LVAD and 20 patients (43%) treated 
with IABP did not survive 30 days of follow-up (p=0.80). The pooled estimate of the relative risk 
revealed no significant difference in 30-day mortality using percutaneous LVAD compared with 
IABP (RR 1.06, 95% CI 0.68-1.66). (Figure 3)
Adverse events
Reported adverse events as well as results obtained from both fixed effect models and random 
effects models showing the RR are presented in Table 3. Using a random effects model, similar 
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incidence rates of leg ischemia were observed using percutaneous LVAD when compared with 
IABP (RR 2.59, 95% CI 0.75-8.97, p=0.13). (Figure 4) Bleeding (RR 2.35, 95% CI 1.40-3.93, p<0.01) 
was more frequently reported as a complication related to the TandemHeart. Furthermore, 
Thiele et al. reported that fresh frozen plasma (p<0.01) and platelets (p<0.05) were more often 
required in the TandemHeart group. However, Burkhoff et al. found no significant difference 
in thrombocytopenia, but these investigators did find a trend toward more haemolysis with 
Figure 2. Meta-analysis showing the mean difference in haemodynamic parameters with use of percutaneous left ventricular assist devices. 
Random effects models were used for meta-analysis. Weighted mean differences with 95% confidence intervals are presented on the right of 
the figure. Abbreviations: IABP, intra-aortic balloon pump; LVAD, left ventricular assist device.
9
F ure 2. Meta-analysis showing the mean differenc  in aemodynamic parameters with use 
of percutane u l ft ventricular assist d vices.
Percutaneous LVAD vs. IABP in cardiogenic shock: a meta-analysis 87
Figure 3. Meta-analysis showing the relative risk of crude 30-day mortality with use of percutaneous left ventricular assist devices. Random 
effects model was used for meta-analysis. Relative risks with 95% confidence intervals are presented on the right of the figure. Abbreviations: 
IABP, intra-aortic balloon pump; LVAD, left ventricular assist device.
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Figure 4. Meta-analysis showing the relative risk of adverse events with use of percutaneous left ventricular assist devices. Random effects 
models were used for meta-analysis. Relative risks with 95% confidence intervals are presented on the right of the figure. Abbreviations: IABP, 
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Figure 4. Meta-analysis showing the relative risk of adverse events with use of percutaneous 
left ventricular assist devices.
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higher peak values in plasma-free haemoglobin in patients treated with the Tandemheart 
(p=0.10).
No reports were found on Impella-related incidence of bleeding and fever and/or sepsis. 
However, a trend was reported for more packed red blood cells (Impella 2.6 ± 2.7 units versus 
IABP 1.2 ± 1.9 units, p=0.2) and fresh frozen plasma (Impella 1.8 ± 2.5 units versus IABP 1.0 ± 1.7 
units, p= 0.4) administered to Impella patients. Hemolysis was assessed by measurements of 
free haemoglobin, which was significantly higher in Impella patients (p<0.05).
DiSCUSSiON
This is the first meta-analysis of controlled trials comparing percutaneous LVAD with IABP, pre-
senting a survey of available data. Our main findings were that although use of percutaneous 
LVAD resulted in a better haemodynamic profile compared with IABP counterpulsation, this did 
not translate into improved 30-day survival. Moreover, patients treated with a percutaneous 
LVAD tended to have a higher incidence of leg ischemia and device-related bleeding.
The main limitation of an IABP is the lack of active cardiac support: the IABP requires a certain 
residual level of left ventricular function. As an alternative, percutaneous LVADs are promising 
devices since these provide active circulatory support. This meta-analysis indeed confirms that 
a percutaneous LVAD is a more powerful device than IABP, which is clearly reflected by a better 
haemodynamic profile after implantation.
Although both types of percutaneous LVADs improved the haemodynamic profile, it is dis-
appointing that both devices did not improve 30-day outcome when compared with current 
routine treatment including IABP. Besides, it is important to note that both percutaneous LVADs 
are currently about 10 times as expensive as an IABP catheter.
We reported similar complication rates within both types of percutaneous LVADs. However, 
it might be possible that the Impella is a safer device than the TandemHeart due to its smaller 
catheter size, potentially resulting in a lower incidence of leg ischemia or groin bleeding,(24) 
although this is not clearly demonstrated by this meta-analysis. 17 French cannulas were used 
in TandemHeart patients and 13 French sheaths were used in Impella patients, whereas most 
IABPs are currently introduced using 8 French sheaths. Although the way of vascular closure was 
not consistently reported in the trials, this could also be a factor involved in the development of 
vascular complications. Whether haemolysis is a clinically significant problem associated with 
Impella use, has to be investigated further.
Some limitations of our meta-analysis need to be acknowledged. First, we compared dif-
ferent types of percutaneous LVADs (i.e. TandemHeart and Impella) with IABP. However, there 
was no heterogeneity between TandemHeart and Impella studies in 30-day mortality and in 
most secondary study outcomes. Because the small number of trials included could possibly 
lead to a type II error of the heterogeneity test, all conclusions were based on results obtained 
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from random effects models. Second, the number of patients included in this meta-analysis 
was small. However, we included all available trials and we did not even observe a trend in a 
reduced 30-day mortality rate associated with LVAD use. The results from this meta-analysis 
suggest that potential benefit of percutaneous LVADs on 30-day survival might in fact be very 
limited. Owing to the small sample size, there is a probability of missing a clinically meaningful 
benefit if one exists (type II error).(25) However, given a total sample size of 100 patients, an 
observed p-value (α) of 0.80 and a presumed effect size of at least 10% (event rate of 45% 
in IABP patients and 40% in percutaneous LVAD patients), post-hoc analysis showed that the 
probability for type II error (β) does not exceed 12%. A third limitation was that we did not have 
access to individual patient data. It may be very well possible that subgroups of cardiogenic 
shock patients might benefit from percutaneous LVAD therapy, but we could not perform these 
analyses, also given the limited number of patients included in the currently available reports. 
A final limitation was that the included trials were not described in sufficient detail to judge 
adequateness of randomization, so that we were not able to exclude the potential risk of bias 
in these trials.
Hopefully, further technical improvements on percutaneous LVAD systems, together with 
enhanced experience with these devices, will improve prognosis of cardiogenic shock patients 
in the future. A larger, adequately powered, randomized controlled trial using the Impella device 
is necessary to provide more definite information about potential benefit on 30-day survival. 
Some investigators have shown the feasibility of introduction of surgical LVADs in patients 
with acute myocardial infarction complicated by cardiogenic shock.(26) A major problem of 
implanting a surgical LVAD includes apical cannulation in infarcted myocardium. The recent 
development of a micropump, inserted via a mini-thoracotomy and providing substantial left 
ventricular support, is very promising, but has to be investigated in larger studies and in the 
setting of cardiogenic shock.(27)
In conclusion, in patients presenting with cardiogenic shock, the use of a percutaneous 
LVAD provides superior haemodynamic support compared with the use of IABP. However, a 
better haemodynamic profile associated with percutaneous LVAD use did not result into a 
reduced 30-day mortality rate. Furthermore, a higher rate of adverse events was encountered 
by the higher invasive nature of LVAD, especially of the TandemHeart device. Larger random-
ized controlled trials using the Impella device are needed to better evaluate clinical outcome 
and adverse events. Until now, we cannot recommend to replace IABP counterpulsation by the 
more powerful percutaneous LVAD for the treatment of cardiogenic shock patients who do not 
respond sufficiently to pharmacologic therapy.
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ABSTrACT
Objective: Complications after cardiac surgery may involve multiple organ failure, which 
carries a high mortality. Development of multiple organ failure may be related to impaired 
microcirculatory perfusion as a result of systemic inflammation. Microcirculatory blood flow 
alterations have been associated with impaired outcome. We investigated whether these 
alterations occurred before, during, and after coronary artery bypass grafting.
Methods: We observed 25 consecutive patients who underwent elective coronary artery 
bypass grafting with cardiopulmonary bypass. The sublingual microcirculation was investi-
gated using Sidestream Dark Field imaging. Sidestream Dark Field imaging was performed 
before (baseline), during and after surgery. Microvascular blood flow was analyzed using a 
semi-quantitative microvascular flow index in small, medium, and large microvessels. Changes 
in microvascular flow were tested with Wilcoxon signed rank test.
results: Median microvascular flow index of medium blood vessels decreased after starting 
cardiopulmonary bypass relative to that after anesthetic induction (2.6, interquartile range 1.6-
3.0, vs 3.0, interquartile range 2.8-3.0, p=0.02). There was a trend toward decreased microvascu-
lar flow index of small and large vessels relative to baseline (p=0.08 and p=0.05, respectively). 
Decreases in microvascular flow index occurred irrespective of changes in systemic blood pres-
sure. After each patient’s return to the intensive care unit, microvascular flow index increased 
and normalized in all microvessels.
Conclusions: For the first time, sublingual microvascular blood flow alterations have been 
observed during cardiopulmonary bypass-assisted coronary artery bypass grafting.
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iNTrODUCTiON
Coronary artery bypass grafting (CABG) is a well-established treatment modality for patients 
with severe ischemic heart disease. In on-pump CABG surgery, the circulation is preserved 
with an extracorporeal cardiopulmonary bypass (CPB) device, while the heart is arrested by 
a cardioplegic solution. These days, excellent results are obtained with both on-pump and 
off-pump cardiac surgery, with low morbidity and mortality.(1) Nevertheless, cardiac surgery, 
especially CPB-assisted cardiac surgery, is associated with activation of inflammatory media-
tors and systemic inflammatory response syndrome. This inflammatory response, together 
with procedure-related formation of microemboli, may result in capillary dysfunction and 
postoperative multiple organ dysfunction.(2) Organ dysfunction after cardiac surgery is known 
to be associated with a prolonged postoperative intensive care unit stay and high 30-day and 
long-term mortalities.(3) A relationship between microcirculatory dysfunction and the degree 
of organ failure has previously been suggested in patients with sepsis.(4) In view of the inflam-
matory response induced by cardiac surgery, we investigated whether microcirculatory blood 
flow alterations occur during and after CPB-assisted cardiac surgery.
MATEriALS AND METhODS
Study design
We conducted an observational pilot study at our university hospital. Data collection was based 
on sidestream dark field (SDF) imaging and on routine measurements. The institutional ethical 
committee approved the protocol and informed consent was obtained from each patient.
Patients
Twenty-five consecutive patients scheduled for elective CABG with CPB were included. Before 
the operation, in-hospital mortality risk was predicted with the EuroSCORE.(5, 6)
Anesthesia, surgery and CPB management
Anesthesia was intravenously induced with midazolam (0.15-0.25 mg/kg), sufentanyl (1 μg/kg) 
and pancuronium bromide (0.1 mg/kg), to which an intravenous bolus of enoximone (0.25 mg/
kg) was added. Dexamethasone (1 mg/kg) was intravenously administered at the discretion of 
the attending anesthesiologist. Phenylephrine hydrochloride was given when mean arterial 
pressure was below 60 mm Hg. A 9.5F five-lumen central venous catheter (Multicath, Vygon, 
Ecouen, France) was inserted into the right internal jugular vein. A urinary bladder catheter with 
temperature measurement feature (179360CH14, Willy-Rüsch, Kernen, Germany) was inserted. 
Bladder temperature was regarded as an estimate of body core temperature. In the operating 
room, anesthesia was maintained with intravenous midazolam (0.1 mg/kg/hr) and intravenous 
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sufentanil (0.5-1.0 μg/kg/hr), to which inhalation of sevoflurane (1%-2% by volume) during the 
pre-bypass period might be added according to the discretion of the attending anesthesiolo-
gist. Nonpulsatile CPB (Stockert-Shiley Multiflow Roller Pump, Soma Technology Inc., Cheshire, 
Conn, USA) was established through a standard median sternotomy with aortic root and right 
atrial cannulation. Surgery was performed under mild hypothermia (32 ºC). After aortic cross-
clamping, antegrade ice-cold St. Thomas’ hospital cardioplegia was administered. Anticoagula-
tion was established with intravenous heparin (3-4 mg/kg) given 10 minutes before initiation 
of CPB. Target activated clotting time was 440 seconds. At the end of CPB, anticoagulation was 
antagonized with intravenous protamine sulfate (4 mg/kg). Hematocrit was kept above 0.20 
L/L. After surgery, patients were rewarmed with warm-air blankets until bladder temperature 
reached 36.5 ºC.
Macrohemodynamic monitoring
Arterial and central venous pressures were monitored invasively in all cases. Continuous car-
diac output measurements were performed in 16 of 25 patients because the PiCCO system 
was not always available. In these patients, before induction a 4F thermistor-tipped catheter 
(PV2014L50LGW, Pulsiocath, Pulsion Medical Systems, Munich, Germany) was inserted under 
local anesthesia into the left radial artery. This catheter was then connected to a monitor (PiCCO 
Plus, Pulsion Medical Systems). After calibration by transcardiopulmonary thermodilution, 
cardiac output was continuously measured.
Microcirculatory assessment and analysis
The SDF device (Microscan, Microvision Medical, Amsterdam, the Netherlands) was used to 
obtain 2-dimensional video images of microcirculatory blood flow.(7) SDF imaging is the suc-
cessor technology adapted from orthogonal polarization spectral (OPS) imaging, which was 
validated previously.(8-10) Sublingual SDF imaging and subsequent semiquantitative analysis 
were performed as reported before.(9) In short, steady video images with duration of ≥20 sec 
were obtained after gentle removal of saliva by a gauze, avoiding pressure artifacts as much as 
possible. Pressure artifacts can be noticed by an alteration of flow velocity in the vessels under 
investigation, depending on application of pressure with the tip of the probe. Video sequences 
were stored and analyzed blindly and in random order. Each SDF video clip was divided into 
four equal quadrants. Quantification of flow (0 for no flow, 1 for intermittent flow, 2 for sluggish 
flow, and 3 for continuous flow) was scored per quadrant in small (diameter 10-25 µm), medium 
(25-50 µm), and large (50-100 µm) microvessels, as applicable. This score, the microvascular 
flow index (MFI), was the sum of each quadrant’s scores divided by the number of quadrants in 
which the vessel type was visible.
The first SDF measurements were performed at the day before surgery (T0). Thereafter, 
sublingual microvascular perfusion was determined in the following measurement periods, 
successively: after anesthetic induction (T1), on nonpulsatile CPB immediately after complete 
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administration of cardioplegia (T2), postoperatively, just after admission to the intensive care 
unit (T3), and when body core temperature had reached 36.5ºC (T4).
Statistical analysis
Categorical variables are presented as absolute numbers and percentages. Global hemo-
dynamic data are presented as means ± SD. Variables that were not normally distributed, 
including MFI, are presented as medians and inter-quartile ranges (IQR, [P25-P75]). Repeated 
measures analysis of variance (r-ANOVA) and subsequent Bonferroni tests were used to test 
changes in global hemodynamic variables. Changes in MFI between time points were tested 
with Wilcoxon signed ranks test. Changes in categorized MFI (preserved vs. impaired) over time 
were tested with Cochran’s Q test. Linear correlations between macro- and microcirculatory 
parameters were calculated with Spearman’s correlation test. Mann-Whitney test was used to 
assess differences in MFI between subgroups. A two-sided p value of <0.05 was regarded as 
statistically significant.
rESULTS
Study population
Twenty-five consecutive patients undergoing elective CABG were enrolled in the study. Twenty 
of them underwent isolated CABG. Table 1 shows the patients’ characteristics. Two patients 
died. An 84-year-old man died in the intensive care unit of failure of the heart and the kidneys 
12 days after CABG and mitral valve repair. A 77-year-old man undergoing CABG, aortic valve 
replacement, and left ventricular reconstruction died in the operating room of progressive 
cardiac pump failure despite optimal treatment.
Global hemodynamics
After induction of anesthesia mean arterial pressure (MAP) decreased by about 25% (T1 vs. T0; 
p<0.001). Minimal MAP was observed after starting CPB: 63 ± 11 mm Hg versus 75 ± 17 mm Hg 
after induction (p<0.05). MAP recovered after surgery and remained stable during re-warming 
(Table 2).
The indexed flow delivered by the heart lung machine was 2.5 ± 0.3 mL/min/m2. This index 
was similar to the preoperative cardiac index measured by the PiCCO system (2.8 ± 0.6). Postop-
eratively measured cardiac index values (3.2 ± 0.7 mL/min/m2) did not differ from preoperative 
measurements (Table 2).
Central venous pressure after initiation of CPB (7 ± 4 mm Hg) did not change relative to 
the central venous pressure measured after anesthetic induction (8 ± 4 mmHg). Higher central 
venous pressure values were observed, however, after return to the intensive care unit relative 
to the situation during CPB (10 ± 2 vs 7 ± 4 mmHg, p<0.01). Large decreases in hemoglobin 
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concentration and hematocrit occurred during surgery, whereas no elevations in serum lactate 
were observed during CPB (Table 2).
Table 1. Characteristics of the study population (n=25).
Variable Count (%) or median [IQR]
Age (yrs) 65 [61-74]
Gender male 20 (80)
Preoperative cardiovascular risk factors:
Hypertension
Current smoking
Dyslipidemia
Diabetes mellitus
17 (68)
6 (24)
10 (40)
6 (24)
Logistic EuroSCORE (%) 1.5 [1.2-4.0]
Type of surgery:
Isolated CABG procedure
CABG + valve surgery
CABG + LV reconstruction procedure
CABG + valve surgery + LV reconstruction procedure
20 (80)
3 (12)
1 (4)
1 (4)
Total anastomoses:
Left ITA
Right ITA
Venous bypass
29*
10
53
CPB duration (min) 102 [94-140]
Aortic cross-clamping time (min) 65 [56-84]
Continuous variables are presented as medians [IQR]. Categorical variables are presented as numbers and percentages (%). Abbreviations: 
IQR, interquartile range; EuroSCORE, European system for Cardiac Operative Risk Evaluation; CABG, coronary artery bypass grafting; LV, left 
ventricular; ITA, internal thoracic artery; CPB, cardiopulmonary bypass. *In some cases, a single internal thoracic artery graft was used to 
prepare more than one anastomosis.
Table 2. Global and microcirculatory variables - Evolution through time.
Before surgery
(T0)
After induction
(T1)
CPB
(T2)
Arrival iCU
(T3)
Temp≥36.5°C
(T4)
Temp (ºC) 37.0 ± 0.4 36.3 ± 0.5 34.2 ± 1.0 34.9 ± 0.7 36.8 ± 0.6
HR (b/min) 69 ± 16 69 ± 12 - 78 ± 15 84 ± 14
MAP (mmHg) 101 ± 16 75 ± 17 63 ± 11 83 ± 11 80 ± 14
CVP (mm Hg) - 8 ± 4 7 ± 4 10 ± 2 13 ± 4
CI (mL/min/m2)* - 2.8 ± 0.6 2.5 ± 0.3 3.2 ± 0.7 3.1 ± 0.6
Hb (mmol/L) 8.7 ± 0.9 7.0 ± 0.9 4.7 ± 0.4 6.1 ± 0.6 6.2 ± 0.5
Ht (L/L) 0.41 ± 0.0 0.32 ± 0.0 0.22 ± 0.0 0.28 ± 0.0 0.29 ± 0.0
Lactate (mmol/L) - 1.0 ± 0.3 1.0 ± 0.3 1.2 ± 0.3 1.6 ± 0.7
MFI small 2.8 [2.0-3.0] 3.0 [3.0-3.0] 3.0 [1.3-3.0] 3.0 [3.0-3.0] 3.0 [2.9-3.0]
MFI medium 2.5 [2.0-3.0] 3.0 [2.8-3.0] 2.6 [1.6-3.0]# 3.0 [2.9-3.0] 3.0 [2.6-3.0]
MFI large 2.8 [2.8-3.0] 3.0 [2.8-3.0] 3.0 [1.7-3.0] 3.0 [3.0-3.0] 3.0 [2.9-3.0]
All data, except microvascular flow index, are presented as mean ± SD; microvascular flow index is shown as median with interquartile range. 
T0, 1day before surgery; T1, after anesthetic induction; T2, after cardioplegia on CPB; T3, arrival to intensive care unit; T4, core body temperature 
greater than 36.5°C achieved. *Cardiac index values were obtained in 16 of 25 patients. # p<0.05 versus T1.Abbreviations: Temp, body core 
temperature; HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; CI, cardiac index; Hb, hemoglobin; Ht, hematocrit; MFI, 
microvascular flow index regarding “small”, “medium” and “large” micro-vessels.
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Microcirculatory measurements
In general, sublingual SDF imaging was more difficult to perform 1 day before surgery than 
under anesthesia, as a result of movement of the tongue in the nonsedated patient. More 
pressure artifacts were therefore visible at T0. Preoperative MFIs were 2.8 [2.0-3.0], 2.5 [2.0-3.0] 
and 2.8 [2.8-3.0] for small, medium and large microvessels, respectively (Table 2). In 46% of the 
investigated patients, MFI less than 2.50 for medium microvessels was observed just after initia-
tion of nonpulsatile CPB (T2; Figure 1). This MFI was lower than the microvascular perfusion after 
anesthetic induction (T2 vs. T1, p<0.05). There was a trend toward a decrease in micro-vascular 
perfusion at T2 for small (p=0.08) and large (p=0.05) microvessels as well. Postoperative SDF 
imaging showed fast microvascular blood flow in all micro-vessels. This resulted in a high MFI 
in small (3.0 [3.0-3.0]), medium (3.0 [2.9-3.0]) and large (3.0 [3.0-3.0]) microvessels (T3; Table 
2). Postoperative MFI had risen to normal values in all microvessels relative to microvascular 
perfusion assessed during CPB (T3 vs. T2, all p<0.02; Table 2). MFI for all sizes of microvessels 
did not change after central body temperature had reached 36.5ºC (T4 vs. T3, all differences not 
significant; Table 2). Retrospectively, a large decrease in microvascular perfusion during CPB 
was observed in the patient who finally died of heart and renal failure (patient #1; Figure 2).
Figure 1. Changes in perfusion of medium sized micro-vessels over time (n=25). Bars indicate distribution of patients who had preserved 
microcirculation (defined as microvascular flow index ≥2.5, open bars) versus those who had impaired microcirculation (microvascular flow 
index <2.5, black bars). In 46% of patients, microvascular flow index less than 2.5 was seen after initiation of cardiopulmonary bypass (CPB; T2). 
T1, After anesthetic induction; T2, cardiopulmonary bypass; T3, arrival at intensive care unit; T4, body temperature greater than 36.5 ºC.
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Figure 1. Changes in perfusion of medium microvessels with time (n=25).
Figure 2. Detailed perioperative macrohemodynamic and microcirculatory parameters 
through time of 2 patients who died.Changes in microvascular perfusion in relationship to mean arterial pressure, 
lactate and preoperative risk factors
We investigated whether impaired microvascular blood flow during CPB was associated with 
simultaneous decrease in systemic perfusion pressure (ie, MAP). We plotted the change in 
MFI (T2-T1) versus change in MAP (T2-T1). No association was visible (r=0.23, correlation not 
significant).
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Two patients had a slightly elevated serum lactate concentration just after surgery: 1.9 and 
2.2 mmol/L, respectively (upper reference limit 1.7 mmol/L in our laboratory). In both patients, 
intraoperative hypoperfusion of small and medium microvessels occurred. In the first patient, 
MFIs at T2 was 2.00, 1.25, and 1.50 for small, medium and large sized blood vessels, respectively. 
In the second patient these values were 1.00, 1.75, and 1.75, respectively.
There were no significant differences in MFI during CPB regarding medium sized blood 
vessels when patients were stratified according to preoperative risk factors of hypertension 
(p=0.62), current smoking (p=0.90) and diabetes mellitus (p=0.69). Microvascular blood flow 
did not differ between patients who underwent isolated CABG and those operated for com-
bined heart disease (p=0.33).
DiSCUSSiON
For the first time, a 2-dimensional imaging technique, in this case SDF imaging, was used to 
investigate the human microcirculation during cardiac surgery. We demonstrated the feasibility 
of using SDF imaging to monitor the microcirculation at the bedside, as well as in the operat-
ing room. We found that sublingual microcirculatory flow decreased during CPB. This finding 
applied significantly to medium blood vessels. MFI recovered in the postoperative state.
Two patients died. In our opinion, the case of patient #1 is more interesting than that of 
patient #2. We think that the main cause of death in patient #2 was acute heart failure after 
Figure 2. Detailed perioperative macrohemodynamic and microcirculatory parameters through time of 2 patients who died. Both patients 
had a higher than average mortality risk. Patient #1 died in intensive care unit of multiple organ failure. Retrospectively, hypoperfusion 
of microcirculation was present after anesthetic induction as well as after initiation of cardiopulmonary bypass. In contrast, sublingual 
microcirculation was preserved in patient #2, who died in operating room of progressive cardiac failure after cessation of cardiopulmonary 
bypass.
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Figure 1. Changes in perfusion of medium microvessels with time (n=25).
Figure 2. Detailed perioperative macrohemodynamic and microcirculatory parameters 
through time of 2 patients who died.
Abbreviations: CABG, coronary artery bypass grafting; MVR, mitral valve repair; AVR, aortic valve replacement; LVR, left ventricular restoration; 
MFI, microvascular flow index for “small”, “medium”, and “large” sized micro-vessels; CPB, cardiopulmonary bypass; Temp, body temperature; HR, 
heart rate; MAP, mean arterial pressure.
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cessation of CPB (duration 360 minutes). In contrast, the microcirculation might have played an 
important role in the bad outcome of patient #1. Impaired microcirculation was also observed 
in both of the patients who had elevated postoperative lactate levels. Although all these 
patients represent only case observations, and other factors different from the microcirculation 
might have played significant roles, these examples indicate that peri-operative optimization 
of macrohemodynamic parameters (such as blood pressure) is not always sufficient to optimize 
perfusion at the microvascular level.
Several studies have reported on the use of tonometry to assess microcirculatory function 
during cardiac surgery. These studies all suggested impaired intestinal perfusion during car-
diac surgery, although it is still questionable whether a resuscitation strategy that is based on 
tonometry measurements is more beneficial than are conventional strategies that are based on 
classical indexes of perfusion.(11-13). We used a novel imaging modality in our study and the 
results are consistent with these tonometry reports. We found that the decrease in microvascu-
lar perfusion was independent of changes in systemic perfusion pressure, which is in line with 
previous experimental and clinical data in sepsis.(14-17)
Limitations
Although SDF imaging is an improved technique relative to OPS imaging, it still has its limita-
tions. Pressure artifacts hinder the analysis of the images captured from a nonsedated patient 
who moves the tongue and the adjacent sublingual area continuously. For the same reason, 
pressure artifacts thwart comparisons between images captured 1 day before surgery (T0) and 
images taken after the patient was sedated (T1 and thereafter). This phenomenon raises the 
question which measurement is the true baseline (T0 or T1). A second limitation of the tech-
nique is that it is hardly impossible to record the same selected sublingual area during different 
measurement periods, resulting in heterogeneous images of the microcirculation. Although 
quantification partially corrects for this heterogeneity, it makes off-line analysis less easy and 
emphasizes the importance of blinding the images before final quantification.
Microvascular perfusion did not decrease during CPB in all patients. The period after the 
start of CPB is an interval in which many factors influence microcirculatory function. Examples 
of these factors are the switch from pulsatile to nonpulsatile CPB blood flow, the sudden 
entrance into the circulation of the CPB priming fluid, continuous changes in hematocrit, 
cardiac manipulations by the surgeon and administration of bolus doses of vasoactive drugs. 
Interpatient differences in these factors may explain our heterogeneous results.
Clinical perspective and conclusion
The basic task of the cardiovascular system is to provide the metabolic requirements of the 
tissues. Inadequate perfusion leads to the activation of anaerobic metabolism pathways, oxy-
gen debt and tissue acidosis.(18) Conventional parameters, however, such as cardiac output, 
blood pressure, heart rate, and diuresis, are limited in predicting the state of the local organ 
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blood supply.(19) Instruments that monitor perfusion at the microvascular level are therefore 
valuable.
In conclusion, SDF imaging is a promising technique to visualize microcirculatory alterations 
at the bedside or even in the operating room. In this pilot study, a decrease in microvascular 
perfusion, not associated with a decrease in systemic perfusion pressure, was observed after 
the start of nonpulsatile CPB. Further investigations are necessary to confirm these findings 
and to discover whether the severity and duration of these changes are associated with patient 
outcome, as was previously demonstrated for sepsis.(4) A further intriguing question would be 
whether a resuscitation strategy that is based on, and monitored with, SDF imaging could be 
beneficial to reduce multiorgan failure after cardiac surgery.
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ABSTrACT
Background: In vivo videomicroscopy has been used for years to visualize subpleural alveoli 
in animal studies. This has led to a better understanding of alveolar physiology. We tested the 
hypothesis whether a novel handheld videomicroscope could be used for intraoperative detec-
tion of alveoli in surgical patients during mechanical ventilation.
Materials and Methods: Using Sidestream Dark Field imaging, we observed 6 patients (3 
adults and 3 children) who underwent elective cardiac surgery. In each patient, the tip of the 
microscope was placed on the visceral pleural surface of the left upper pulmonary lobe after 
weaning from cardiopulmonary bypass. The acquired images were converted into a digital 
signal and captured on a computer.
results: Although cardiac motion artifacts were present, visceral pleural microvascular blood 
flow could be observed in adults and infants. Subpleural cavities, i.e. alveoli, were only observed 
in infants. These alveoli were remarkably similar in dimension and structure as those identified 
previously as true alveoli in animal studies. Quantification of these alveoli demonstrated that 
mean alveolar diameter, perimeter and area increased over age among the investigated infants 
(all parameters p<0.001).
Conclusions: High-quality images of visceral pleural microvessels as well as subpleural cavities, 
reflecting superficial alveoli, could be obtained in infants. These findings create the opportu-
nity to start human intervention studies, which should investigate alveolar dynamics during 
mechanical ventilation in cardio-thoracic surgery in more detail.
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iNTrODUCTiON
Mechanical ventilation using positive end-expiratory pressure (PEEP) is frequently applied 
in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). It 
has been shown that application of PEEP can open collapsed alveoli and can maintain their 
patency.(1, 2) However, it is recognized that providing ventilatory support to ALI and ARDS 
patients might introduce ventilator-induced lung injury (VILI).(1, 3-6)
Current imaging technology is useful to investigate lung physiology and pathophysiology. 
Several imaging modalities have received attention in the recent literature: videomicroscopy, 
magnetic resonance imaging, micro-computed tomography, micro-positron emission tomog-
raphy, optical imaging, and molecular markers.(7, 8) Videomicroscopy can be used during 
mechanical ventilation of small animals.(9) Although we gained extensive knowledge and 
insights on VILI and underlying mechanisms by employing intravital videomicroscopy in animal 
models, in vivo assessment of alveolar geometry by videomicroscopy could never be done in 
humans. This was probably due to the relatively thick visceral pleura in humans with respect 
to animals. As a result of reflection and optical scattering by this membrane, image quality 
was dramatically reduced which limited the applicability of epi-illumination-based microscopic 
imaging systems. However, a recently introduced videomicroscopic technique called Side-
stream Dark Field (SDF) imaging might overcome this shortcoming of epi-illumination-based 
systems and provide high quality images of human sub-pleural alveolar structures.(10, 11)
In the present study, we investigated the feasibility of imaging sub-pleural alveoli in patients 
during cardio-thoracic surgery employing SDF imaging.
MATEriALS AND METhODS
Study design and patient management
We conducted an observational feasibility study in 6 consecutive patients who underwent 
cardiac surgery (3 infants and 3 adults). This study was performed as a sub-study of the CARdiac 
failure and the MicroCIrculation (CARMICI) study, for which approval was obtained from the insti-
tutional ethical committee.(12) All patients underwent median sternotomy and incision of the 
parietal pleura followed by cardiac surgery with assistance of a non-pulsatile cardiopulmonary 
bypass device. The lungs were ventilated in a volume-controlled mode. Respiratory frequency 
was adjusted to maintain PaCO2 between 34 and 49 Torr (4.5 and 6.5 kPa), tidal volume 8-10 
ml/kg, I/E ratio 1:2, inspiratory pause 10% and PEEP of 8 cmH2O. FiO2 was set at 60%. In infants, 
PEEP was 5 cmH2O. During the measurements, an inspiratory hold was performed, resulting in 
CPAP of 20 cmH2O.
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Microvascular and alveolar imaging
The Microscan (MicroVisionMedical, Amsterdam, the Netherlands) was used as an intravital 
microscope, employing SDF illumination, to obtain two-dimensional video images (at 25 Hz) of 
pulmonary structures. Principles of this novel technique have been described previously and are 
demonstrated in Figure 1.(10) Briefly, the SDF imaging device consists of a central light guide, 
surrounded by, but isolated from, concentrically placed light emitting diodes that stroboscopi-
cally emit green light for illumination, which results in darkly imaged red blood cells due to the 
optical absorption of (oxy)hemoglobin and lightly imaged alveolar structures due to reflection 
of the light by alveolar walls. Penetration depth of this light into the tissue is approximately 500 
μm. In contrast to epi-illumination microscopy, SDF illumination prevents capturing of reflected 
and backscattered light by the human pleural membrane (thickness less than 80 μm)(13), which 
allows imaging of sub-pleural structures. So far, SDF imaging, incorporated in a handheld device, 
has mainly been applied to investigate the microcirculation in critically ill patients in intensive 
care units.(14) The tip of the Microscan, in direct contact with the lung surface, was covered with 
a sterile disposable lens (MicroVisionMedical, Amsterdam, the Netherlands) while the rest of the 
camera was covered with a sterile camera drape (Drapex Excel, Medical Disposables Manufac-
turing Ltd., Malta). To improve microvascular and alveolar imaging, the lung surface was cleaned 
from remaining blood using isotonic saline-drenched gauzes. After the patient was weaned 
from cardiopulmonary bypass, the attending cardio-thoracic surgeon imaged the pulmonary 
surface of the left upper pulmonary lobe in three areas. The surgeon served the hand-held 
camera, which was kept perpendicularly on the lung surface through the sternotomy opening. 
Acquired images were captured on a computer, allowing offline analysis of alveolar geometry.
Figure 1. Sidestream Dark Field imaging setup.
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Figure 1. Sidestream Dark Field imaging setup. 
Figure 2. Structures observed with Sidestream Dark Field imaging.
Images were acquired using a Sidestream Dark Field (SDF) imaging device (left) and displayed on a monitor (upper right). In the SDF device 
a central light guide is surrounded by, but isolated from concentrically placed light emitting diodes that stroboscopically emit green light for 
illumination. SDF illumination prevents capturing of reflected and backscattered light by the human pleural membrane (lower right). Modified 
with permission from (23).
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image analysis
An investigator, not involved in the image acquisition, contoured the individual alveoli manu-
ally using a black line (grayscale value of zero) in Photoshop 7.0.1 (Adobe Systems Incorporated, 
San Jose, CA, USA). Subsequently, alveolar contours were isolated applying a grayscale thresh-
old in NI Vision Assistant (National Instruments Corp., Austin, TX, USA). The contours were filled 
by the use of a convex hull function, which fills up the space inside a closed polygonal chain 
(i.e., the contours). Finally, the isolated alveoli were analyzed for major and minor diameters, 
perimeter, and area. All parameters were obtained in pixel dimensions and were converted to 
µm and µm2 via calibration of the imaging setup.
Statistical analysis
Statistical analyses of alveolar diameters, perimeter, and area, were performed with SPSS 15.0 
(SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov and Shapiro-Wilk tests confirmed the normal 
distribution of the data sets. All data are presented and reported as mean ± SD. Differences 
between means were tested with one-way analysis of variance (ANOVA) followed by Bonfer-
roni’s multiple comparison test. A p-value <0.05 was considered statistically significant.
rESULTS
All patients (n=6) were non-smokers and had a normal lung function. None of the patients had 
asthma or chronic obstructive pulmonary disease in the medical history. Characteristics of the 
patients are shown in Table 1.
Table 1. Baseline characteristics of the study population.
Patient No. Age Gender Surgery
1 3 months female Repair of trunctus arteriosus
2 8 months female Closure patent foramen ovale
Closure of ventricular septal defect
Repair of double-chambered right ventricle
3 3 years female Closure of atrial septal defect
4 63 years male Coronary artery bypass grafting
5 64 years male Coronary artery bypass grafting
6 86 years female Coronary artery bypass grafting
Aortic valve replacement
Microcirculation
In children (n=3) as well as in adults (n=3), microvasculature in the visceral pleura running on 
the lung surface could be clearly observed. Panels E and F of Figure 2 show an SDF image of 
the visceral pleural microvasculature and an SDF image of adipose tissue within the thorax, 
respectively. Movement artifacts, due to cardiac contractions, hindered analysis of microvas-
cular perfusion. By adjusting the focus of the videomicroscope, sub-pleural alveoli with white 
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contours and diverse sizes were observed in infants. Microvessels were observed between 
alveolar walls and in between groups of alveoli, respectively. These observations were much 
easier in children than in adults, probably because children have a thinner visceral pleura and 
less anthracosis (i.e., the black spots in figures 4A and 4C).
Alveolar imaging
In total, 119 alveoli (Figure 2: panels A, B, and C) could be analyzed in infants (46, 51, and 22 
alveoli for patients 1, 2, and 3, respectively). All results with respect to alveolar geometry (i.e., 
major and minor alveolar diameters, alveolar perimeter, and alveolar area) measured in chil-
dren are presented in figure 3. All alveolar parameters increased with age (p<0.001; Figure 3). 
Alveolar imaging in adults was much harder than in infants. Besides alveoli also air bubbles 
were observed between the tip of the SDF device and the pleural surface (Figures 2D and 4). 
These air bubbles were very similar to alveoli and it was hard to discriminate between the two 
in still images. However, in video sequences, alveoli moved as rigid structures due to cardiac 
movement, whereas air bubbles, in contrast, deformed and moved independently from each 
other. Alveoli, on the contrary, moved due to cardiac contractions, but did not change in size 
and shape during the inspiratory hold maneuver. Air bubbles were further distinguished from 
alveoli by the fact that visceral pleural microvessels were seen below transparent air bubbles 
but these microvessels were in fact observed on top of true alveoli.
Figure 2. Structures observed with Sidestream Dark Field imaging.
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Figure 1. Sidestream Dark Field imaging setup. 
Figure 2. Structures observed with Sidestream Dark Field imaging.
SDF images of alveolar structures in patient 1, 2, and 3 (panels A, B, and C, respectively). Alveolar structures (A, B, and C) and air bubbles (D) 
are imaged very similarly. However, alveolar structures move as a rigid configuration, whereas air bubbles, in contrast, move and deform 
independently from each other due to cardiac contractions. Air bubbles were located between the tip of the SDF device and the pleural surface. 
Additionally, below the air bubbles, moving structures and flowing blood could be observed, which was not the case for the alveoli. Panel E 
shows an SDF image of the visceral pleural microvasculature. In panel F, an SDF image of adipose tissue within the thorax is shown.
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DiSCUSSiON
To the best of our knowledge, this is the first study demonstrating the feasibility of SDF illumi-
nation of the visceral pleura in living humans during cardiac surgery using a novel handheld 
microscopic technique. Moreover, we were able to observe human alveoli and to quantify 
alveolar geometry, in terms of diameter, perimeter, and area, in the three investigated infants. 
Quantitative analysis of alveolar microcirculation, however, failed due to movement artifacts. In 
Figure 3. Alveolar diameters, perimeter, and alveolar area measured in infants.
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Figure 3. Alveolar diameters, perimeter, and alveolar area measured in infants. 
Figure 4. SDF images of adult lungs.
Patient numbers correspond to the numbers listed in table 1. Ages of patients were 3 months (patient 1), 8 months (patient 2), and 3 years 
(patient 3). In total, 119 alveoli could be analyzed (46, 51, and 22 alveoli for patients 1, 2, and 3, respectively). Alveolar size increased with age 
(all figures: p<0.001). Individual comparisons are shown (***: p<0.0001, ns: non-significant). Data are presented as mean±SD.
Figure 4. Sidestream Dark Field images of adult lungs.
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Figure 3. Alveolar dia eters, perimeter, and alveolar area measured in infants. 
F gure 4. SDF images of adult lungs.
Still video frames of patient 4 (panel A), patient 5 (panel B), and patient 6 (panel C). The dark spots demonstrate pulmonary anthracosis, 
whereas the white structures depict air bubbles.
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adults, alveoli could hardly be observed due to low image quality. However, the visceral pleural 
microcirculation could be visualized, although the bronchial circulation might be less interest-
ing from a clinical point of view.
In a previous study using in vivo videomicroscopy, Carney et al. directly observed and 
quantified alveolar mechanics, defined as the changes in alveolar size throughout a ventilatory 
cycle during mechanical ventilation in normal and injured lungs.(15) The authors showed that 
normal alveoli, once recruited, did not change in size during tidal ventilation. In contrast, in 
lungs after surfactant deactivation, alveolar mechanics showed a pattern of repeated alveo-
lar collapse and expansion (RACE). Several experimental studies have indeed confirmed the 
importance of RACE, demonstrated by videomicroscopy, as a determinant of VILI and ALI/ARDS 
in the setting of animal models.(16-20)
Interestingly, the sub-pleural structures observed using SDF imaging are remarkably similar 
when compared to those observed in the above-mentioned animal studies. A great advantage 
of our technique is, however, that SDF imaging is incorporated into a clinically applicable hand-
held device. In addition, we present a method to quantify alveolar size. Standard deviation of 
alveolar diameter may reflect alveolar instability in future studies. Alveolar instability, reflected 
by increased alveolar heterogeneity, might be improved by recruitment procedures, which has 
to be investigated in before-after studies. We believe that our current preliminary study might 
initiate further research on the development and treatment of lung injury in humans as it can 
be applied to investigate alveolar mechanics during cardio-thoracic surgery.
However, our study has its limitations. Cardiac movement artifacts hindered focusing and 
analysis of the acquired images for microvascular blood flow velocities. Carney et al. solved this 
problem by lifting the animal lung off the heart, thereby eliminating cardiac motion artifacts.
(21) Moreover, the presence of anthracosis in adult patients undergoing CABG resulted in 
worse image quality in comparison with young children. Furthermore, our observations were 
made at the left upper lobe of the lung, since this part of the lungs was most easily accessible 
for the current feasibility study. However, the caudal parts of the lung are most prone to atelec-
tasis when the patient is in a supine position(22) and actually it would be more interesting to 
investigate alveolar mechanics in these basal parts of the lung. However, the caudal pulmonary 
lobes are not well accessible after median sternotomy. Finally, visualization of alveoli in adult 
patients was difficult and problems can be expected in those patients in whom the visceral 
pleural is (subclinically) thickened, e.g. in the presence of empyema. However, although this 
study describes only the application of a novel method to a small number of patients, it will 
contribute to the development of clinical studies in this subspecialty.
In conclusion, the handheld SDF imaging device can be used to investigate alveolar mechan-
ics during cardio-thoracic surgery. Further research should address optimization of the SDF 
imaging technique in this setting, primarily by eliminating cardiac motion artifacts. SDF imaging 
should be used as a microscopic imaging modality to translate knowledge on VILI and underly-
ing mechanisms, such as RACE, obtained in small and large animal models to clinical practice.
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ABSTrACT
Aim: To investigate the correlation between sublingual perfused capillary density (PCD) and 
clinical course (i.e., occurrence of organ failure and mortality) in cardiogenic shock patients.
Methods: We performed a prospective cohort study. Using Sidestream Dark Field imaging, PCD 
was measured immediately after hospital admission (T0, baseline) and at 24 hours (T1). We 
compared patients with baseline PCD ≤median (“impaired microcirculation”) with patients with 
baseline PCD >median (“preserved microcirculation”). Sequential Organ Failure Assesment 
(SOFA) scores were calculated at both time points. Kaplan-Meier cumulative 30-day survival 
analyses were performed. Univariate and multivariate logistic regression was done to identify 
predictors of 30-day mortality.
results: We investigated 104 patients (impaired PCD: n=54; preserved PCD: n=50). Patients 
with impaired PCD had less improvement in SOFA score relative to patients with preserved 
PCD (ΔSOFA 0 [-1; 2] vs. –1 [-2; 0], p= 0.03). Organ failure improved more frequently in patients 
with preserved PCD than in patients with impaired PCD (52% vs. 31%, p=0.04). Thirty-two 
patients (31%) died: 23 patients (43%) with impaired PCD vs. 9 patients (18%) with preserved 
PCD (p<0.01). After adjustment, age (OR 1.08, 95%CI [1.03-1.12]), cardiac power index (OR 0.63, 
95%CI [0.46-0.86]), and PCD (OR 0.59, 95%CI [0.43-0.80]) remained significant predictors of 
30-day outcome. Patients with impaired baseline PCD that improved at T1, had a considerable 
better prognosis relative to patients who had a persistently impaired PCD.
Conclusion: Diminished sublingual PCD, at baseline or following treatment, is associated with 
development of organ failure and is a predictor of worse outcome in cardiogenic shock.
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iNTrODUCTiON
Cardiogenic shock is the most important cause of death in patients hospitalized with acute 
myocardial infarction.(1, 2) Although in-hospital survival of cardiogenic shock is currently 
improving, 30-day mortality rates remain high.(3, 4)
It has been accepted for years that cardiogenic shock is caused by a decrease of cardiac 
output. In this classic concept of cardiogenic shock, it is obvious that normalization of hemo-
dynamic parameters is one of the main objectives in the treatment of cardiogenic shock.
(5) However, it has been shown that 45% of non-survivors of cardiogenic shock die with a 
normal cardiac index (i.e. > 2.2 L.min.m-2), indicating that optimization of macrohemodynamic 
parameters alone may fail to save the patient.(6) In line with these data, post-hoc analysis of 
data from the SHOCK-trial demonstrated that the classic notion of systemic vasoconstriction 
did not apply to all patients with cardiogenic shock. This was, furthermore, emphasized by 
enormous variability in cardiac index and systemic vascular resistance (SVR) among patients 
during cardiogenic shock, even despite application of vasopressor therapy.(7) These data have 
changed the concept of cardiogenic shock from being solely a cardiac problem into a disease 
of derangements in the entire circulatory system.(8) It is currently accepted that cardiogenic 
shock causes a systemic inflammatory response (SIRS), which is characterized by the release 
of inflammatory mediators and neurohormones as well as by alterations in tissue microvas-
culature, which may result in multiple organ failure.(9, 10) Several studies have reported that 
markers of SIRS are predictive of short-term mortality in cardiogenic shock.(11-15) However, 
mechanisms involved in the pathogenesis of multiple organ failure in cardiogenic shock 
patients are largely unknown. It has been postulated that impaired splanchnic perfusion at 
the micro-vascular level, modulated by the severity of heart failure, the degree of SIRS, and by 
the administration of vasoactive agents, might play an important role in the pathogenesis of 
multiple organ failure and the persistence of shock.(16-18)
Sublingual microcirculation is regarded a surrogate marker of splanchnic perfusion and can 
be measured at the bedside using novel imaging technology.(17, 19, 20) Aim of the current 
study was to investigate the correlation between sublingual microcirculation and outcome (i.e., 
(change in) SOFA score, occurrence of multiple organ failure and mortality) in patients with 
cardiogenic shock.
METhODS
Study design
This prospective study was conducted at the Intensive Cardiac Care Unit of the Thoraxcenter, 
Erasmus University Medical Center, the Netherlands. We included patients who were admitted 
with cardiogenic shock from all causes between May 2007 and May 2009. Cardiogenic shock 
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was defined as a cardiac index <2.2 L.min-1.m-2 and clinical signs of hypoperfusion (i.e., cold 
extremities, oliguria or altered mental state), not responsive to fluid resuscitation. Patients with 
oral bleeding were excluded from the study. The institutional ethical committee approved the 
protocol, and written informed consent was obtained from each patient or, in case of patients 
who were sedated, from a relative authorized to consent on behalf of such a patient.
hemodynamic monitoring
All patients were monitored with a radial artery catheter (arterial cannula with FloSwitch, 
Ohmeda, Swindon, UK). Seventy-three (70%) patients were monitored with a pulmonary 
artery catheter (PAC: Becton Dickinson Criticath SP5107H, Sandy, UT, USA or CCOmbo, Edwards 
Lifesciences, Saint-Prex, Switzerland). In the remaining patients, central venous pressure was 
measured via a three-lumen central venous catheter (Multicath; Laboratoires Pharmaceutiques 
Vygon, Ecouen, France), inserted into the right internal jugular vein. In these patients, cardiac 
index (CI) was calculated according to the Cuschieri formula, which shows close correlation 
with the cardiac index measured with a pulmonary artery catheter.(21)
Data collection
Data collection included central body temperature, heart rate (HR), mean arterial pressure 
(MAP), central venous pressure (CVP), pulmonary capillary wedge pressure (PCWP), mean 
pulmonary artery pressure (MPAP), cardiac index (CI), systemic vascular resistance (SVR), 
lactate level and central-venous or mixed-venous oxygen saturation (SvO2). Systemic vascular 
resistance (SVR) was calculated as (MAP-CVP)*80/cardiac output. Cardiac power index (CPI) was 
computed as mean arterial pressure*CI/451.(22) Glomerular filtration rate (GFR) was estimated 
by the Modification of Diet in Renal Disease (MDRD) equation.(23)
Microcirculatory assessment and analysis
The Sidestream Dark Field (SDF) imaging device (MicroScan; Microvision Medical, Amsterdam, 
The Netherlands) was used to obtain 2-dimensional video images of sublingual microcircula-
tory blood flow. This technique has been described previously.(24) In short, the camera emits 
green light that is absorbed by red blood cells within microvessels. In this way, red blood cells 
are used as the contrast agent to visualize sublingual blood flow in patent microvessels. This 
is the reason why oral bleeding was an exclusion criterion for the study. Per time point, 3-5 
steady video sequences of at least 20 seconds duration were obtained, stored and analyzed 
in a randomized and blinded fashion. Quantification of the images was done using dedicated 
software (Automated Vascular Analysis 3.0, MicrovisionMedical, Amsterdam, the Netherlands) 
by a blinded investigator. Perfused capillary density (PCD) was calculated by measuring total 
length of perfused capillaries divided by image area. Capillaries were regarded as perfused if 
they had either of the following flow classifications obtained by visual inspection: sluggish, 
continuous or hyperdynamic.(25, 26) Since SDF imaging enables visualization of flowing 
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intravascular erythrocytes rather than microvessel walls, an increase in PCD was regarded as 
capillary recruitment. This approach has been validated previously.(27, 28) Capillaries were 
defined as microvessels with a diameter less than 20 μm.
Study protocol
The sublingual microcirculation was investigated immediately after the patient’s admission to 
the hospital and after informed consent had been obtained (T0, baseline). Measurements were 
repeated 24 hours after the first measurement or earlier, pending the individual clinical course 
of the patient (i.e., occurrence of death within 24 hours). In addition, at both time points, all 
components of the Sequential Organ Failure Assesment (SOFA) score were calculated, with the 
exception of the central nervous system, because the majority of the patients received central 
nervous system depressant drugs at the time of evaluation.(15, 29) The total SOFA score was 
calculated by summing the subscores for each of the components (i.e. cardiac, renal, respira-
tory, coagulation, and liver).(30)
follow-up
Vital status at 30 days was registered for all patients. In patients who were transported to other 
hospitals or were discharged during the 30 days following baseline measurements, vital status 
was acquired from municipal civil registries. Response rate was 100% and no patients were lost 
during 30 days of follow-up.
Statistical analysis
Categorical variables are presented as absolute numbers with percentages. Continuous 
variables are presented as mean ± standard deviation. Non-normally distributed continuous 
variables are presented as median [interquartile range]. Because this study is the first study 
that presents PCD measurements in patients with cardiogenic shock, we decided a priori to 
compare the patients with baseline PCD ≤ median (“impaired microcirculation”) with those 
patients in whom baseline PCD was > median (“preserved microcirculation”). Categorical 
variables were compared by chi-square test or Fisher’s exact test, when appropriate. Differ-
ences between groups were tested with Student’s T-test or the Mann-Whitney test, when 
appropriate. Microcirculatory changes between time points were tested with the paired T-test. 
Correlations between variables were investigated with Pearson or Spearman correlation test, 
when appropriate. Kaplan-Meier cumulative 30-day survival was calculated and Kaplan-Meier 
survival curves were compared by the Log-rank test. Univariate and multivariate logistic regres-
sion analyses were performed to identify predictors of 30-day all-cause mortality. Final results 
are presented as unadjusted and adjusted odds ratios (OR) and 95% confidence intervals 
(95%CI). In multivariate analysis, the following baseline variables were entered into the model: 
Age, N-terminal pro B-type natriuretic peptide (NT-proBNP), cardiac power index, baseline 
SOFA score, and sublingual perfused capillary density. Log-transformation of NT-proBNP was 
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performed to achieve normality. Cardiac power index was categorized into units of 0.10 W.m-2.
(22) A p-value <0.05 was regarded statistically significant.
rESULTS
We investigated 104 patients with cardiogenic shock. Baseline characteristics of the study 
population are presented in Table 1. Mean age was 59 ± 14 years and 64% of the patients were 
male. Cardiogenic shock was most frequently resulting from acute myocardial infarction (65%). 
Patients with impaired microcirculation (n=54) had higher NT-proBNP levels than patients in 
whom microcirculation was preserved (n=50: 5924 [2657; 13,945] pg/mL vs. 3462 [1203; 8877] 
pg/mL, p=0.04, Table 1). Median baseline SOFA score was not significantly different between 
Table 1. Baseline characteristics.
All patients
(n=104)
PCD ≤ Median
(n=54)
PCD > Median
(n=50)
P-value
Age, yrs (mean ± SD) 59 ± 14 58 ± 13 60 ± 15 NS
Gender, male 67 (64%) 36 (67%) 31 (62%) NS
Etiology
 AMI
 Cardiomyopathy
 valvular heart disease
 Post cardiac surgery
68 (65%)
26 (25%)
6 (6%)
4 (4%)
36 (67%)
14 (26%)
1 (2%)
3 (6%)
32 (64%)
12 (24%)
5 (10%)
1 (2%)
NS
Cv risk factors
 Hypertension
 Diabetes mellitus
 Current smoking
 Dyslipidemia
40 (39%)
27 (26%)
21 (20%)
26 (25%)
20 (37%)
16 (30%)
12 (22%)
15 (28%)
20 (40%)
11 (22%)
9 (18%)
11 (22%)
NS
NS
NS
NS
Mechanical ventilation 68 (65%) 33 (61%) 35 (70%) NS
iABP 36 (35%) 22 (41%) 14 (28%) NS
ECMO 5 (5%) 1 (2%) 4 (8%) NS
NT-proBNP, pg/mL (median, iQr) 4347 [1691; 11,492] 5924 [2657; 13,945] 3462 [1203; 8877] 0.04
hemoglobin (mmol/L) 6.6 [5.8; 7.6] 6.6 [5.8; 7.6] 6.7 [5.9; 7.7] NS
WBC count, *109/L (median, iQr) 11.4 [8.6; 15.4] 11.3 [8.7-15.2] 11.5 [8.6-16.5] NS
CrP (mg/L)
(median, iQr)
47 [13; 131] 55 [21; 133] 38 [9; 129] NS
Gfr (ml/min) 54 [34; 78] 47 [33; 72] 59 [35; 83]
SOfA score (median, iQr)
 Total
 Cardiac
 Renal
 Respiratory
 Coagulation
 Liver
6 [4; 8]
2 [2; 3]
1 [0; 2]
2 [1; 2]
0 [0; 1]
0 [0; 1]
6 [4; 8]
2 [2; 3]
1 [0; 2]
2 [1; 2]
0 [0; 1]
0 [0; 0]
6 [4; 7]
3 [2; 3]
1 [0; 1]
2 [1; 2]
0 [0; 1]
0 [0; 1]
NS
NS
NS
NS
NS
NS
Abbreviations: SD, standard deviation; NS, non-significant; AMI, acute myocardial infarction; CV, cardiovascular; IABP, intra-aortic balloon pump; 
ECMO, extracorporeal membrane oxygenation; NT-proBNP, N-terminal proB-type natriuretic peptide; IQR, interquartile range; WBC, white blood 
cell; CRP, C-reactive protein; GFR, glomerular filtration rate; SOFA, sequential organ failure assessment.
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both groups. Patients with an impaired microcirculation had a higher PCWP (23 [19; 25] mmHg 
vs. 18 [14; 23] mmHg, p=0.03), a lower CPI (0.39 [0.28; 0.52] W.m-2 vs. 0.44 [0.34; 0.57], p=0.04) 
W.m-2 and a lower SvO2 (64 [59; 71] % vs. 69 [61; 75] %, p=0.03) than patients with a preserved 
microcirculation (Table 2).
Baseline sublingual perfused capillary density
Median PCD was 10.3 [8.8; 11.9] mm.mm-2. PCD correlated to NT-proBNP levels (ρ=-0.20, 
p=0.04), MAP (ρ=0.27, p=0.005), and PCWP (ρ=-0.26, p=0.03), but not significantly to baseline 
SOFA score or to the other baseline parameters listed in Table 2. Baseline PCD correlated to the 
SOFA score at T1 (ρ= -0.23, p=0.02) and to the change in SOFA score between T1 and T0 (ΔSOFA; 
ρ=-0.27, p=0.006). Patients with an impaired baseline microcirculation had less improvement 
in SOFA score after 24 hours as compared with patients with preserved PCD (ΔSOFA 0 [-1; 2] vs. 
–1 [-2; 0], p= 0.03). Patients with preserved PCD improved more frequently in total SOFA score 
(52% vs. 31%, p=0.04), as well as in cardiac SOFA score (50% vs. 30%, p=0.04) and renal SOFA 
score (12% vs. 2%, p=0.04), as compared to patients with impaired PCD.
Thirty-two patients (31%) died during 30 days of follow-up. Of the patients who had an 
impaired microcirculation, twenty-three (43%) died vs. 9 (18%) of the patients with preserved 
microcirculation (p=0.009, Figure 1). Sublingual PCD had a greater predictive value on 30-day 
mortality than baseline SOFA score (area under the receiver operator characteristic curve 0.71 
vs. 0.61). Age (OR 1.05, 95%CI [1.02-1.09]) was significantly associated with 30-day mortality, 
whereas CPI (OR 0.67, 95%CI [0.50-0.89]) and PCD (OR 0.68, 95%CI [0.53-0.85]) were significantly 
associated with improved 30-day survival. After adjustment, age (OR 1.08, 95%CI [1.03-1.12]), 
CPI (OR 0.63, 95%CI [0.46-0.86]), and PCD (OR 0.59, 95%CI [0.43-0.80]) remained significant 
predictors of 30-day outcome (Figure 2).
Table 2. Baseline hemodynamic parameters.
All patients
(n=104)
Microcirculation 
impaired
(n=54)
Microcirculation 
preserved
(n=50)
P-value
hr, bpm 90 [71; 104] 92 [73; 106] 89 [71; 100] NS
MAP, mmhg 69 [61; 82] 66 [59; 81] 73 [65; 83] NS
CvP, mmhg 15 [12; 18] 16 [12; 19] 14 [12; 17] NS
PCWP, mmhg* 21 [16; 24] 23 [19; 25] 18 [14; 23] 0.03
MPAP, mmhg* 28 [24; 34] 31 [25; 37] 27 [24; 31] NS
Ci, L.min-1.m-2 2.5 [2.0; 3.5] 2.4 [1.9; 3.0] 2.6 [2.0; 3.8] NS
CPi, W.m-2 0.42 [0.31; 0.55] 0.39 [0.28; 0.52] 0.44 [0.34; 0.57] 0.04
Svr, dynes.sec.cm-5 1056 [771; 1360] 1071 [735; 1369] 1045 [794; 1369] NS
SvO2, % 66 [60; 74] 64 [59; 71] 69 [61; 75] 0.03
Lactate, mmol.L-1 1.3 [1.0-2.2] 1.4 [1.0; 2.5] 1.2 [0.9; 2.2] NS
Abbreviations: HR, heart rate; NS, non-significant; MAP, mean arterial pressure; CVP, central venous pressure; PCWP, pulmonary capillary wedge 
pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index; CPI, cardiac power index; SVR, systemic vascular resistance; SvO2, central-
venous oxygen saturation.
* Data available in 73 (70%) of the patients.
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impact of changes in PCD on outcome
In 81 patients (78%), PCD measurements were repeated (T1). In the remaining patients, PCD 
measurements at T1 were not possible because of logistic reasons. Overall, PCD increased at T1 
Figure 1. Kaplan-Meier survival curve stratified according to perfused capillary density at baseline.
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Figure 3. Kaplan-Meier survival curve stratified according to perfused capillary density at baseline and after 24 hours.
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Figure 3. Kaplan-Meier survival curve stratified according to perfused capillary density at 
baseline and after 24 hours.
Low-high: Impaired microcirculation at T0, preserved microcirculation at T1 (n=20)
High-high: Preserved microcirculation at T0, preserved microcirculation at T1(n=29)
High-low: Preserved microcirculation at T0, impaired microcirculation at T1 (n=8)
Low-low: Impaired microcirculation at T0, impaired microcirculation at T1(n=24)
Abbreviation: ns, non-significant
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relative to T0 (10.3 ± 2.0 at T0 vs. 10.9 ± 2.1 at T1, p=0.03). In the total study group no significant 
correlation between changes in PCD and changes in SOFA score was found. However, patients 
who had an impaired PCD at both T0 and T1 had higher SOFA scores at T1 relative to patients 
who had a preserved PCD at both T0 and T1 (7 [4; 9] vs. 4 [3; 6], p=0.001). Survival of patients 
stratified to the level of PCD at both time points is shown in Figure 3. Patients who had an 
impaired microcirculation at baseline, which improved at T1 (“low-high”), had a considerable 
better prognosis as compared to patients who had a persistently impaired PCD (“low-low”). An 
increase in PCD was significantly associated with a better outcome (OR 0.70, 95%CI [0.54-0.92]).
DiSCUSSiON
In this study, we demonstrated a significant inverse correlation between baseline PCD and 
SOFA score after 24 hours, as well as an inverse correlation between baseline PCD and change 
in SOFA score. Patients with an impaired baseline PCD were less likely to improve in total 
SOFA score, as well as in cardiac and renal SOFA subscores. Moreover, we found that patients 
with impaired baseline PCD had a higher risk to die and that baseline PCD was strongly and 
independently associated with 30-day outcome. Finally, in a subgroup of patients in whom 
measurements were repeated, we demonstrated that patients who had an impaired PCD at 
both T0 and T1 were at high risk of adverse outcome, as opposed to those patients in whom 
microcirculation recovered at T1. In the latter patients, survival rates were similar to these of 
patients with preserved PCD at both T0 and T1.
Using a semi-quantitative analysis technique, De Backer et al. have previously described 
sublingual microcirculatory alterations in 31 patients with cardiogenic shock.(18) The authors 
reported a weak correlation of the proportion of perfused capillaries with mean arterial pres-
sure, which is in line with our findings. In this study, we also found that patients with impaired 
PCD had higher NT-proBNP levels, which has not been reported previously. In general, patients 
with impaired PCD had more severe heart failure, as demonstrated by higher NT-proBNP levels, 
higher PCWP, lower CPI and lower SvO2. Interestingly, PCD did not correlate to cardiac power 
index. The dissociation between macrocirculation (hemodynamic measurements) and micro-
circulation (perfusion) has been demonstrated previously and encourages to examine whether 
monitoring of the microcirculation has an additional prognosticating value in the management 
of cardiogenic shock patients.(31, 32)
Trzeciak et al. recently demonstrated that increased sublingual microcirculatory flow during 
resuscitation of septic shock was associated with lower SOFA scores at 24 hours.(33, 34) We did 
not find a linear correlation between changes in PCD and changes in SOFA score between T0 
and T1. Nevertheless, we demonstrated that PCD at baseline was predictive for the occurrence 
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of (multiple) organ failure. In addition, patients who had an impaired PCD at T0 as well as at T1 
had the highest SOFA scores at T1.
Hasdai and colleagues have demonstrated the predictive value of a cold, clammy skin on 
30-day mortality in patients with cardiogenic shock complicating acute myocardial infarction.
(11) In addition, De Backer et al. demonstrated that the proportion of sublingual perfused capil-
laries, measured after hospital admission, was higher in patients who survived than in patients 
who did not survive (64% vs. 43%, p<0.05).(18) Using multivariate logistic regression, in our 
(larger) study, we, furthermore, demonstrated that baseline PCD constitutes an independent 
predictor of outcome and that baseline PCD is a better predictor of outcome than baseline 
SOFA score.
These findings arise the question whether PCD can be improved, and, if so, whether such a 
strategy will be associated with improved outcome. We demonstrated recently that PCD is 
improved by pharmacologic therapy (nitroglycerin) as well as by mechanical circulatory sup-
port devices.(35, 36) The current study demonstrates that patients who had an impaired PCD 
at both time points were at a high risk of adverse outcome, as opposed to patients in whom 
microcirculation was initially impaired, but recovered at 24 hours. The latter patients actually 
had a similar prognosis relative to patients who had a preserved PCD at both time points. These 
results indeed suggest that therapies directed at improving SDF-imaging-derived sublingual 
PCD might improve outcome in patients with cardiogenic shock.
Several limitations of our study need to be acknowledged. First, not all patients received a 
pulmonary artery catheter. It is currently a clinical challenge to convince attending clinicians of 
the usefulness of this monitoring device, even in research settings.(37) However, the majority of 
the patients were monitored with a Swan-Ganz catheter. Second, PCD measurements could not 
be repeated in a minority of patients. Finally, we measured patients only after informed consent 
had been obtained. This implies that specific patients, e.g. a patient with cardiogenic shock 
from acute myocardial infarction who died at the catheterization laboratory just after hospital 
admission, could not be included.
In conclusion, sublingual PCD is associated with the development of (multiple) organ failure. 
In addition, this parameter is an independent, strong predictor of outcome. Because of the 
independent and strong association with prognosis in cardiogenic shock, assessment of sublin-
gual PCD using Sidestream Dark Field imaging should be considered as a simple non-invasive 
approach to assess outcome of patients. Single values obtained after hospital admission, might 
help in estimating the clinical course of patients with cardiogenic shock. In case of an impaired 
PCD, much effort should be put to improve not only global hemodynamics, but also micro-
vascular perfusion. Whether such a strategy will improve survival of patients with cardiogenic 
shock, should preferably be tested in a future, multi-center randomized trial.
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ABSTrACT
Cardiogenic shock (CS) may result from ischemic heart disease, cardiomyopathy, valvular heart 
disease, inflammation, myocardial contusion, and cardiac surgery. CS is the leading cause of 
in-hospital death in patients with acute myocardial infarction. Although early revascularization 
strategies have resulted in a better prognosis, in-hospital mortality from CS remains exception-
ally high. Notably, long-term annual mortality is similar in survivors of CS relative to patients 
with myocardial infarction without shock. This underlines the importance of aggressive sup-
port of the failing heart in the acute phase of CS. Because CS reflects a state of hypoperfusion 
induced by heart failure, management of CS should aim at improving cardiac function as well 
as at optimization of tissue perfusion. This review evaluates the current treatment of CS. In 
addition, novel approaches to monitor and modulate peripheral circulation at the bedside 
are highlighted. It is expected that these techniques will improve our understanding of the 
pathogenesis of CS and will offer new opportunities to guide therapy in CS patients to improve 
prognosis.
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iNTrODUCTiON
CS is the leading cause of death in patients who are admitted to the hospital with acute myocar-
dial infarction.(1) In most cases, CS develops after loss of cardiomyocyte function due to acute 
myocardial infarction. Other causes of CS include mechanical compliations of acute myocardial 
infarction, cardiomyopathy, valvular heart disease, myocarditis, myocardial contusion, and 
following cardiotomy.(2) Among other acute heart failure syndromes, CS is defined as tissue 
hypoperfusion induced by heart failure after correction of preload.(3) Although CS cannot 
easily be defined by global hemodynamic parameters, it is usually characterized by reduced 
mean arterial pressure (MAP, <60 mm Hg) due to heart failure, a low urine output (<0.5 mL/
kg/h), and a heart rate exceeding 90 bpm (Table 1). Early mortality rates of patients with CS are 
very high. However, Global Utilization of Streptokinase and TPA for Occluded coronary arter-
ies (GUSTO)-I investigators recently showed that 30-day survivors of CS had a similar annual 
long-term mortality rate (2%-4%/yr) relative to patients with ST-segment elevation myocardial 
infarction who did not have shock.(4) Similarly, at Erasmus University Medical Center, Valk et 
al. performed a cohort study of patients who received an intra-aortic balloon pump (IABP) for 
cardiogenic shock between 1990 and 2004.(5) Despite a high mortality at 30 days (32%) in 
patients who received an IABP for cardiogenic shock, Kaplan-Meier estimated 10-year survival 
was 41% for 30-day survivors of CS and annual mortality rate beyond the first year was 4.2% 
(Figure 1). This rate approximates long-term annual mortality after ST-segment elevation myo-
cardial infarction without shock.(4) Moreover, these findings demonstrate that 30-day survivors 
of cardiogenic shock have a relatively favorable prognosis, which emphasizes the importance 
of supporting the failing heart intensively in the acute phase of myocardial infarction. In this 
article, we review the current management of CS due to acute myocardial infarction and focus 
on tissue microcirculation as a novel target to improve prognosis of CS patients.
Table 1. Common hemodynamic characteristics in cardiogenic shock
Systolic blood pressure (mmHg) Low, usually <90
Cardiac index (L/min/m2) <2.2
Cardiac power output (W) Low
Pulmonary capillary wedge pressure (mmHg) >18
Diuresis Low
Hypoperfusion of end organs Yes
Abbreviation: Bpm, beats per minute. Cardiac power output is calculated as mean arterial pressure*cardiac output/451. A cardiac power output 
≤0.53 has been demonstrated to be a predictor for in-hospital mortality (c-statistic 0.69).(72)
David r. holmes Jr: “A crucial aspect in CS is the extraordinarily high early mortality; this is 
balanced however in those patients who survive the initial hospital stay out to 30 days that 
the prognosis then becomes similar to that of other patients experiencing acute myocardial 
infarction who do not have shock. An essential tenet is that we must make urgent efforts to 
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“tide” these shock patients over during the early phase of their illness so that they can have 
improved longer term outcome.”
ANATOMy AND PAThOPhySiOLOGy
Most patients (about 65%) presenting with acute myocardial infarction complicated by CS have 
3-vessel coronary artery disease on coronary angiography.(6, 7) In most cases, the left main 
coronary artery or the left anterior descending artery is identified as the culprit lesion.(8) It 
has been accepted for years that CS is caused by a decrease of cardiac output due to cardio-
myocyte dysfunction. When cardiac output, and thus systemic blood flow, acutely decreases, 
compensatory redistribution of blood volume (partly by active venoconstriction) results in a 
decrease in peripheral vascular capacitance, thereby increasing cardiac filling pressures and 
cardiac output. In the classic paradigm of CS, outlined above, the depression of cardiac output 
after acute myocardial infarction also causes intense arteriolar vasoconstriction, in response, 
resulting in elevation of systemic vascular resistance, thus increasing coronary perfusion pres-
sure.(9) (Figure 2). Normalization of hemodynamic parameters is 1 of the main objectives in the 
treatment of CS.
Figure 1. Kaplan-Meier event curve of cardiogenic shock patients treated with intra-aortic balloon pump counterpulsation – analysis of 30-day 
survivors. This curve demonstrates long-term estimated all-cause mortality of 30-day survivors of intra-aortic balloon pump counterpulsation 
(n=222). Despite the known high in-hospital mortality for CS patients treated with IABP counterpulsation, 10-year estimated survival of 30-day 
survivors was 41%. The slope of the reference line (y=0.042*x+0.14) represents a mean annual mortality rate beyond the first year of 4.2%.
17
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Figure 1. Kaplan-Meier event curve of cardiogenic shock patients treated with intra-aortic 
balloon pump counterpulsation – analysis of 30-day survivors.
Figure 2. Path physiology f car iogenic shock.
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PhArMACOLOGiC TrEATMENT Of CArDiOGENiC ShOCK
Pharmacologic treatment aims at improving symptoms and at stabilizing the hemodynamic 
condition to warrant sufficient oxygen delivery at the cellular level. To reach these objectives, 
normalization of atrial and ventricular filling pressures and optimization of cardiac index are 
important goals in the treatment of CS. The Forrester classification, based on cardiac index (CI) 
and pulmonary capillary wedge pressure (PCWP) may still be helpful to guide pharmacologic 
treatment in CS after mechanical complications have been excluded by echocardiography 
(Figure 3).(10) In general, several vasoactive pharmacologic agents can be administered after 
achievement of adequate preload, of which vasodilators (in patients with PCWP >18 mm Hg, CI 
<2.2 L/min/m2 and MAP >60 mm Hg) and inotropic agents (PCWP >18 mm Hg, CI <2.2 L/min/
m2 and MAP <60 mm Hg) are discussed below (Table 2).
vasodilators
Guidelines recommend the use of vasodilators, including nitroglycerin, nitroprusside, or nesirit-
ide, preferably instead of inotropic agents and in addition to diuretics to achieve hemodynamic 
and symptomatic improvement in patients with elevated filling pressures and a low CI.(3, 11) 
However, because CS patients have hypotension by definition and because vasodilators may 
Figure 2. Pathophysiology of cardiogenic shock. The classic notion on the pathogenesis of cardiogenic shock is shown in continuous arrows. 
Myocardial dysfunction causes a decrease in cardiac output and mean arterial pressure. An increase in afterload due to compensatory arteriolar 
vasoconstriction further contributes to myocardial dysfunction. Systemic inflammation modulates these compensation mechanisms, but may 
also (further) contribute to impaired tissue microcirculation. Copied from Reynolds and Hochman with permission of the publisher.(54)
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Figure 1. Kaplan-Meier event curve of cardiogenic shock patients treated with intra-aortic 
balloon pump counterpulsation – analysis of 30-day survivors.
Figure 2. Pathophysiology of cardiogenic shock.
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Figure 3. Forrester classification. Classification of heart failure based on the levels of cardiac index and pulmonary capillary wedge pressure 
(PCWP). The way of treatment (presented in italic) is still based on this classification. Although vasodilators are the first choice of treatment, a 
low mean arterial pressure may require administration of inotropic agents or vasopressors.
18
Figure 3. Forrester classification.
Table 2. Most important classes of intravenously administered pharmacologic agents in cardiogenic shock – Effects on hemodynamic 
parameters and human study outcomes
Ci PCWP MAP Major trials Control group Primary result
vasodilators
 Nitroglycerin ↑ ↓ ↓ - - -
 Nitroprusside ↑ ↓ ↓↓ Mullens et al. (23) Conventional 
therapy
Improvement in 
hemodynamic 
measurements ↑
All-cause mortality ↓
 Nesiritide ↑ ↓ ↓ - - -
Catecholamines
 Norepinephrine ↑/-
/↓*
↑ ↑↑ - - -
 Dopamine ↑ -/↑* ↑ Mueller(73) - Cardiac performance ↑
Myocardial oxygen 
demand ↑
 Dobutamine ↑ ↓ = Keung et al.(74)
Francis et al.(75)
Dopamine + 
nitroprusside
Dopamine
Hemodynamic benefits =
Stroke index and cardiac 
index increase ↑
PCWP increase ↓
PDE inhibitors
 Enoximone ↑ ↓ ↓ Caldicott et 
al.(76)
Dobutamine Arrhythmias ↓
 Milrinone ↑ ↓ ↓ Seino et al.(77)
Loh et al. (78)
Placebo
Nitroglycerin
CI ↑, PCWP ↓
Increase in CI ↑
Decrease in PCWP ↓
Ca2+-sensitizers
 Levosimendan ↑ ↓ ↓ SURVIVE(34)
Fuhrmann et al. 
(35)
Dobutamine
Enoximone
180-day mortality =
30-day survival ↑
Abbreviations: CI, cardiac index; PCWP, pulmonary capillary wedge pressure; MAP, mean arterial pressure; PDE, phosphodiesterase.
* Effect depends of dosage. =, equal; ↓, significantly lower or less relative to control; ↑, significantly higher or greater relative to control.
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significantly reduce mean arterial pressure, these agents are usually not indicated as mono-
therapy in the early treatment of CS.
Nitroglycerin is a nitric oxide (NO) donor that is frequently administered intravenously in 
patients with cardiogenic shock in whom arterial blood pressure has been restored.(12) At low 
dosages, nitroglycerin primarily dilates venules, resulting in a reduction in cardiac filling pres-
sures, which increases the pressure gradient for myocardial perfusion and decreases myocardial 
oxygen demand.(13, 14) At higher dosages, nitroglycerin increases cardiac output by reducing 
left and right ventricular afterload.(15) Recent studies showed that low-dose nitroglycerin, on 
top of concomitant therapy, improves tissue microcirculation in patients with shock.(16, 17) 
However, current administration of nitroglycerin is merely based on consensus than on ran-
domized trials incorporating strong endpoints such as mortality.(18) Clinical difficulties include 
nitrate resistance in heart failure patients as well as nitrate tolerance, which may develop within 
several hours after initiation of therapy.(19-21)
Sodium nitroprusside is a balanced arterial and venous vasodilator which acts by production 
of nitrosothiol in the vasculature, which in turn generates cyclic guanosine monophosphate in 
vascular smooth muscle and evokes relaxation.(22) This agent is currently only recommended 
in patients with heart failure in whom afterload is severely increased, such as hypertensive 
heart failure.(3) A recent nonrandomized study reported a beneficial effect of nitroprusside on 
in-hospital survival in patients with low-output acute heart failure(23). This promising finding 
should be confirmed in a randomized controlled trial.
Nesiritide is a novel recombinant B-type natriuretic peptide with vasodilatory effects that, in 
contrast with the United States, is not available for the European market. Several randomized 
controlled trials have reported a beneficial effect of nesiritide on hemodynamic parameters in 
patients with acute heart failure, but the agent has not been tested in CS.
inotropic agents
Inotropic agents are frequently administered as continuous infusion to patients with CS to 
improve the hemodynamic profile; more specifically to increase cardiac output, to decrease 
PCWP, and to increase MAP. If possible, these agents may be given in addition to diuretics and 
vasodilators at optimal dosages.(3) Several classes of inotropic agents exist (ie, catecholamines, 
phosphodiesterase inhibitors, and Ca2+-sensitizers). Most important agents in those classes are 
listed in Table 2.
Catecholamines stimulate cardiac beta-receptors, which increases heart rate and cardiac 
output. Some beta-sympathicomimetics have a high affinity for alfa-receptors and act as vaso-
pressors (ie, dopamine in high doses, norepinephrine, and epinephrine). Catecholamines have 
been used for years in the treatment of CS. Although catecholamines generally improve the 
hemodynamic profile and have an important role in the early stabilization of patients with CS, 
one has to realize that increased contractility induced by inotropic agents has been associated 
with increased myocardial oxygen demand and cardiac arrhythmias.(24)
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Phosphodiesterase inhibitors increase contractility by inhibiting the cAMP-specific phospho-
diesterase activity; this indirectly increases cAMP levels which, in turn, increases contractility.
(25) Phosphodiesterase inhibitors are inodilators, because they also have a vasodilator action. 
Potential benefits of phosphodiesterase inhibitors compared to catecholamines may be the 
minimal chronotropic and arrhythmogenic effects without a substantial increase in myocardial 
oxygen demand.(26, 27) An important disadvantage of this class is the relatively long half-life, 
especially in patients with renal dysfunction.
The inodilator levosimendan is a relatively new agent that also has positive lusitropic effects. 
Levosimendan may be considered in CS patients.(3) Several randomized trials have demon-
strated that levosimendan is superior to dobutamine regarding improvement of hemodynamic 
parameters and renal function in patients with CS.(28-33) Levosimendan was recently com-
pared to dobutamine in patients with acute decompensated heart failure.(34) This trial, called 
Survival of patients with acute heart failure in need of intravenous inotropic support (SURVIVE), 
failed to demonstrate a significant difference in all-cause mortality at 180 days between both 
groups. Because CS patients were not included in the SURVIVE trial, a recent small single-center 
trial compared levosimendan with enoximone added to current therapy (i.e. revascularization, 
IABP, and other inotropes) in 32 patients with refractory CS.(35) Survival rate at 30 days was 
significantly higher in the levosimendan-treated group compared with the enoximone group 
(69% vs. 37%, p=0.02). In view of the negative results from SURVIVE and bearing in mind that 
a randomized head-to-head comparison of vasoactive drugs in critically ill patients with small 
case numbers in both groups remains a great challenge, final conclusions from this study have 
to be drawn very carefully. The promising findings should be confirmed in a larger, preferably 
multi-center study.
MEChANiCAL SUPPOrT Of ThE fAiLiNG hEArT
IABP counterpulsation has become an important component of the treatment of patients 
with CS who do not respond adequately to standard treatment.(3) However, the efficacy of 
IABP counterpulsation in patients with CS has not been evaluated in an adequately powered 
randomized controlled trial. Evidence for its efficacy was mainly derived from either post-hoc 
analyses of randomized trials, which investigated revascularization strategies, or from registries. 
First, post-hoc analysis of the GUSTO-I-database demonstrated that unadjusted 1-year mortal-
ity in patients presenting with CS treated with IABP counterpulsation was lower as compared 
to those who did not receive an IABP (57% vs. 67%, respectively, p=0.04).(36) However, IABP-
patients were significantly more treated with either percutaneous coronary intervention (PCI) 
or coronary artery bypass grafting (CABG), which hinders interpretation of the results. Second, 
Sanborn et al. used the data from the Should we emergently revascularize occluded coronaries 
for cardiogenic shock (SHOCK)-trial registry to investigate whether patients treated with IABP 
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and thrombolytic therapy had a lower mortality compared to patients who were treated with 
thrombolytic therapy alone.(37) More than 800 CS patients were evaluated in this study and it 
was found that those selected for IABP had lower in-hospital mortality than those who did not 
receive IABP (50% vs. 72%, respectively, p<0.0001). In addition, patients who received IABP and 
thrombolytic therapy had lower in-hospital mortality (47%) than those receiving IABP alone 
(52%), only thrombolytic therapy (63%), or neither (77%, p<0.0001). However, once again, 
revascularization rates were higher in patients treated with IABP, which might have biased 
the better outcome. Finally, National Registry of Myocardial Infarction (NRMI) investigators 
reported outcomes of 23,180 CS patients.(38) IABP was used in 7,268 (31%) patients. Treat-
ment with IABP was associated with a significant reduction in in-hospital mortality rates in 
patients who received thrombolytic therapy (67% vs. 49%). After multivariate analysis, IABP use 
remained significantly associated with in-hospital survival (OR 0.82; 95% CI 0.72-0.93). However, 
IABP use was not associated with any mortality benefit in patients treated with primary angio-
plasty. Recent guidelines advised IABP counterpulsation in each patient with cardiogenic shock 
caused by an acute coronary syndrome (class of recommendation I, level of evidence C).(3)
Besides IABP support, ventricular-assist devices (VADs) can be considered in patients with 
CS refractory to standard therapy.(3) However, emergency surgical left ventricular-assist device 
(LVAD) placement in CS patients has been associated with significant morbidity and mortality.
(39) Recently, percutaneous ventricular assist devices (PVAD) have become available that can be 
used as a bridge to surgical LVAD and/or heart transplantation in selected cases. Idelchik et al. 
treated 18 patients in severe refractory CS with a TandemHeart (CardiacAssist, Inc. Pittsburgh, 
PA) PVAD.(40) Fourteen of these patients were successfully bridged to LVAD or heart trans-
plantation. Mortality rate was 27% at 30 days and 33% at 6 months. Two randomized studies 
have compared the TandemHeart with IABP counterpulsation. Burkhoff et al. randomized 42 
patients and found no difference in overall 30-day survival and severe adverse events, despite 
a significant improvement of hemodynamic parameters in the TandemHeart group.(41) Thiele 
et al. randomized 41 patients with CS to either IABP or TandemHeart support. Although it was 
observed that cardiac power index (the primary outcome measure) was higher in the VAD group, 
TandemHeart support was associated with a higher complication rate, whereas 30-day mortal-
ity was similar (45% in IABP group and 43% in VAD group).(42) A second promising PVAD is the 
Impella (Abiomed Europe, Aachen, Germany) device, which efficacy in CS has to be investigated 
more comprehensively.(43) In summary, results from VAD studies are encouraging, but larger-
scale studies are required to assess the effects of improved hemodynamics by VADs on survival.
David r. holmes Jr: “Given the urgent need to support patients with cardiogenic shock early 
on, it has been somewhat puzzling that newer devices that provide better hemodynamic sup-
port have not impacted on the outcome. As the authors point out, however, the number of 
patients studied to date has been rather meager. In addition, these devices may have associ-
ated unique complications, which could offset a small improvement in mortality.”
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ThE iMPOrTANCE Of EArLy rEvASCULArizATiON ThErAPy iN MyOCArDiAL 
iNfArCTiON COMPLiCATED By ShOCK
Because the most important cause of CS is acute myocardial infarction, it has been suggested 
that early revascularization, using percutaneous coronary intervention (PCI) or coronary artery 
bypass graft (CABG) surgery, could improve survival in patients with acute myocardial infarc-
tion complicated by cardiogenic shock. This hypothesis was tested in the landmark SHOCK 
trial that prospectively included 302 patients who developed CS within 36 hours or less after 
acute myocardial infarction. Patients were randomized to initial medical stabilization versus 
coronary revascularization with PCI or CABG within 6 hours after randomization. Although early 
revascularization did not significantly reduce all-cause mortality at 30 days, improved survival 
was observed after six months as well as during long-term (six years) follow-up.(6, 44) The 
benefit on survival was also reported for patients with CS who were immediately transferred to 
hospitals with emergency revascularization capability.(45) In addition to these data, the afore-
mentioned NRMI survey included 25,311 CS patients and demonstrated that primary PCI was 
associated with decreased odds of death during hospitalization (OR 0.46; 95%CI 0.40-0.53).(46) 
Accordingly, revascularization by emergency PCI or CABG is advised in the current guidelines 
for patients with an acute coronary syndrome complicated by cardiogenic shock.(3, 47)
Revascularization in the multicenter SHOCK trial could be percutaneous or surgical, deter-
mined by site investigators. One-year survival was similar in PCI-treated patients compared to 
patients who underwent CABG.(48) However, in clinical practice, more than 60% of patients 
with an acute coronary syndrome complicated by CS are currently treated with PCI, which is 
a rapid procedure, whereas CABG is performed in less than 5% of the cases.(49) Patients with 
mechanical complications of acute myocardial infarction should immediately undergo surgery, 
but it is currently unclear whether CABG is better than PCI in patients with three-vessel or left 
main stem coronary artery disease.
David r. holmes Jr: “The issue of early revascularization therapy is well explored by the authors. 
It is of interest that the primary endpoint of the SHOCK trial was indeed negative. It was not 
until later outcomes were tabulated that survival was found to be improved with revasculariza-
tion. Certainly, revascularization is a mainstay of therapy for these patients.”
ShOrT-TErM MOrTALiTy iN CArDiOGENiC ShOCK rEMAiNS 
ExCEPTiONALLy hiGh
Although early revascularization has contributed to an improved prognosis of CS patients in 
the last decade, in-hospital mortality remains over 50% in most studies.(50) NRMI data dem-
onstrated that all-cause in-hospital mortality in CS patients decreased from 60.3% in the year 
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1995 to 47.9% in the year 2004 (p<0.001).(46) Using the SHOCK trial registry, Fincke et al. found 
that cardiac power output and cardiac power index were the most important independent 
hemodynamic correlates of in-hospital mortality.(51)
ThE PAThOPhySiOLOGy Of CArDiOGENiC ShOCK ALSO iNvOLvES BLOOD 
vESSELS
It has been accepted for years that CS is caused by a decrease of cardiac output. In this classic 
concept of CS, it is obvious that normalization of hemodynamic parameters is one of the main 
objectives in the treatment of CS. However, it has been shown that 45% of nonsurvivors of CS 
die with a normal cardiac index (ie, >2.2 L/min/m2), indicating that optimization of macrohe-
modynamic parameters alone may fail to save the patient.(52) In line with these data, post-hoc 
analysis of data from the SHOCK-trial demonstrated that the classic notion of systemic vaso-
constriction did not apply to all patients with CS, as demonstrated by a enormous variability in 
CI and systemic vascular resistance among patients, with median systemic vascular resistance 
during CS in the normal range, even despite vasopressor therapy.(53) These data have changed 
the concept of CS from being only a cardiac problem into a disease of derangements in the 
entire circulatory system.(54) It is currently accepted that myocardial infarction and heart 
failure can cause the systemic inflammatory response syndrome (SIRS), which is characterized 
by the release of inflammatory mediators and neurohormones as well as alterations in tissue 
microvasculature, which may result in multi-organ dysfunction syndrome.(54-58) The level of 
SIRS may interfere with classically known responses of the body to shock(55) (Figure 2). Several 
studies have reported that markers of SIRS and impaired tissue perfusion are predictive of 
short-term mortality in cardiogenic shock. These makers included impaired skin perfusion, 
elevated lactate concentrations, elevated interleukin-6 plasma concentrations, metabolites in 
arginine and NO pathways, renal dysfunction, and impaired sublingual microvascular blood 
flow.(58-63) In addition, it has been postulated that inappropriate vasodilation and thus inad-
equate perfusion at the micro-vascular level might play an important role in the pathogenesis 
of multiple organ failure and the persistence of shock.(64, 65) Inappropriate vasodilation may 
occur during systemic inflammation of the body due to a high production of nitric oxide by 
nitric oxide synthase (NOS). Accordingly, strategies were developed to inhibit NOS in patients 
with shock. Small studies indeed demonstrated that NOS inhibition improved blood pressure in 
patients with cardiogenic shock.(66-68) Next, the TRIUMPH-trial was designed to test whether 
administration of tilarginine, a nonselective NOS-inhibitor, would improve 30-day survival in 
patients with myocardial infarction complicated by cardiogenic shock. Enrolment of patients 
was recently terminated at 398 patients based on a lack of efficacy. There was no difference in 
30-day all cause mortality between patients who received tilarginine (48% died) and placebo 
(42% died, risk ratio 1.14: 95% CI 0.92-1.41).(69)
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David r. holmes Jr: “A fascinating feature that has been increasingly well recognized is that 
“45% of nonsurivors of CS die with a normal cardiac index (ie, >2.2 L/min/m2).” There are many 
things that are unknown about this observation. Perhaps that is why the advanced hemody-
namic support devices have so far not been found to be beneficial. As the authors point out, 
new approaches are needed urgently.”
ThE rOLE Of TiSSUE MiCrOCirCULATiON iN ThE PAThOGENESiS Of 
CArDiOGENiC ShOCK
The importance of intensive treatment in the acute phase of CS has been outlined above. The 
negative results of TRIUMPH(69) demonstrated that the pathophysiology of vascular involve-
ment in CS is not completely understood. In fact, microvascular dysfunction in CS may vary 
over time and among patients. Several investigators have reported direct measurements of 
tissue microcirculation in CS patients. Using venous air plethysmography, Kirschenbaum and 
co-workers measured forearm blood flow in patients with CS before and after arterial occlu-
sion. The authors reported an attenuated microcirculatory response during reactive hyper-
emia, which indicates an impaired capacity for vasodilation.(70) In addition, De Backer et al. 
measured sublingual microcirculation in patients with cardiogenic shock, using a 2D imaging 
technique called orthogonal polarization spectral imaging.(58) These investigators reported 
a decreased proportion of functional capillaries in patients with CS relative to patients with 
acute heart failure and control patients who were examined before cardiac surgery (49% vs. 
63% vs. 92%, respectively, p<0.001). These alterations in microcirculatory blood flow correlated 
to ICU mortality. Time course of microcirculatory alterations during CS was not clear from this 
study and it is still unclear whether microcirculatory alterations can be improved by vaso-active 
agents and, if the case, whether this has a favourable effect on survival. Additional research 
is necessary to understand the nature and mechanisms of impaired tissue perfusion more 
comprehensively, and how this can be measured and monitored at the bedside. In addition, 
the effects of vasoactive agents at the microcirculatory level are frequently unpredictable in 
individual patients. In fact, adequate tissue perfusion (ie, blood flow instead of pressure) should 
be an ultimate treatment objective in CS.
David r. holmes Jr: “The role of tissue microcirculation has been accorded increasing impor-
tance. The concept of “functional capillaries” needs further study. As the authors point out, it is 
adequate tissue perfusion rather than maintenance of more normal arterial pressure that is a 
crucial determinant of outcome.”
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NOvEL APPrOAChES TO iMPrOvE TiSSUE PErfUSiON
Recently, new techniques were introduced to investigate tissue microcirculation at the bedside. 
These techniques include laser-Doppler flowmetry, near-infrared spectroscopy and Sidestream 
Dark Field imaging.(55, 71) It is expected that these novel monitoring devices may provide 
more knowledge on the pathophysiology of cardiogenic shock and its response to pharmaco-
logic treatment.(71) Using orthogonal polarization spectral imaging, Spronk et al. measured a 
significant improvement in capillary blood flow after intravenous nitroglycerin administration 
in critically ill patients with severe sepsis.(16) Research on CS related to this topic is still in its 
premature stages. The novel imaging techniques might be used as future tools to target vaso-
active therapy more accurately to patients, thereby making significant savings by more tailored 
therapy. Such an approach might lower the still dramatic in-hospital mortality rate of patients 
and aid patients through the critical acute phase of CS.
CONCLUSiONS
CS is a life-threatening state of tissue hypoperfusion, and short-term mortality is still very high 
despite an increasing number of monitoring tools and treatment modalities. Pharmacologic 
treatment of patients with CS has not changed substantially in the last decades. Although 
novel pharmacologic agents were introduced and demonstrated to improve hemodynamic 
parameters in patients with CS, results from almost all randomized trials incorporating clinical 
endpoints were either negative or inconclusive. The overwhelming amount of negative studies 
in the area of critical care is a major problem, which might be due to disease complexity, patient 
heterogeneity, and lack of statistical power. Early primary revascularization has significantly 
improved the prognosis of CS patients. The efficacy of intra-aortic balloon pump counterpulsa-
tion in cardiogenic shock has not been proven by means of randomized clinical trials, but there 
is general agreement that this treatment modality is beneficial. Results from VAD studies in 
selected patients are promising, but we have to wait for further data, taking into account the 
costs and adverse events of these highly specialized treatment techniques. However, aggres-
sive support of the failing heart in the acute phase of cardiogenic shock is considered of utmost 
importance, partly because long-term prognosis of patients with cardiogenic shock is not 
worse compared to the prognosis of patients with myocardial infarction without shock. New 
approaches like therapy directed by and targeted to microcirculatory imaging parameters may 
possibly result in a better survival of CS patients. This will be the challenging subject of future 
studies.
David r. holmes Jr: “Cardiogenic shock continues to account for the highest mortality in 
patients with myocardial infarction who survive to hospitalization. Given the morbidity and 
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mortality associated with shock, there have been intensive efforts to evaluate pathophysiologic 
mechanisms involved to identify risk stratification algorithms and develop new treatment strat-
egies. The current article reviews these efforts in substantial detail. While there are many take-
home messages, several stand out, as follows: (1) cardiogenic shock continues to be a highly 
lethal event, (2) somewhat surprisingly, a substantial number of nonsurvivors of cardiogenic 
shock die with a relatively preserved cardiac index, (3) in those patients who survive shock, 
the long-term outcome is favorable and similar to patients with infarction who do not develop 
shock, (4) revascularization is an essential component of care, and (5) there is still much that we 
do not know.”
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ABSTrACT
Aims: Impaired tissue perfusion is often observed in patients with acute heart failure. We tested 
whether low-dose nitroglycerin (NTG) improves microcirculatory perfusion in patients admit-
ted for acute heart failure.
Methods and results: In 20 acute heart failure patients, NTG was given as intravenous infusion 
at a fixed dose of 33 μg/min. Using Sidestream Dark Field (SDF) imaging, sublingual microvascu-
lar perfusion was evaluated before (T0, average of two baseline measurements) and 15 minutes 
after initiation of NTG (T1). In a subgroup of 7 patients, SDF measurements were repeated after 
NTG had been stopped for 20 min. Capillaries were defined as microvessels with a diameter 
of <20 μm. Perfused capillary density (PCD) was determined as the parameter of tissue perfu-
sion. Values are expressed as median and inter-quartile range [P25; P75]. The median age of 
the subjects was 60 [52; 73] years and 65% were male. Patients were stable before starting 
NTG. Nitroglycerin decreased central venous pressure (17 [13;19] mmHg at T0 vs. 16 [13;17] 
mmHg at T1, p=0.03) and pulmonary capillary wedge pressure (23 [18;31] mmHg at T0 vs. 19 
[16;25] mmHg at T1, p=0.03). It increased PCD (10.7 [9.9;12.5] mm.mm-2 at T0 vs. 12.4 [11.4;13.6] 
mm.mm-2 at T1, p=0.01). After cessation of NTG, PCD returned to baseline values (p=0.04).
Conclusion: Low-dose NTG significantly reduces cardiac filling pressures and improves micro-
vascular perfusion in patients admitted for acute heart failure.
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iNTrODUCTiON
Patients with acute heart failure are haemodynamically compromised, and are at risk for impaired 
perfusion of organs and tissues. Cardiac filling pressures as well as lactate levels are often 
elevated whereas mixed venous oxygen saturation is low. Various drugs, including nitroglycerin 
(NTG), may be given to stabilize patients clinically, to normalize filling pressures, and to optimize 
perfusion to vital organs.(1) However, global haemodynamic and laboratory measurements may 
severely underestimate local tissue hypoperfusion, i.e. the imbalance between tissue oxygen 
delivery and oxygen consumption.(2) Novel two-dimensional imaging techniques provide 
direct visualization of capillaries in tissues covered by a thin epithelial layer at the bedside. Using 
these techniques, changes in microvascular blood flow can be analysed in patients with a variety 
of disease states, including acute heart failure. Impaired microvascular perfusion, as assessed 
by these methods, has been shown to be associated with worse intensive care unit survival.(2)
Cardiac and vascular nitric oxide (NO) bioavailability is reduced in heart failure, contributing 
to contractile dysfunction, ventricular hypertrophy, and remodelling, as well as endothelial 
dysfunction.(3, 4) Nitrates are powerful NO donors, that are frequently administered to patients 
with acute heart failure.(5) Low-dose NTG administration primarily results in venodilation, thus 
lowering cardiac filling pressures, increasing the pressure gradient for myocardial perfusion 
and decreasing myocardial oxygen demand.(1, 6, 7) Recent guidelines recommended the 
use of vasodilators, including nitroglycerin (NTG), in order to achieve haemodynamic and 
symptomatic improvement.(8) However, the effect of nitroglycerin on tissue perfusion has not 
been studied in patients with acute heart failure. In this study, we tested the hypothesis that 
enhancement of NO bioavailability by intravenous administration of NTG at a fixed, low dose 
improves microvascular tissue perfusion in patients with acute heart failure.
METhODS
Study design
This pre-post intervention study was conducted at the Intensive Cardiac Care Unit of the Tho-
raxcenter, Erasmus Medical Center, the Netherlands. Twenty patients admitted with acute heart 
failure were included. Exclusion criteria were: (i) oral bleeding, (ii) mean arterial pressure (MAP) 
below 65 mmHg, and (iii) acute right ventricular myocardial infarction.
In addition, 20 age-matched patients without heart failure, who were evaluated 1 day before 
undergoing coronary artery bypass grafting,(9) served as controls for the baseline measure-
ments only. Nitroglycerin was given to the patients for study purposes. The institutional Ethics 
Committee approved the protocol, and written informed consent was obtained from each 
patient or, in case of patients who were sedated, from a relative authorized to consent on behalf 
of such a patient.
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haemodynamic monitoring
Patients were monitored with a radial artery catheter (arterial cannula with FloSwitch, Ohmeda, 
Swindon, UK). Ten patients were monitored with a pulmonary artery catheter (PAC: Becton 
Dickinson Criticath SP5107H, Sandy, UT, USA). In the other 10 patients, central venous pres-
sure (CVP) was measured via a three-lumen central venous catheter (Multicath; Laboratoires 
Pharmaceutiques Vygon, Ecouen, France), inserted into the right internal jugular vein. In these 
patients, cardiac index (CI) was calculated according to the Cuschieri formula, which shows 
close correlation with the cardiac index measured with a PAC.(10) Data collection included cen-
tral body temperature, heart rate (HR), MAP, CVP, pulmonary capillary wedge pressure (PCWP), 
mean pulmonary artery pressure (PAP), CI, systemic vascular resistance (SVR), lactate level and 
mixed-venous oxygen saturation (SvO2).
Microcirculatory assessment and analysis
The Sidestream Dark Field (SDF) imaging device (MicroScan; Microvision Medical, Amsterdam, 
The Netherlands) was used to obtain two-dimensional video images of sublingual microcircula-
tory blood flow (Figure 1). This technique has been described and validated previously.(11, 12) 
In short, the camera emits green light that is absorbed by red blood cells within microvessels. In 
this way, red blood cells are used as the contrast agent to visualize sublingual blood flow in pat-
ent microvessels. This is the reason why oral bleeding was an exclusion criterion for the study. 
Three to five steady video sequences of at least 20 seconds duration, were obtained, stored 
and analyzed by an investigator blinded to the patient’s diagnosis and therapy. Quantification 
Figure 1. Sidestream Dark Field imaging setup. Video frames of the sublingual microcirculation were acquired using a Sidestream Dark Field 
(SDF) imaging device (left) and captured on a computer (upper right). In the SDF device a central light guide is surrounded by, but isolated from 
concentrically placed light emitting diodes that stroboscopically emit green light for illumination. This green light is absorbed by erythrocytes 
flowing through the tissue under investigation. The haemoglobin is actually used as the contrast agent, so that red blood cells are imaged 
as dark moving globules against a white/grayish background. This implies that intravascular erythrocytes rather than microvessel walls are 
visualized.
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Figure 1. Sidestream Dark Field imaging setup.
Figure 2. Change in sublingual perfused capillary density over time.
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of the images was performed using software (AVA 3.0, MicrovisionMedical, Amsterdam, the 
Netherlands). Perfused capillary density (PCD) was calculated by measuring the total length of 
perfused capillaries divided by the image area. As SDF imaging enables visualization of flowing 
intravascular erythrocytes rather than microvessel walls, an increase in PCD was regarded as 
capillary recruitment. Capillaries were defined as microvessels with a diameter <20 μm.
Study protocol
To minimize the effect of regression to the mean due to spontaneous variation in microcircula-
tory perfusion, two baseline measurements were performed with a time interval of 15 min. 
Perfused capillary densities from both baseline measurements were averaged to produce one 
baseline value (T0). After the second baseline measurement, NTG was given as a bolus equal to 
the volume of the particular intravenous line (i.e. a volume of <2 mL). Immediately thereafter, 
a continuous intravenous infusion of NTG at a fixed dose of 33 μg/min was started. After 15 
min, the microcirculation was assessed again (T1). In the second part of the study, we also 
investigated whether the observed changes in microcirculatory flow were reversed by discon-
tinuation of the NTG infusion. Hence, in 7 patients, the measurements were repeated after the 
NTG infusion had been stopped for 20 min (T2). Patients did not receive NTG between hospital 
admission and baseline measurements. During execution of the study, ventilator settings and 
dosages of other intravenous medications were stable.
Statistical analysis
Categorical variables are presented as absolute number with percentage. All continuous vari-
ables are presented as median with interquartile range (IQR, [25th; 75th percentiles]). Changes 
over time were tested with the Wilcoxon signed ranks test. The Mann–Whitney test was used to 
assess differences between groups. Pearson’s chi-square test was used to test the association 
between categorical variables.
rESULTS
Study population
Twenty patients admitted for acute heart failure were included in this study: 14 patients had 
new onset acute heart failure after acute myocardial infarction, and 6 patients had acute wors-
ening of pre-existing chronic heart failure (Table 1). Median age was 60 [52;73] years, 65% were 
male and the median NT-proBNP level was 264 [83;641] pmol/L (reference values 0-17 pmol/L). 
Median central body temperature was 36.7 [34.1-37.9] °C. Twelve patients (60%) required 
mechanical ventilation and 9 patients (45%) were treated with at least one inotropic agent 
during execution of the study protocol. The median time period between hospital admission 
and the start of the measurements was 22 [11-29] h.
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Global haemodynamic parameters and sublingual perfused capillary density
There were no significant differences in global haemodynamic or microcirculation parameters 
between the two baseline measurements, indicating that patients were in a stable condition 
before NTG was started. Averaged baseline PCD in the acute heart failure group was sig-
nificantly lower compared with baseline values in control patients (10.7 [9.9-12.5] mm.mm-2 vs. 
12.4 [12.0-13.1] mm.mm-2, p=0.003). NTG infusion decreased CVP (17 [13;19] mmHg at T0 vs. 16 
[13;17] mmHg at T1, p=0.03) as well as PCWP (23 [18; 31] mmHg at T0’ vs. 19 [16; 25] mmHg at 
T1, p=0.03). Median PCD increased significantly after NTG infusion (10.7 [9.9;12.5] mm.mm-2 at 
T0 vs. 12.4 [11.4;13.6] mm.mm-2 at T1, p=0.01), and this effect was reversed in seven patients in 
whom NTG was stopped for 20 minutes (12.4 [11.4;13.6] mm-1 at T1 vs. 10.9 [9.6;12.7 mm-1) at 
T2, p=0.04, Table 2 and Figure 2).
Table 1. Clinical characteristics of the study population (n=20).
Characteristic
Age, years (median [IQR]) 60 [52; 73]
Male 13 (65%)
CV risk factors:
 Hypertension
 Current smoking
 Dyslipidaemia
 Diabetes mellitus
9 (45%)
4 (20%)
6 (30%)
5 (25%)
Diagnosis at admission:
 New onset AHF due to AMI
 Acute decompensation of CHF
14 (70%)
6 (30%)
Classification of heart failure based on SBP at presentation[21]:
 Hypotensive (SBP <120 mmHg)
 Normotensive (SBP 120-139 mmHg)
 Hypertensive (SBP >140 mmHg)
9 (45%)
9 (45%)
2 (10%)
Left ventricular function:
 Reduced (ejection fraction <40%)
 Preserved (diastolic dysfunction)
17 (85%)
3 (15%)
NT-proBNP level, pmol/L (median [IQR]) 264 [83; 641]
Mechanical ventilation 12 (60%)
Intravascular cooling after OHCA 5 (25%)
IABP counterpulsation 6 (30%)
Pulmonary artery catheterization 10 (50%)
Cumulative fluid balance, mL (median [IQR]) 307 [-551; 1663]
Pharmacologic therapy
 Any inotropic agent
 Dobutamine
 Dopamine
 Norepinephrine
 Enoximone
9 (45%)
6 (30%)
1 (5%)
2 (10%)
3 (15%)
ICU stay, days (median [IQR]) 6 [3; 11]
Death during ICU stay 3 (15%)
Values are expressed as n (%) unless otherwise noted. Abbreviations: IQR, interquartile range; AHF, acute heart failure; AMI, acute myocardial 
infarction; CHF, chronic heart failure; SBP, systolic blood pressure; NT-pro-BNP, N-terminal brain natriuretic propeptide; OHCA, out-of-hospital 
cardiac arrest; IABP, intra-aortic balloon pump; ICU, intensive care unit.
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Changes after nitroglycerin administration for responders vs. non-responders
Perfused capillary density improved in 14 patients (“responders”, 70%, ΔPCDT1-T0 >0), whereas 
PCD did not improve in 6 patients (“non-responders”, 30%, ΔPCDT1-T0 ≤0: figure 3). There were 
no differences in the clinical characteristics listed in Table 1 between these subgroups. Changes 
in global haemodynamic and microcirculatory parameters at T1 versus T0 were calculated 
(Δ…T1-T0) for both responders and non-responders (Table 3). Responders had a greater decrease 
in central venous pressure (ΔCVPT1-T0) compared to non-responders (–2 [-3;-1] mmHg vs. 0 [-1;2] 
mmHg, respectively, p=0.02, Table 3).
Table 2. Parameters of macro- and microcirculation at baseline and changes induced by low-dose nitroglycerin.
T0
Averaged baseline 
measurements
(n=20)
ΔT1-T0
After NTG
(n=20)
P-value
(T1 vs. T0)
ΔT2-T1
NTG stopped
(n=7)
P-value
(T2 vs. 
T1)
hr (bpm) 102 [68; 108] +0 [-1; 3] 0.82 +0 [-3; 3] 0.75
MAP (mmhg) 81 [77; 90] -5 [-10; 2] 0.02 +7 [-3; 12] 0.12
CvP (mmhg) 17 [13; 19] -1 [-2; 0] 0.03 +1 [-4; 2] 0.89
PCWP (mmhg)* 23 [18; 31] -2 [-4; -1] 0.03 +0 [-7; 4] 0.68
Mean PAP (mmhg)* 35 [29; 41] -3 [-3; -2] 0.07 +1 [-5; 12] 0.53
Ci (L.min-1.m-2) 2.2 [1.9; 3.0] +0.1 [-0.2; 0.3] 0.70 -0.1 [-1.3; 0.0] 0.17
Svr (dynes.sec.cm-5) 1137 [822; 1489] -35 [-326; 83] 0.31 +8 [-60; 113] 0.48
Lactate (mmol.L-1) 1.5 [1.0; 2.3] +0.0 [-0.6; 0.3] 0.83 -0.3 [-1.3; 0.1] 0.20
SvO2 (%)* 68 [56; 78] -1[-3; +1] 0.28 +0 [0; 0] 0.29
PCD (mm.mm-2) 10.7 [9.9; 12.5] +1.1 [-0.3; 2.5] 0.01 -1.6 [-2.7; 0.0] 0.04
T0: averaged baseline measurements; T1: 15 minutes after initiation of nitroglycerin; T2: 20 minutes after cessation of the nitroglycerin infusion. 
Changes in variables between time points are depicted as delta(T..-Tprevious measurement). All values are shown in medians [25th;75th percentiles]. 
Abbreviations: CI, cardiac index; CVP, central venous pressure; HR, heart rate; MAP, mean arterial pressure; PAP, pulmonary artery pressure; 
PCD, perfused capillary density; PCWP, pulmonary capillary wedge pressure; SvO2, mixed-venous oxygen saturation; SVR, systemic vascular 
resistance. *Pulmonary artery catheterization was performed in 10 of 20 patients.
Figure 2. Change in sublingual perfused capillary density over time. Values are expressed as median and interquartile range. *P<0.05 relative 
to previous measurement. NTG was stopped in 7 of 20 patients.
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Figure 1. Sidestream Dark Field imaging setup.
Figure 2. Change in sublingual perfused capillary density over time.
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DiSCUSSiON
This is the first study demonstrating that the NO donor nitroglycerin can increase the number 
of patent capillaries in patients admitted for acute heart failure. A significant increase in PCD 
was found after administration of low-dose, intravenous nitroglycerin at a fixed dose of 33 μg/
min. In addition, we documented the venodilator effect of low-dose NTG on the pulmonary 
and systemic circulation. The observed improvement in microcirculation was reversed after 
discontinuation of NTG in the 7 patients in whom these measurements were available.
De Backer et al.(2) have shown that severe micro-vascular alterations are present in patients 
with acute heart failure. These alterations did not correlate to CI and probably demonstrated 
locally impaired tissue perfusion. The severity of these alterations was found to be associated 
with ICU mortality. However, the pathophysiology of an altered microcirculation in the setting 
Figure 3. Change in perfused capillary density (ΔPCD) after nitroglycerin administration compared with two consecutive baseline 
measurements at the individual patient level. Lines represent medians. Dots depict the change in perfused capillary density (ΔPCD) between 
both baseline measurements and after nitroglycerin administration (i.e. T1 minus averaged baseline measurements).
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Figure 3. Change in perfused capillary density (ΔPCD) after nitroglycerin administration 
compared with two consecutive baseline measurements at the individual patient level.
Table 3. Change in global haemodynamic and microcirculatory parameters between T1 (after nitroglycerin) and averaged baseline 
measurements for all subjects and both subgroups.
All subjects
(n=20)
responders
(n=14)
Non-responders
(n=6)
P-value*
Δ hr (bpm) 0 [-1; 3] 0 [-1; 2] 0 [-13; 3] 0.62
Δ MAP (mmhg) -5 [-10; 2] -3 [-14; 2] -5 [-9; -1] 0.97
Δ CvP (mmhg) -1 [-2; 0] -2 [-3; -1] 0 [-1; 2] 0.02
Δ Ci (L.min-1.m-2) 0.1 [-0.2; 0.3] -0.1 [-0.7; 0.3] 0.2 [-0.2; 0.4] 0.31
Δ Svr (dynes.sec.cm-5) -35 [-326; 83] 9 [-522; 117] -145 [-310; 17] 0.43
Δ PCD (mm.mm-2) 1.1 [-0.3; 2.5] 2.0 [0.9; 2.8] -0.9 [-1.2; -0.3]
All values are shown in median [25th;75th percentiles]. Abbreviations: HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; 
CI, cardiac index; SVR, systemic vascular resistance; PCD, perfused capillary density. *Comparing improvers in perfused capillary density 
(responders) versus PCD non-improvers (non-responders).
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of acute heart failure is complex and not completely understood.(13) There is a critical bal-
ance between vasoconstrictor and vasodilator stimuli in patients with acute heart failure. Both 
compensatory vasoconstriction as a response to low cardiac output and impaired production 
of NO may impair tissue perfusion.(13-15) In addition, patients with acute heart failure may 
present with distinct clinical conditions (e.g. hypertensive heart failure or cardiogenic shock)
(16, 17) and whether the severity of microcirculatory alterations and the response to therapy 
differs among these clinical conditions needs to be investigated.
Our data demonstrate that low-dose intravenous nitroglycerin is safe and beneficial for the 
microcirculation in a specific tissue away from the heart, i.e. the sublingual area. This beneficial 
effect was observed on top of routine therapy in a stabilized, heterogeneous population of 
patients admitted for acute heart failure. However, 30% of the investigated patients did not 
respond. To find an explanation for the lack of response in these subjects, we performed 
a subgroup analysis of responders versus non-responders. We found that responders had a 
greater decrease in CVP after NTG. The clinical response to NTG is known to be highly vari-
able between patients; this may be explained by vascular resistance to NTG in patients with 
heart failure.(6, 18). Katz et al. reported a two-fold increase in femoral artery blood velocity 
after intra-arterial infusion of NTG in normal subjects.(19) However, this response was markedly 
attenuated in patients with heart failure and could be overcome only by increasing the dose, 
suggesting vascular resistance to NTG in patients with heart failure. This resistance to NTG has 
been explained by impaired enzymatic bioconversion of nitroglycerin to NO.(20) Since we gave 
low-dose nitroglycerin, non-responders might simply have less venodilation than responders 
due to an insufficient dose of NTG in those patients. Future studies might examine the response 
to higher doses of nitroglycerin, to nitroprusside (which releases nitric oxide by non-enzymatic 
means) and to hydralazine (a non-NO donor vasodilator) in order to better understand the 
non-responders.
Several limitations of our study should be acknowledged. The small and heterogeneous 
sample size limits drawing strong conclusions. Whether the beneficial effects of nitroglycerin 
also apply to other microvascular beds, and whether recruitment of microcirculation will reduce 
cellular dysfunction, organ failure and mortality in patients with acute heart failure, needs to 
be investigated further.
In conclusion, this is the first study demonstrating that an impaired microcirculation can 
be improved by a simple strategy, i.e. starting a low-dose intravenous NTG infusion. Whether 
dosing of vasodilator agents can be optimized by monitoring tissue microcirculation has to be 
investigated in future studies.
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ABSTrACT
introduction: Microcirculatory abnormalities are frequently observed in patients with severe 
heart failure and correlate to worse outcome. We tested the hypothesis that nitroglycerin dose-
dependently improves perfusion in severe heart failure and that this could be monitored by 
measuring central-peripheral temperature gradient and with Sidestream Dark Field imaging of 
the sublingual mucosa.
Methods: A dose-response study was performed in 17 patients with cardiogenic shock (n=9) 
or end-stage chronic heart failure (n=8) admitted to Erasmus University Medical Center. We did 
hemodynamic measurements at baseline and during increasing infusion rates of nitroglycerin 
(up to a maximum dose of 133 μg.min-1). As parameters of tissue perfusion, we measured 
central-peripheral temperature gradient (delta-T) and sublingual perfused capillary density 
(PCD).
results: Nitroglycerin dose-dependently decreased mean arterial pressure (p<0.001) and car-
diac filling pressures (both central venous pressure (CVP) and pulmonary capillary wedge pres-
sure: p<0.001). It increased cardiac index (p=0.01). Nitroglycerin decreased delta-T (p<0.001) 
and increased sublingual PCD (p<0.001). Significant changes in delta-T and PCD occurred 
earlier, i.e. at a lower dose of NTG, than changes in global hemodynamics. Macrohemodynamic 
and microcirculatory responses to nitroglycerin infusion were consistent in patients with either 
cardiogenic shock or end-stage chronic heart failure. Changes in microcirculatory parameters 
occurred independently of changes in cardiac index.
Conclusions: Nitroglycerin dose-dependently increases tissue perfusion in patients with 
severe heart failure, as observed by a decrease in central-peripheral temperature gradient and 
an increase in sublingual perfused capillary density.
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iNTrODUCTiON
In recent years, investigators have increasingly acknowledged severe heart failure and cardio-
genic shock not only as a cardiac problem but also as a disease of derangements in the entire 
circulatory system (1, 2). Moreover, it has been found that global hemodynamic parameters do 
not reflect differential patterns of regional organ blood flow or compromised tissue perfusion 
of the splanchnic bed associated with shock states (3-10). Therefore, optimization of tissue 
microcirculation should be an objective of the treatment of critically ill patients (11). However, 
it is still largely unknown whether pharmacologic interventions do improve tissue capillary 
perfusion. Goal-directed manipulation of hemodynamics is the key to understanding the 
interventions required to reduce the morbidity and mortality associated with multi-organ and 
hepatorenal failure in patients with end-stage heart disease or cardiogenic shock.
Nitric oxide (NO) bioavailability is reduced in patients with heart failure, contributing to 
contractile dysfunction, ventricular hypertrophy and remodelling, as well as microvascular 
endothelial dysfunction (12-14). In addition, hypervolemia, as reflected by an elevated central 
venous pressure, may cause organ dysfunction (15). To overcome this clinical problem, nitrates, 
which are powerful NO donors and venodilators, are often given to patients with heart failure 
(16, 17). We recently demonstrated that, in patients with decompensated heart failure, nitro-
glycerin (NTG), administered at a fixed low dose, lowered cardiac filling pressures and increased 
sublingual perfused capillary density (PCD) (18), which is an important measure for tissue 
perfusion (19). However, in 30% of the patients measured in this study, the microcirculation 
did not respond. To investigate whether significant changes in PCD occur at the same dose as 
global hemodynamic changes, and to investigate the maximum response of the microcircula-
tion to NTG, we performed the current dose-response study. We tested the hypothesis that 
NTG, presumably by enhancement of NO bioavailability and venodilation, dose-dependently 
improves tissue perfusion, as assessed by measurements of central-peripheral temperature 
gradient (delta-T) and sublingual PCD in patients with cardiogenic shock or end-stage chronic 
heart failure.
MATEriALS AND METhODS
Study design
This dose-response study was conducted at the Intensive Cardiac Care Unit and at the Heart 
Failure/Heart Transplant ward of the Thoraxcenter, Erasmus University Medical Center, the 
Netherlands. We included patients who were admitted with cardiogenic shock or end-stage 
chronic heart failure. Cardiogenic shock was defined as a cardiac index <2.2 L.min-1.m-2 and 
clinical signs of hypoperfusion (cold extremities, oliguria or altered mental state), not respon-
sive to fluid resuscitation. The patients with end-stage heart failure were included after they 
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underwent right heart catheterization for screening for cardiac transplantation. Exclusion 
criteria were: (i) oral bleeding, (ii) mean arterial pressure below 55 mmHg, (iii) acute right ven-
tricular myocardial infarction and (iv) severe aortic valve stenosis. In cardiogenic shock patients, 
nitroglycerin was given for study purposes. In chronic heart failure patients, nitroglycerin was 
routinely given to assess reversibility of pulmonary hypertension (i.e. mean pulmonary artery 
pressure >25 mmHg). The institutional ethical committee approved the protocol, and written 
informed consent was obtained from each patient or, in case of patients who were sedated, 
from a relative authorized to consent on behalf of such a patient.
haemodynamic monitoring
Cardiogenic shock patients were monitored with a radial artery catheter (arterial cannula with 
FloSwitch, Ohmeda, Swindon, UK). In the other patients, arterial blood pressure was measured 
non-invasively. All patients were monitored with a pulmonary artery catheter (Criticath 
SP5107H, Becton Dickinson, Sandy, UT, USA or CCOmbo, Edwards Lifesciences, Saint-Prex, 
Switzerland). Macro-hemodynamic data collection included central body temperature (mea-
sured at the tip of the pulmonary artery catheter), heart rate (HR), mean arterial pressure (MAP), 
central venous pressure (CVP), pulmonary capillary wedge pressure (PCWP), mean pulmonary 
artery pressure (PAP), cardiac index (CI), systemic vascular resistance (SVR), and mixed-venous 
oxygen saturation (SvO2). SVR was calculated as (MAP-CVP)*80/Cardiac output.
Microcirculatory assessment and analysis
Central-peripheral temperature gradient (delta-T) was defined and calculated as the difference 
between central blood and skin temperature. Skin temperature was measured with a probe 
affixed to the dorsum of the foot under constant room temperature (temperature probe 
170075; Ellab Inc., Centennial, CO, USA).
The Sidestream Dark Field (SDF) imaging device (MicroScan; Microvision Medical, Amster-
dam, the Netherlands) was used to obtain 2-dimensional video images of sublingual microcir-
culatory blood flow. This technique has been described and validated previously (20). In short, 
the camera emits green light that is absorbed by red blood cells within microvessels. In this 
way, red blood cells are used as the contrast agent to visualize sublingual blood flow in patent 
microvessels. This is the reason why oral bleeding was an exclusion criterion for the study. Per 
time point, three steady video sequences of at least 20 s duration were obtained, stored and 
analyzed. Quantification of the images was performed using software (Automated Vascular 
Analysis 3.0, MicrovisionMedical, Amsterdam, the Netherlands) by an investigator blinded to 
the timing of the images. Perfused capillary density (PCD) was calculated by measuring total 
length of perfused capillaries divided by image area. Capillaries were regarded as perfused if 
they had either of the following flow classifications obtained by visual inspection: sluggish, 
continuous or hyperdynamic (21). Since SDF imaging enables visualization of flowing intravas-
cular erythrocytes rather than microvessel walls, an increase in PCD was regarded as capillary 
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recruitment. This approach has been validated previously (22, 23). Capillaries were defined as 
microvessels with a diameter less than 20 μm.
Study protocol
To minimize the effect of regression to the mean due to spontaneous variation in microcircula-
tory perfusion, two series of baseline measurements were performed with a time interval of 15 
min. PCD values from both baseline measurements were averaged to obtain one baseline value 
(T0). After the second baseline measurement, NTG was given as a bolus equal to the volume 
of the used intravenous line. Immediately thereafter, a continuous intravenous infusion of NTG 
was started at a dose of 8 μg.min-1 for 15 min. Then, all measurements were repeated (T1). Eight 
micrograms per minute (i.e., 0.5 mg/h) is the lowest nitroglycerin infusion rate given in our 
hospital. Subsequently, the nitroglycerin infusion rate was doubled stepwise (i.e. 17 μg.min-1 
(T2); 33 μg.min-1 (T3); 67 μg.min-1 (T4); 133 μg.min-1 (T5)). Each infusion rate was maintained 
for 30 min, which was the time period necessary to reach the intended effect (15 min) plus 
the time period necessary to collect all data (15 min). The nitroglycerin infusion was stopped 
when patients developed significant hypotension (i.e. MAP <50 mmHg). In each patient, all 
measurements were repeated when NTG had been stopped for 20 min (T6). During execution 
of the study, dosages of other intravenous medications were stable.
Statistical analysis
Categorical variables are presented as absolute numbers with percentages. Continuous vari-
ables are presented as mean ± standard deviation (SD) or as median and interquartile range 
(IQR), when appropriate. The one-sample Kolmogorov-Smirnov goodness of fit test was used to 
test normal distribution of the data. Reproducibility of the PCD measurements was defined as 
the standard deviation of the differences between both baseline measurements. Changes over 
time were tested with one-way repeated measures analysis of variance (ANOVA), followed by 
Bonferroni’s multiple comparison tests. Comparisons between repeated measurements within 
subgroups were tested with two-way repeated measures ANOVA. We defined improvement of 
cardiac index as an increase ≥ two times the standard deviation of the differences between both 
baseline measurements, relative to T0. A p-value <0.05 was regarded statistically significant.
rESULTS
Study population and execution of the protocol
Seventeen patients were included in this study. Nine patients (53%) had cardiogenic shock and 
8 patients (47%) had end-stage chronic heart failure and were screened for heart transplanta-
tion (Table 1). Mean age was 55 ± 12 years, 65% were male and median NT-proBNP level was 
418 [204-733] pmol.L-1 (reference values 0-17 pmol.L-1). Mean central body temperature was 
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36.0 ± 1.7°C. All patients received NTG up to 67 μg.min-1 (T4). In seven patients, the highest 
dose of nitroglycerin (i.e. T5) could not be given because of arterial hypotension (MAP below 50 
mmHg; n=6) or pulmonary shunting and hypoxia (PaO2 60 torr; n=1). Accordingly, the dose of 
133 μg.min-1 was given to ten patients.
Effects of nitroglycerin on parameters of global hemodynamics
There were no significant differences in global hemodynamic parameters between the two 
baseline measurements, indicating that patients were in a stable condition before NTG was 
started. NTG infusion decreased MAP (p<0.001) and cardiac filling pressures (CVP: p<0.001; 
PCWP: p<0.001; Table 2 and Figure 1). It increased cardiac index (p=0.01). Between time points 
T4 and T5, there were no further changes in macrocirculatory parameters. Systemic parameters 
returned to baseline values after cessation of NTG infusion. Haemodynamic responses to 
nitroglycerin infusion were consistent in patients with either cardiogenic shock or end-stage 
chronic heart failure.
Table 1. Baseline characteristics of the study population (n=17).
Characteristic
Age, years (mean ± SD) 55 ± 12
Gender, male 11 (65%)
Cardiovascular risk factors
 Hypertension
 Current smoking
 Dyslipidaemia
 Diabetes mellitus
5 (29%)
3 (18%)
2 (12%)
3 (18%)
Diagnosis at admission
 Cardiogenic shock
 End-stage chronic heart failure
9 (53%)
8 (47%)
Underlying disease
 Acute myocardial infarction (complicated by shock)
 Mitral valve disease (complicated by shock)
 Dilated cardiomyopathy
 Ischemic cardiomyopathy
8 (47%)
1 (6%)
7 (41%)
1 (6%)
NT-proBNP level, pmol.L-1 (median [IQR]) 418 [204-733]
Mechanical ventilation 7 (41%)
IABP counterpulsation 4 (24%)
Pharmacologic therapy
 Any inotropic agent
 Dobutamine
 Norepinephrine
 Enoximone
9 (53%)
5 (29%)
3 (18%)
1 (6%)
Values are expressed as n (%) unless otherwise noted.
Abbreviations: SD, standard deviation; IQR, interquartile range; NT-pro-BNP, N-terminal brain natriuretic propeptide; IABP, intra-aortic balloon 
pump.
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Figure 1. Aligned dot plots demonstrating the effects of nitroglycerin at individual patient level. Each time point, changes relative to the 
averaged baseline measurements are shown.
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severe heart failure.
Figure 1. Aligned dot plots demonstrating the effects of nitroglycerin at individual patient 
level.
T0, averaged baseline; T1, NTG 8 μg/min; T2: NTG 17 μg/min; T3: NTG 33 μg/min; T4: NTG 67 μg/min; T5: NTG 133 μg/min; T6: NTG stopped. Lines 
represent means. P-values were obtained with repeated measures ANOVA, followed by Bonferroni’s multiple comparison test of the specific time 
point compared to baseline (*, p<0.05; **, p<0.01; ***, p<0.001).
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Table 2. Parameters of macro- and microcirculation during execution of the study protocol (n=17).
T0
(Averaged 
baseline)
T1
(8 
μg.min-1)
T2
(17 
μg.min-1)
T3
(33 
μg.min-1)
T4
(67 
μg.min-1)
T5*
(133 
μg.min-1)
T6
(NTG 
stop)
P-value 
for trend
hr (bpm) 73 ± 16 72 ± 15 72 ± 15 71 ± 15 72 ± 16 74 ± 16 70 ± 13 0.08
MAP (mmhg) 78 ± 14 75 ± 14 75 ± 14 74 ± 13 70 ± 13 67 ± 15 75 ± 12 <0.001
CvP (mmhg) 11 ± 6 10 ± 6 9 ± 6 9 ± 6 6 ± 5 4 ± 3 10 ± 7 <0.001
PCWP (mmhg) 21 ± 8 18 ± 8 18 ± 8 16 ± 7 14 ± 7 13 ± 6 17 ± 7 <0.001
Mean PAP 
(mmhg)
31 ± 7 28 ± 6 29 ± 6 28 ± 6 24 ± 5 23 ± 5 28 ± 6 <0.001
Ci (L.min-1.m-2) 2.2 ± 0.5 2.5 ± 0.5 2.6 ± 0.6 2.7 ± 0.6 2.5 ± 0.4 2.4 ± 0.5 2.5 ± 0.5 0.01
Svr (dyne.sec.
cm-5)
1327 ± 348 1182 ± 
440
1120 ± 
356
1069 ± 
355
1081 ± 
334
1175 ± 
376
1173 ± 
394
0.005
SvO2 (%) 68 ± 9 68 ± 8 67 ± 8 67 ± 7 66 ± 7 64 ± 7 66 ± 8 0.07
Lactate 
(mmol.L-1)
1.3 ± 0.8 1.3 ± 0.8 1.3 ± 0.8 1.3 ± 0.8 1.2 ± 0.7 0.9 ± 0.4 1.3 ± 0.8 0.99
Delta-T (°C) 6.1 ± 2.7 5.4 ± 2.2 5.2 ± 2.1 5.0 ± 2.1 4.8 ± 2.1 4.5 ± 2.1 5.0 ± 2.2 <0.001
PCD (mm.
mm-2)
7.8 ± 1.4 8.8 ± 2.5 10.0 ± 2.1 11.1 ± 2.1 11.4 ± 1.8 11.2 ± 1.7 8.9 ± 1.8 <0.001
Values represent median [interquartile range]. * Measurements were performed in 10 patients. T0, averaged baseline values; T1, NTG 8 μg.min-1; 
T2: NTG 17 μg.min-1; T3: NTG 33 μg.min-1; T4: NTG 67 μg.min-1; T5: NTG 133 μg.min-1; T6: NTG stop. Abbreviations: HR, heart rate; MAP, mean arterial 
pressure; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; PAP, pulmonary artery pressure; CI, cardiac index; SVR, systemic 
vascular resistance; SvO2, mixed-venous oxygen saturation; Delta-T, central-peripheral temperature gradient; PCD, perfused capillary density.
Figure 2. Individual values of microcirculatory parameters at each dose of nitroglycerin.
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Figure 2. Individual values of microcirculatory parameters at each dose of nitroglycerin.
Figure 3. Temporal behaviour of microcirculatory parameters in patients with and without 
improvement in cardiac index. 
P-values were obtained with one-way repeated measures ANOVA, followed by Bonferroni’s multiple comparison tests comparing all pairs of 
time points. Asterisks just above the upper individual line represent statistical significance vs. second baseline measurement, whereas the other 
asterisks represent significance between time points (*, p<0.05; **, p<0.01; ***, p<0.001). Black lines represent mean + SD.
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Effects of nitroglycerin on parameters of microcirculation
There were no statistically significant differences in microcirculatory parameters between the 
two baseline measurements. Mean difference ± standard deviation (reproducibility) in PCD 
between both baseline measurements was 0.3 ± 1.1 mm.mm-2. Nitroglycerin decreased delta-T 
(p<0.001) and improved sublingual PCD (p<0.001, Table 2 and Figure 2). Significant changes in 
delta-T and PCD occurred earlier, i.e. at a lower dose of NTG (T2), than changes in global hemo-
dynamics. Between time points T4 and T5, there were no further changes in microcirculatory 
parameters. Mean PCD values returned to baseline after the NTG infusion had been stopped 
for 20 minutes, but mean delta-T values did not. Microcirculatory responses to nitroglycerin 
infusion were consistent in patients with either cardiogenic shock or end-stage chronic heart 
failure. Finally, temporal behaviour of microcirculatory parameters was not different between 
patients who improved in cardiac index vs those who did not improve (Figure 3).
Figure 3. Temporal behaviour of microcirculatory parameters in patients with and without improvement in cardiac index. Lines represent mean 
± SD for improvers and non-improvers in cardiac index. Improvement of cardiac index was defined as an increase ≥ two times the standard 
deviation of the differences between both baseline measurements (i.e., 0.6 L.min-1.min-2), relative to T0. Curve comparison was performed 
using two-way repeated measures ANOVA.
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Figure 2. Individual values of microcirculatory parameters at each dose of nitroglycerin.
Figure 3. Temporal behaviour of microcirculatory parameters in patients with and without 
improvement in cardiac index. 
DiSCUSSiON AND CONCLUSiONS
Using conventional and novel microcirculation assessment technologies, this is the first study 
demonstrating that the nitric oxide (NO) donor and venodilator nitroglycerin dose-dependently 
improves tissue perfusion, as demonstrated by a gradual decrease in temperature gradient and 
a progressive increase in perfused capillary density in patients with severe heart failure.
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Global hemodynamics
Elkayam et al. have demonstrated the hemodynamic effects of nitroglycerin given to eight 
patients hospitalized for acute decompensated heart failure. These investigators up-titrated 
NTG to achieve a 30% or greater reduction in pulmonary capillary wedge pressure or until a 
maximum dose of 560 μg.min-1 (24, 25). They reported a substantial reduction in right and left 
ventricular filling pressures, systemic vascular resistance, and systemic blood pressure, as well 
as an increase in cardiac index. Our study confirms those findings.
Microcirculation
We observed a significant improvement in tissue perfusion, measured by two independent 
parameters, i.e. delta-T and sublingual PCD. Measuring peripheral temperature is a conven-
tional approach to assess peripheral perfusion (26), that can be used to monitor changes in 
tissue perfusion as also demonstrated by our study. However, the accuracy of this technique 
depends highly on the stability of ambient temperature (27). The novel, validated, bed-side 
Sidestream Dark Field imaging technique allows clinicians to directly observe blood flow in 
capillaries covered by a thin epithelial layer, as is the case in the sublingual area (20). De Backer 
et al. (6) were the first to describe sublingual microvascular alterations in patients with severe 
heart failure, and they found that these alterations correlated with in-hospital mortality. Our 
study is the first to demonstrate a progressive improvement of microcirculatory parameters 
following increasing rates of nitroglycerin. Due to the microcirculation’s autoregulatory nature, 
changes in the microcirculation may occur independently from changes in macrocirculation 
(28-30). Interestingly, as clearly demonstrated by our study, changes in microcirculation (i.e., 
both delta-T and PCD) occurred earlier, at a lower dose of NTG, than did changes in global 
hemodynamics. In addition, these changes occurred independently of changes in cardiac 
index. These findings underline the great value of monitoring microcirculation in critically ill 
patients.
Methodological considerations
Microcirculation experts recently published an important concensus statement.(21) Core of 
this statement was that measurement of flow alone, such as microvascular flow index (MFI), is 
regarded as insufficient reporting. However, as opposed to several previous studies which pre-
sented only MFI (10, 31-33), we used a software-derived parameter in which flow and density 
are combined, i.e. perfused capillary density. This parameter has recently been demonstrated to 
be accurate and precise (22, 23). The relatively low standard deviation (1.1 mm.mm-2) of the dif-
ferences between both baseline measurements confirms the precision of PCD measurements.
Limitations
Several limitations of our study should be acknowledged. The small and heterogeneous 
sample size limits drawing strong conclusions. Nevertheless, the consistent and reproducible 
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microvascular response to NTG in almost all patients strengthens our findings. Moreover, 
whether the beneficial effects of nitroglycerin also apply to other microvascular beds, and 
whether recruitment of the microcirculation will reduce cellular dysfunction, organ failure and 
mortality in patients with severe heart failure, needs to be investigated.
Clinical perspective
Measuring tissue perfusion with SDF imaging might be a novel tool to tailor inotropic and 
vasodilator therapy to patients with severe heart failure. Our study is a preliminary confirma-
tion of this concept, demonstrating the feasibility of serial monitoring of the microcirculation, 
while a gradual and consistent improvement of tissue perfusion was observed by titration of 
an intravenous vasodilator.
In conclusion, this study provides evidence for a dose-dependent improvement of micro-
vascular perfusion by administration of nitroglycerin. Whether monitoring of tissue microcircu-
lation optimizes current treatment strategies in patients with severe heart failure, and whether 
such a strategy will favorably affect outcome, warrants further investigation.
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ABSTrACT
Aim: To investigate the effects of inotropic agents on parameters of tissue perfusion in patients 
with cardiogenic shock.
Methods and results: Thirty-two patients with cardiogenic shock were included. Patients 
received dobutamine (n=10), enoximone (n=13), or norepinephrine (n=9). We performed 
hemodynamic measurements at baseline and after titration of the inotropic agent until cardiac 
index (CI) ≥2.5 L.min-1.m-2 or mixed-venous oxygen saturation (SvO2) ≥70% (dobutamine or 
enoximone), and mean arterial pressure (MAP) ≥70 mmHg (norepinephrine). As parameters of 
tissue perfusion, we measured central-peripheral temperature gradient (delta-T) and sublin-
gual perfused capillary density (PCD).
Both dobutamine and enoximone decreased pulmonary capillary wedge pressure (PCWP) 
(p=0.02 and p=0.01), increased CI (p=0.02 and p=0.003), decreased systemic vascular resistance 
(SVR; p=0.02 and p=0.005), decreased delta-T (p=0.02 and p=0.008), and increased PCD (p=0.04 
and p=0.001). Norepinephrine increased MAP (p=0.008), central-venous pressure (p=0.007), 
PCWP (p=0.008), mean pulmonary artery pressure (p=0.01), SVR (p=0.008) and SvO2 (p=0.02), 
whereas it decreased PCD (p=0.02).
Conclusion: This study demonstrates a beneficial effect of dobutamine and enoximone on 
parameters of tissue perfusion in patients with cardiogenic shock. Conversely, norepinephrine 
decreased PCD. Interventions directed at improving microcirculation may eventually help 
bridge the gap between improved hemodynamics and the dismal patient outcome in cardio-
genic shock.
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iNTrODUCTiON
Patients with cardiogenic shock are at risk for impaired perfusion of organs and tissues.(1) Low 
peripheral skin temperature as well as impaired sublingual tissue perfusion have been associ-
ated with multiple organ failure and adverse outcome in hemodynamically compromised 
patients.(2-5) Inotropic agents have the potential to maintain or restore adequate end-organ 
perfusion and function, but their use in heart failure has been associated with increased myo-
cardial oxygen demand and cardiac arrhythmias.(6) Nevertheless, inotropic therapy is often 
considered necessary in patients with cardiogenic shock to improve the hemodynamic status; 
more specifically to increase cardiac output, to decrease pulmonary capillary wedge pressure, 
and to increase mean arterial pressure.(7) Pharmacologic treatment of patients with cardio-
genic shock has several clinical challenges. First, the utility of inotropic therapy in restoring 
end-organ perfusion in patients with cardiogenic shock is based primarily on clinical experience 
rather than clinical trial data.(6) However, clinical examination may be inaccurate in identifying 
patients with low output states and impaired organ perfusion.(8) Second, global hemodynamic 
parameters do not reflect differential patterns of regional organ blood flow or compromised 
tissue perfusion of the splanchnic bed associated with shock states. For example, mean arterial 
blood pressure is often clinically used as a surrogate marker for tissue perfusion. However, not all 
patients with low output states present with hypotension and not all patients with hypotension 
have impaired organ perfusion.(8, 9) This is further demonstrated by the results of the ESCAPE 
trial which did not support the routine use of pulmonary artery catheter guided therapy in 
acute heart failure.(10) Therefore, there is a great need for techniques that directly assess tissue 
perfusion in patients at the bedside.(11) These novel techniques should provide guidance for 
the evaluation of existing and future vasoactive therapies for acute heart failure syndromes and 
may be the key to understand the interventions required to reduce the morbidity and mortality 
associated with multiple organ failure in patients with cardiogenic shock. Aim of this pilot study 
was therefore to investigate the effects of inotropic therapy on parameters of tissue perfusion, 
including sublingual microcirculation as a surrogate for splanchnic perfusion.
METhODS
Study design
This observational study was conducted at the Intensive Cardiac Care Unit of the Thoraxcenter, 
Erasmus University Medical Center, the Netherlands. We included patients who were admitted 
with cardiogenic shock. Cardiogenic shock was defined as a cardiac index <2.2 L.min-1.m-2 and 
clinical signs of hypoperfusion (cold extremities, oliguria or altered mental state), not responsive 
to fluid resuscitation. Patients with oral bleeding were excluded from the study. The decision 
to start inotropic agents was made by the attending physician. Dobutamine or enoximone, 
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depending on the preference of the attending physician, were given when cardiac index was 
<2.2 L.min-1.m-2 or when mixed-venous oxygen saturation was <65%. Both inotropic agents 
were up titrated until cardiac index was ≥2.5 L.min-1.m-2 or SvO2 was ≥70%. Norepinephrine 
was given to patients when mean arterial pressure (MAP) was <60 mmHg. Norepinephrine was 
up titrated until MAP ≥70 mmHg. The institutional ethical committee approved the protocol, 
and written informed consent was obtained from each patient or, in case of patients who were 
sedated, from a relative authorized to consent on behalf of such a patient.
hemodynamic monitoring
All patients were monitored with a radial artery catheter (arterial cannula with FloSwitch, 
Ohmeda, Swindon, UK) and a pulmonary artery catheter (Criticath SP5107H, Becton Dickinson, 
Sandy, UT, USA or CCOmbo, Edwards Lifesciences, Saint-Prex, Switzerland). Data collection 
included central body temperature, heart rate (HR), mean arterial pressure (MAP), central 
venous pressure (CVP), pulmonary capillary wedge pressure (PCWP), mean pulmonary artery 
pressure (PAP), cardiac index (CI), systemic vascular resistance (SVR), and mixed-venous oxygen 
saturation (SvO2). SVR was calculated as (MAP-CVP)*80/cardiac output.
Microcirculatory assessment and analysis
Central-peripheral temperature gradient (delta-T) was defined and calculated as the difference 
between central blood and skin temperature. Skin temperature was measured with a probe 
sticked on the dorsum of the foot under constant room temperature (temperature probe 
170075; Ellab Inc., Centennial, CO, USA).
The Sidestream Dark Field (SDF) imaging device (MicroScan; Microvision Medical, 
Amsterdam, The Netherlands) was used to obtain 2-dimensional video images of sublingual 
microcirculatory blood flow. This technique has been described previously.(12) In short, the 
camera emits green light that is absorbed by red blood cells within microvessels. In this way, 
red blood cells are used as the contrast agent to visualize sublingual blood flow in patent 
microvessels. This is the reason why oral bleeding was an exclusion criterion for the study. Per 
time point, three steady video sequences of at least 20 seconds duration were obtained, stored 
and analyzed. Quantification of the images was done using dedicated software (Automated 
Vascular Analysis 3.0, MicrovisionMedical, Amsterdam, the Netherlands). An investigator who 
was blinded for the patient’s therapy performed quantification. Perfused capillary density 
(PCD) was calculated by automated measuring the total length of perfused capillaries divided 
by image area. Since SDF imaging enables visualization of flowing intravascular erythrocytes 
rather than microvessel walls, an increase in PCD was regarded as capillary recruitment. This 
approach has been validated previously.(13, 14) Capillaries were defined as microvessels with 
a diameter less than 20 μm.
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Study protocol
To minimize the effect of regression to the mean due to spontaneous variation in microcircula-
tory perfusion, two series of baseline measurements were performed with a time interval of 
15 minutes. Values from both baseline measurements were averaged to obtain single baseline 
values. After the second baseline measurement, the inotropic agent was given as a bolus equal 
to the volume of the used intravenous line. Immediately thereafter, a continuous intravenous 
infusion was started and titrated. All measurements were repeated 10 minutes (dobutamine or 
norepinephrine) or 30 minutes (enoximone) after the maximum infusion rate had been started.
Statistical analysis
Categorical variables are presented as absolute numbers with percentages. All continuous 
variables are presented as median and interquartile range (IQR). Differences between groups 
were tested with the chi-square test, the Mann-Whitney test or the Kruskal-Wallis test, when 
appropriate. Changes between time points were tested with the Wilcoxon signed ranks test. 
Correlations between variables were investigated with Spearman’s correlation test. A p-value 
<0.05 was regarded statistically significant.
rESULTS
Study population
Thirty-two patients with cardiogenic shock were included in this study. Ten patients received 
dobutamine (dobu), 13 patients received enoximone (enox), and 9 patients received norepi-
nephrine (nor). There were no major differences in baseline characteristics between the groups 
(Table 1). The following maximum dosages of intropic agents were administered: 5 [5-5] μg.kg-1.
min-1 (dobutamine), 2.0 [1.5-2.0] μg.kg-1.min-1 (enoximone), and 0.10 [0.05-0.25] μg.kg-1.min-1 
(norepinephrine). No inotrope-induced arrhythmias occurred during execution of the study.
Effects on systemic and pulmonary circulation
There were no significant differences in global hemodynamic or microcirculatory parameters 
between the two baseline measurements in the three groups, indicating that patients were in 
a stable condition before the inotropic agent was started. Baseline hemodynamic parameters 
were not significantly different between patients receiving dobutamine or enoximone. How-
ever, patients treated with norepinephrine had a lower baseline MAP (dobu vs. nor: p=0.001; 
enox vs. nor: p<0.001), and a lower baseline SVR (dobu vs. nor: p=0.01; enox vs. nor: p<0.001) 
(Table 2).
Absolute changes in parameters are shown in Table 3. Figure 1 shows the changes in CVP 
and CI at individual patient level. Both dobutamine and enoximone decreased PCWP (p=0.02 
and p=0.01, respectively), increased CI (p=0.02 and p=0.003, respectively), and decreased SVR 
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(p=0.02 and p=0.005, respectively). Norepinephrine increased MAP (p=0.008), CVP (p=0.007), 
PCWP (p=0.008), MPAP (p=0.01), SVR (p=0.008), and SvO2 (p=0.02).
Dobutamine increased heart rate significantly more than the other inotropes (dobu vs. enox: 
p=0.003; dobu vs. nor: p=0.02; Table 3). Changes in other macrohemodynamic parameters were 
not significantly different between patients receiving dobutamine or enoximone. ΔMAP was 
higher in patients receiving norepinephrine (dobu vs. nor: p<0.001; enox vs. nor: p<0.001), 
Table 1. Baseline characteristics of the study population.
Characteristic Dobutamine
(n=10)
Enoximone
(n=13)
Norepinephrine
(n=9)
P-value
Age, years (median [IQR]) 61 [49-77] 57 [49-72] 63 [56-80] NS
Male 5 (50%) 9 (69%) 5 (56%) NS
CV risk factors
 Hypertension
 Current smoking
 Dyslipidaemia
 Diabetes mellitus
5 (50%)
2 (20%)
4 (40%)
2 (20%)
6 (46%)
2 (15%)
5 (39%)
6 (46%)
3 (33%)
1 (11%)
5 (56%)
2 (22%)
NS
NS
NS
NS
Main cause of cardiogenic shock
 AMI
 Cardiomyopathy
 Post CP resusctitation
 Post cardiac surgery
9 (90%)
1 (10%)
0 (0%)
0 (0%)
7 (54%)
4 (31%)
0 (0%)
2 (15%)
4 (44%)
2 (22%)
1 (11%)
2 (22%)
NS
NT-proBNP level, pmol.L-1 
(median [IQR])
844 [189-1386] 708 [435-1966] 1176 [393-1819] NS
Mechanical ventilation 8 (80%) 4 (31%) 7 (78%) 0.02
IABP counterpulsation 4 (40%) 8 (62%) 1 (11%) NS
Abbreviations: IQR, interquartile range; CV, cardiovascular; AMI, acute myocardial infarction; CP, cardiopulmonary; NT-proBNP, N-terminal-pro 
B-type natriuretic peptide; IABP, intra-aortic balloon pump. P-values >0.05 (NS, non-significant) are not shown.
Table 2. Parameters at baseline.
Dobutamine
(n=10)
Enoximone
(n=13)
Norepinephrine
(n=9)
P-value
hr, bpm 84 [57-96] 89 [78-109] 96 [86-116] NS
MAP, mmhg 70 [61-84] 66 [62-82] 53 [51-57] <0.001
CvP, mmhg 13 [9-16] 14 [9-18] 12 [8-17] NS
PCWP, mmhg 21 [16-23] 23 [17-28] 20 [14-23] NS
MPAP, mmhg 30 [22-34] 31 [25-34] 27 [24-31] NS
Ci, L.min-1.m-2 2.0 [1.7-3.4] 2.0 [1.7-2.5] 3.0 [2.4-3.7] NS
Svr, dynes.sec.cm-5 1268 [927-1636] 1023 [829-1677] 589 [497-612] 0.003
SvO2, % 67 [59-69] 61 [56-64] 69 [63-74] NS
Lactate, mmol.L-1 1.1 [1.0-1.3] 1.2 [1.0-2.1] 1.1 [0.9-2.1] NS
Delta-T, °C 6.8 [4.3-8.2] 5.0 [3.6-6.2] 5.1 [3.6-5.6] NS
PCD, mm.mm-2 9.1 [7.7-10.1] 9.4 [8.7-10.6] 11.7 [10.3-12.6] 0.002
Abbreviations: HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; MPAP, 
mean pulmonary artery pressure; CI, cardiac index; SVR, systemic vascular resistance; SvO2, mixed-venous oxygen saturation; delta-T, 
central-peripheral temperature gradient; PCD, perfused capillary density. Values represent median [interquartile range]. P-values >0.05 (NS, 
non-significant) are not shown.
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as well as ΔCVP (dobu vs. nor: p=0.01; enox vs. nor: p<0.001), ΔPCWP (dobu vs. nor: p<0.001; 
enox vs. nor: p<0.001), ΔMPAP (dobu vs. nor: p=0.01; enox vs. nor: p=0.02), ΔSVR (dobu vs. nor: 
p<0.001; enox vs. nor: p<0.001), and Δlactate (dobu vs. nor: p=0.04; enox vs. nor: p=NS). ΔCI 
was lower in patients receiving norepinephrine (dobu vs. nor: p=0.004; enox vs nor: p=0.001).
Figure 1. Changes in central venous pressure, cardiac index, delta-T, and perfused capillary density at individual patient level. ↓↑, decrease or 
increase of parameter following inotropic therapy in terms of percentage relative to baseline.
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Figure 1. Ch nges in central venous pressure, card ac index, delta-T, and perfused capillary 
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Effects on microcirculation
Baseline delta-T and PCD were not significantly different between patients receiving dobuta-
mine or enoximone. Patients who received norepinephrine had a higher baseline sublingual 
perfused capillary density (nor vs. dobu: p=0.001; nor vs. enox: p=0.001, Table 2). Figure 1 shows 
the changes in delta-T and PCD at individual patient level. Both dobutamine and enoximone 
decreased delta-T (p=0.02 and p=0.008, respectively), and increased PCD (p=0.04 and p=0.001, 
respectively, Table 3). Norepinephrine decreased PCD (p=0.02). Changes in delta-T and PCD 
were not significantly different between patients receiving dobutamine or enoximone. 
Table 3. Changes in macro- and microcirculation after administration of inotropic agents.
Dobutamine
(n=10)
Enoximone
(n=13)
Norepinephrine
(n=9)
P-value
Δhr, bpm +11 [+8; +16]** -2 [-7; +5] +1 [-7; +7] 0.01
ΔMAP, mmhg -1 [-10; +14] 0 [-5; +8] +25 [+17; +36]** <0.001
ΔCvP, mmhg -1 [-3; +2] -2 [-3; -1]* +2 [+2; +6]** 0.002
ΔPCWP, mmhg -1 [-2; 0]* -2 [-7; -1]* +5 [+3; +9]** <0.001
ΔMPAP, mmhg 0 [-3; +2] -3 [-1; +1] +4 [+2; +9]* 0.02
ΔCi, L.min-1.m-2 +0.8 [+0.5; +1.6]* +0.8 [+0.3; +1.6]** -0.3 [-0.5; +0.2] 0.003
ΔSvr, dynes.sec.cm-5 -364 [-715; -54]* -379 [-738; -122]** +467 [+138; +504]** <0.001
ΔSvO2, % +4 [+2; +10]* +2 [-1; +8] +3 [+1; +7]* NS
ΔLactate, mmol.L-1 -0.3 [-0.5; -0.1]* +0.1 [-0.1; +0.3] 0.0 [-0.2; +0.2] 0.02
ΔDelta-T, °C -0.5 [-2.4; -0.3]* -1.3 [-2.5; -0.2]** +0.4 [+0.0; +1.1] 0.004
ΔPCD, mm.mm-2 +1.5 [-0.3; +2.5]* +2.5 [+1.1; +3.2]** -1.1 [-3.3; -0.1]* <0.001
Values represent median [interquartile range]. Asterisks indicate statistical significance versus baseline: *, p<0.05; **,p<0.01; ***, p<0.001. 
P-values >0.05 (NS, non-significant) are not shown. Abbreviations: HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; 
PCWP, pulmonary capillary wedge pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index; SVR, systemic vascular resistance; SvO2, 
mixed-venous oxygen saturation; delta-T, central-peripheral temperature gradient; PCD, perfused capillary density.
Figure 2. Inverse correlation between (pooled) changes in central venous pressure and changes in sublingual perfused capillary density.
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Figure 2. Inverse correlation between (pooled) changes in central venous pressure and 
changes in sublingual perfused capillary density.
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However, norepinephrine had a different effect on delta-T (dobu vs. nor: p=0.003; enox vs. nor: 
p=0.003) and PCD (dobu vs. nor: p=0.003; enox vs. nor: p<0.001; Table 3).
Correlations
In this (small) study, we found no significant correlations between changes in CI or SVR and 
changes in either delta-T or PCD. However, there was an inverse correlation between (pooled) 
changes in CVP and changes in PCD (Rho=-0.57, p=0.001, Figure 2). There was no correlation 
between changes in CVP and changes in delta-T.
DiSCUSSiON
This is the first study demonstrating the direct effects of various inotropes on the microcircula-
tion measured at the bedside in patients with cardiogenic shock. Dobutamine and enoximone 
decreased central-to-peripheral temperature gradient and increased the number of sublingual 
patent capillaries, whereas norepinephrine decreased perfused capillary density.
Effects on systemic and pulmonary circulation
Dobutamine and enoximone are the most commonly used intravenous inotropes for the 
management of cardiogenic shock in our center. Both agents are given to increase cardiac con-
tractility by increasing intracellular levels of cyclic adenylate monophosphate (cAMP), although 
they affect cAMP by different mechanisms. Caldicott et al. compared the effects of enoximone 
with dobutamine in patients with severe heart failure following myocardial infarction.(15) 
These authors reported that both agents similarly increased cardiac output. Dobutamine, 
opposite to enoximone, also significantly increased heart rate and produced significantly 
more runs of supraventricular and ventricular tachycardia. Our findings agree with this report. 
Although enoximone is a potent vasodilator, we found no consistent change in mean arterial 
pressure following enoximone infusion. This limited risk of (further) reducing mean arterial 
pressure has been reported previously by Vincent et al.(16, 17) and suggests that, whenever 
possible, enoximone should be preferred over dobutamine in the setting of cardiogenic shock. 
Norepinephrine is an inotropic agent with high affinity for alfa-adrenergic receptors and acts 
therefore mainly as vasopressor.
Norepinephrine increases mean arterial pressure(18), and is therefore frequently used in the 
acute phase of cardiogenic shock to restore mean arterial pressure. In addition, norepinephrine 
may increase coronary blood flow in cardiogenic shock.(19)
Effects on microcirculation
The beneficial effect of dobutamine on parameters of microcirculatory perfusion, i.e. delta-T 
and PCD, was significant in our study, albeit not consistent in all patients. Similarly, De Backer 
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et al. reported a modest improvement of sublingual capillary perfusion in patients with septic 
shock receiving dobutamine, but with large individual variation.(20)
Enoximone improved capillary skin blood flow, measured by a laser Doppler technique, in a 
study in patients undergoing cardiopulmonary bypass surgery.(21) In addition, Kern et al. dem-
onstrated a beneficial effect of enoximone on hepatosplanchnic oxygen consumption and on 
liver function in fluid-optimized septic shock patients.(22) Our study demonstrates a consistent 
increase in PCD and decrease of delta-T in a different patient population, i.e. cardiogenic shock.
The effects of norepinephrine on tissue perfusion are largely unknown. Most studies per-
formed in patients with septic shock demonstrated no effect of norepinephrine on splanchnic 
perfusion.(23, 24) We are not aware of any reports on the effects of norepinephrine on the 
microcirculation in cardiogenic shock. Maier et al. recently investigated the response of the 
sublingual microcirculation to the pure alfa-adrenergic agonist phenylephrine during cardio-
pulmonary bypass surgery. Increasing perfusion pressure from (mean) 47 to (mean) 68 mmHg 
using phenylephrine significantly decreased sublingual capillary microvascular flow index, 
whereas global tissue blood flow, measured with a laser Doppler flowmeter, increased.(25) 
These findings were explained as significant microcirculatory shunting induced by phenyleph-
rine. Indeed, using microspheres, Saxena and Verdouw demonstrated in the year 1985 the pres-
ence of arteriovenous anastomoses in the tongue.(26) In our study, norepinephrine modestly 
but significantly decreased sublingual PCD, whereas cardiac index remained constant and SvO2 
increased. These findings also suggest development of microcirculatory shunting induced by 
norepinephrine in patients with cardiogenic shock.
Correlations between macrocirculation and microcirculation
The apparent lack of correlation between cardiac index and microcirculatory parameters has 
been shown previously.(20, 27) This finding emphasizes that global hemodynamic parameters 
do not predict microcirculatory perfusion and it underlines the importance of monitoring 
macro- as well as microcirculation in patients with cardiogenic shock.(28) Nevertheless, in 
our study we found a modest, but significant correlation between changes in central venous 
pressure and changes in PCD, which confirms the concept that a strategy of reducing CVP may 
favourably affect organ perfusion.(29, 30) There is indeed growing evidence that hypervolemia 
in patients with heart failure is an independent predictor for disease progression and death 
from pump failure.(31) In addition, Mullens et al recently demonstrated that the development 
of renal failure was significantly associated with an elevated central venous pressures and that 
central venous pressure on hospital admission, rather than impaired cardiac output, was a 
predictor for worsening renal function during hospital admission for heart failure.(32)
Limitations
Several limitations of our study should be acknowledged. The small and heterogeneous sample 
size limits drawing strong conclusions. Next, the fact that our study was nonrandomized might 
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have introduced bias. Finally, whether the beneficial effects of nitroglycerin also apply to other 
microvascular beds, whether the observed changes in microcirculatory perfusion are clinically 
significant, and whether recruitment of the microcirculation will reduce cellular dysfunction, 
organ failure and mortality in patients with cardiogenic shock, needs to be investigated.
CONCLUSiON
This study demonstrates the beneficial effects of both dobutamine and enoximone on param-
eters of tissue perfusion. Conversely, norepinephrine decreased perfused capillary density. 
These findings add to the concept that administration of vaso-active agents may potentially 
be guided by monitoring microcirculation in the setting of acute cardiac care. Interventions 
directed at improving macro- as well as microvascular perfusion may eventually help bridge 
the gap between improved hemodynamics and the dismal patient outcome in cardiogenic 
shock. Whether monitoring of tissue microcirculation optimizes current treatment strategies in 
patients with severe heart failure and whether such a strategy will favourably affect outcome, 
warrants further investigation.
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microcirculation in patients with 
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ABSTrACT
Objectives: It was the aim of this study to evaluate the effects of intra-aortic balloon pump 
(IABP) counterpulsation on sublingual microcirculation as a model for splanchnic perfusion.
Methods: In 13 patients with cardiogenic shock treated with IABP, the IABP assist ratio was 
reduced from 1:1 to 1:8 for 15 min. Using sidestream dark field imaging, 117 movie files of the 
sublingual microcirculation were obtained and quantified at different IABP assist ratios at 3 
time points: 1:1 (T0), 1:8 (T1), and 1:1 (T2). Data are presented as the median and interquartile 
range.
results: The median age of the patients was 59 [56-73] years and 62% were males. Discon-
tinuation of IABP decreased the mean arterial pressure (75 [71-84] mmHg at T0 vs. 69 [64-79] 
mmHg at T1, p<0.001), cardiac index (2.9 [1.6-3.3] L/min/m2 at T0 vs. 2.4 [1.5-2.8] L/min/m2 at 
T1, p=0.005), and cardiac power index (0.46 [0.29-0.59] W/m2 at T0 vs. 0.36 [0.24-0.50] W/m2 
at T1, p=0.006). However, these modest changes in macrohemodynamics did not significantly 
influence sublingual perfused capillary density and capillary red blood cell velocity (p=0.28 and 
0.73, respectively).
Conclusion: A temporary, modest decrease in microcirculatory driving force, induced by lower-
ing the IABP assist ratio, does not impair sublingual microcirculatory perfusion as measured by 
a novel 2-dimensional imaging technique.
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iNTrODUCTiON
Tissue hypoperfusion is considered an important factor in the pathophysiology of critical 
diseases and has been associated with in-hospital mortality.(1-3) Optimization of tissue 
microcirculation is one of the objectives of modern treatment of critically ill patients.(4, 5) 
Microcirculatory impairment is thought to play a crucial role in the phenomenon of established 
or improved macrocirculatory hemodynamics, but still poor prognosis in critically ill patients. 
However, the influence of macrocirculatory therapeutic maneuvers on tissue microcirculation 
is largely unknown.
Intra-aortic balloon pump (IABP) counterpulsation has been increasingly used over time to 
improve mean arterial blood pressure, increase diastolic coronary perfusion pressure, reduce 
afterload, and decrease myocardial demand by reducing cardiac work. However, the effects of 
IABP counterpulsation on tissue perfusion have not been investigated extensively. Intra-aortic 
balloon pump counterpulsation increases mean arterial pressure (MAP), which is a prerequisite 
for peripheral blood flow.(6, 7) In addition, Fries and coworkers have reported a close correla-
tion between peripheral capillary blood flow and coronary perfusion pressure in pigs subjected 
to cardiac arrest and resuscitation.(8) We hypothesized that perfusion in a microvascular bed 
away from the heart might be impaired by an interruption in intra-aortic counterpulsation. 
Using a novel handheld videomicroscope applying sidestream dark field imaging (SDF), we 
investigated whether alterations in macrocirculation, induced by a decrease in IABP assist ratio, 
impaired sublingual microcirculation.
MATEriALS AND METhODS
Study design
This real-time pre-/postintervention study was conducted at the Thoraxcenter of Erasmus 
University Medical Center. Data collection was based on SDF imaging and on routine measure-
ments. The institutional ethics committee on human research approved the protocol, and writ-
ten informed consent was obtained from each patient or, in case of patients who were sedated, 
from a relative authorized to consent on behalf of such a patient.
Patients
Thirteen consecutive patients who received an IABP for cardiogenic shock were included in this 
study. All IABPs (AutoCAT2 WAVE; FiberOptix, Arrow International Inc., Reading, PA, USA) were 
inserted at the catheterization laboratory.
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Macrohemodynamic monitoring
Patients were monitored with a radial artery catheter (arterial cannula with FloSwitch, Ohmeda, 
Swindon, UK) and a pulmonary artery catheter (Becton Dickinson Criticath SP5107H, Sandy, 
UT, USA). The following parameters of systemic and pulmonary circulation were collected: 
central body temperature, heart rate, MAP, central venous pressure, pulmonary capillary wedge 
pressure, mean pulmonary artery pressure, cardiac index (CI), systemic vascular resistance, 
lactate level, and mixed venous oxygen saturation. The cardiac power index was calculated as 
MAP*CI/451.(9)
Microcirculatory assessment and analysis
The SDF device (MicroScan; Microvision Medical, Amsterdam, The Netherlands) was used to 
obtain 2-dimensional video images of sublingual microcirculatory blood flow. This technique 
has been described and validated previously(2, 10, 11) and is demonstrated in Figure 1. Each 
time point, 3 steady video sequences with a duration of at least 20 s were obtained, stored 
and subsequently analyzed blindly. In total, 117 video sequences were obtained. Quantification 
of the images was performed using software (AVA 3.0, MicrovisionMedical). Perfused capillary 
density (PCD) was calculated by measuring the total length of perfused capillaries divided 
by image area. Capillaries were defined as the microvessels with a diameter <20 μm. Using 
space-time diagrams, erythrocyte velocity was measured in 5 representative capillaries per 
video sequence. Velocities were calculated by determination of the slope of moving centerline 
intensity of a microvessel, expressed as vertical lines for 10 consecutive frames.
Figure 1. SDF imaging setup. Video frames of the sublingual microcirculation were acquired using an SDF imaging device (left) and captured 
on a computer (upper right). The SDF device applies a central light guide that is surrounded by but isolated from concentrically placed light 
emitting diodes that stroboscopically emit green light for illumination. This green light is absorbed by erythrocytes flowing through the tissue 
under investigation. The hemoglobin is actually used as contrast agent, so that red blood cells are imaged as dark moving globules against a 
white/grayish background. Modified from (15).
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Study protocol
Microcirculation and global hemodynamic parameters were measured at 3 subsequent time 
points. First, all measurements were performed at an IABP assist ratio of 1:1 (T0). Then, the 
IABP assist ratio was set at 1:8 and all measurements were repeated after a time period of 15 
minutes at an IABP assist ratio of 1:8 (T1). After these measurements, the IABP console was 
reprogrammed at 1:1 and all measurements were performed again after an interval of 15 min 
(T2). During execution of the study, dosages of intravenous medications were stable.
Statistical analysis
Categoric variables are presented as absolute number, with percentage. All measurements are 
presented as the median with interquartile range (IQR, [25th–75th percentiles]). Changes over 
time were tested with the Friedman test. Linear correlations between macrocirculatory and 
microcirculatory parameters were calculated with the Spearman correlation test.
rESULTS
Baseline characteristics of the study population are shown in Table 1. Median age was 59 [56-
73] years and 62% were males. Most patients had cardiogenic shock due to acute myocardial 
infarction (69%). All patients tolerated the study protocol without adverse events. Global 
Table 1. Clinical characteristics of the study population (n=13).
Characteristic
Age, years (median and IQR) 59 [56-73]
Male 8 (62%)
CV risk factors: Hypertension
 Current smoking
 Dyslipidemia
 Diabetes mellitus
8 (62%)
3 (23%)
3 (23%)
3 (23%)
Main cause of cardiogenic shock: Acute MI
 Post resuscitation
 Dilated cardiomyopathy
 Mechanical complication of acute MI
 Post cardiotomy
8 (62%)
1 (8%)
2 (15%)
1 (8%)
1 (8%)
Cooling after out-of-hospital CA 3 (23%)
Mechanical ventilation 11 (85%)
NT-pro-BNP level, pmol/L (median and IQR) 673 [265-1674]
CRP level, mg/L (median and IQR) 20 [13-92]
Pharmacologic therapy Any inotropic agent*
 Vasopressors†
 Vasodilators‡
11 (85%)
4 (31%)
7 (54%)
Values are number of patients, with percentages in parentheses, unless otherwise noted. Abbreviations: IQR, interquartile range; CV, 
cardiovascular; MI, myocardial infarction; CA, cardiac arrest; NT-pro-BNP, N-terminal portion of pro-B-type natriuretic peptide; CRP, C-reactive 
protein; ASA, acetyl salicylic acid. * Dobutamine, dopamine, norepinephrine, enoximone or Levosimendan. † Norepinephrine or dopamine at a 
dose >5 μg.kg-1.min-1. ‡ Nitroglycerin, enoximone or levosimendan.
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hemodynamic and microcirculatory parameters over time are shown in Table 2. Lowering 
the IABP assist ratio decreased the MAP (75 [71-84] mmHg at T0 vs. 69 [64-79] mmHg at T1, 
p<0.001), CI (2.9 [1.6-3.3] L/min/m2 at T0 vs. 2.4 [1.5-2.8] L/min/m2 at T1, p=0.005), and cardiac 
power index (0.46 [0.29-0.59] W/m2 at T0 vs. 0.36 [0.24-0.50] W/m2 at T1, p=0.006). However, 
sublingual PCD (10.4 [8.1-11.6] mm-1, 9.6 [7.8-11.5] mm-1 and 10.0 [7.5-12.0] mm-1 at T0, T1 and 
T2, respectively, p=0,28) and red blood cell (RBC) velocity in capillaries (340 [236-428] μm.s-1, 
281 [202-417] μm.s-1 and 301 [237-377] μm.s-1 at T0, T1, and T2, respectively, p=0.73) did not 
change significantly.
In this (small) study, the baseline MAP, CI, and cardiac power index did not correlate with 
baseline PCD or capillary RBC velocity. In addition, changes in mean arterial pressure (ΔMAP), 
cardiac index (ΔCI) or cardiac power index (ΔCPI) did not significantly correlate to changes in 
either PCD (ΔPCD) or capillary RBC velocity (Δ capillary RBC velocity) between T1 and T0.
DiSCUSSiON AND CONCLUSiONS
The most important finding of this study was that, despite statistically significant changes in 
macrohemodynamics, there were no direct, major changes in sublingual microvascular perfu-
sion during lowering of the IABP assist ratio from 1:1 to 1:8.
Future monitoring of critically ill patients admitted to the intensive cardiac care unit might 
increasingly include parameters of tissue perfusion. To our knowledge, this is the first study 
reporting the direct effects of intra-aortic counterpulsation on microcirculation measured at 
the bedside. Although we expected a decrease in microvascular perfusion after reducing the 
Table 2. The effects of lowering the IABP assist ratio on global hemodynamic parameters and sublingual microcirculation.
iABP1:1 (T0) iABP 1:8 (T1) iABP 1:1 (T2) P-value
Central body temperature (°C) 36.6 [33.1-37.4] 36.5 [33.1-37.4] 36.6 [33.1-37.5] 0.22
hr (bpm) 99 [77-112] 99 [78-112] 99 [78-112] 0.27
MAP (mmhg) 75 [71-84] 69 [64-79] 72 [70-82] <0.001
CvP (mmhg) 14 [13-15] 14 [13-16] 13 [12-15] 0.14
Wedge pressure (mmhg) 20 [15-22] 20 [17-23] 18 [14-21] 0.08
Mean PAP (mmhg) 27 [21-34] 28 [25-34] 26 [21-34] 0.50
Ci (L.min-1.m-2) 2.9 [1.6-3.3] 2.4 [1.5-2.8] 2.6 [1.8-3.0] 0.005
Svr (dynes.sec.cm-5) 1107 [635-1714] 1063 [821-1845] 1118 [752-1502] 0.58
CPi (W/m2) 0.46 [0.29-0.59] 0.36 [0.24-0.50] 0.41 [0.29-0.52] 0.006
Lactate (mmol.L-1) 1.8 [1.1-4.8] 2.7 [1.0-4.1] 1.9 [1.0-4.2] 0.35
SvO2 (%) 78 [73-82] 70 [69-73] 76 [73-80] 0.18
PCD (mm-1) 10.4 [8.1-11.6] 9.6 [7.8-11.5] 10.0 [7.5-12.0] 0.28
Capillary rBC velocity (μm.s-1) 340 [236-428] 281 [202-417] 301 [237-377] 0.73
T0: situation at baseline; T1: 15 minutes after switching the IABP ratio to 1:8; T2: 15 minutes after switching the IABP ratio back to 1:1. All values 
are shown in median [25th-75th percentiles]. Abbreviations: IABP, intra-aortic balloon pump; HR, heart rate; MAP, mean arterial pressure; CVP, 
central venous pressure; PAP, pulmonary artery pressure; CI, cardiac index; SVR, systemic vascular resistance; CPI, cardiac power index; SvO2, 
mixed-venous oxygen saturation; PCD, perfused capillary density; RBC, red blood cell.
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IABP assist ratio, there was no change in either PCD or capillary RBC velocity. Several expla-
nations can be offered for our findings. First, lowering IABP assist ratio decreased MAP with 
median 6 mm Hg, whereas the CI decreased with median 0.5 L/min/m2 and cardiac power 
index decreased with median 0.10 W/m2. With such modest changes in microcirculatory driving 
forces, the precapillary sphincter (arterioles) will adapt in radius and thereby hold flow within 
a constant value by the well-know physiological concept termed autoregulation.(12) Second, 
central venous pressure, which in fact reflects microcirculatory afterload, did not change in 
the study. Microcirculatory afterload might be an even more important determinant of tissue 
perfusion(13), which was also demonstrated by recent studies investigating the effects of veno-
dilators in critically ill patients.(14, 15) Third, 54% of the patients were treated with vasodilators, 
which might have influenced the results.
During IABP support, MAP is a complex number. While the overall MAP may increase, the 
diastolic augmentation combined with systolic unloading and a decreased absolute diastolic 
pressure may have a neutral effect on tissue perfusion. Indeed, most studies demonstrated 
little effect of IABP counterpulsation on mean coronary, carotid or cerebral blood flow.(16-19) 
Our findings are consistent with these data. In addition, microcirculatory autoregulation may 
explain why the changes in MAP could not be correlated with alterations in microcirculatory 
parameters, which is conform to a previous study in patients during surgery with cardiopulmo-
nary bypass.(20)
Several limitations of our study should be acknowledged. First, we measured mean red 
blood cell (RBC) velocities for 10 averaged video frames without information on the period of 
the cardiac cycle at that specific time moment. In pulsatile conditions, erythrocyte velocity in 
the microcirculation is variable and coincides with the cardiac cycle.(21) It is very well possible 
that fluctuation in RBC velocities increases during intra-aortic counterpulsation. Unfortunately, 
due to current technical limitations, we did not analyze RBC velocity synchronized to the cardiac 
cycle. Second, due to the limited frame rate of the SDF video camera (25 images/sec), very high 
velocities in microvessels (>1000 μm/s) could not reliably be measured. However, velocities in 
our study were far below this limit. Finally, a time period of 15 minutes between measurements 
might be too short to induce changes in microvascular perfusion. This point is underlined by 
a previous study that demonstrated that several macrohemodynamic parameters increased 
significantly only 3 hours after IABP insertion.(22)
In conclusion, we demonstrated the feasibility of combined monitoring of macrocirculation 
and tissue microcirculation in patients with cardiogenic shock treated with IABP counterpul-
sation. This study demonstrated that a decrease in the IABP assist ratio lasting 15 min does 
not change sublingual microcirculation, providing a novel argument that modest changes 
in macrocirculatory parameters do not necessarily imply alteration of microcirculatory blood 
flow. Further studies should include baseline measurements prior to IABP insertion in order to 
elucidate the full effects of IABP counterpulsation on tissue perfusion.
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ABSTrACT
Objectives: This study evaluated the effects of mechanical circulatory support (MCS) on sublin-
gual microcirculation as a surrogate for splanchnic microvascular perfusion.
Methods: Between May 2008 and April 2009, 10 consecutive patients received an MCS device 
or extracorporeal membrane oxygenation for end-stage chronic heart failure (n=6) or cardio-
genic shock (n=4). Microcirculation was investigated using a hand-held Sidestream Dark Field 
imaging device. Perfused capillary density (PCD) and capillary red blood cell velocity (cRBCv) 
were assessed before device implantation (T0), immediately after implantation (T1), and 1 day 
post implantation (T2). Data are presented as median [interquartile range].
results: Median patient age was 45 [38-52] years and 70% were men. MCS significantly 
decreased pulmonary capillary wedge pressure (p=0.04). Cardiac power index increased (0.29 
[0.21-0.34] W.m-2 at T0 vs. 0.48 [0.39-0.54] W.m-2 at T1, p=0.005) as well as central venous oxygen 
saturation (54 [46-61] % at T0 vs. 78 [67-85] % at T1, p=0.007). There was a 3-fold increase in 
tissue perfusion index (sublingual PCD * cRBCv) during mechanical circulatory support (573 
[407-693] at T0 vs. 1909 [1771-2835] at T1, p=0.005). Microcirculatory parameters remained 
improved at T2.
Conclusion: Mechanical circulatory support for severe heart failure is associated with a consis-
tent, significant and sustained improvement in tissue perfusion, as measured at the bedside by 
a 2-dimensional microcirculation imaging technique.
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iNTrODUCTiON
Mechanical circulatory support (MCS) devices, including ventricular assist devices (VADs), 
are used to provide effective hemodynamic support as a bridge to myocardial recovery or in 
patients awaiting heart transplantation.(1-4) Patients who are eligible to receive a MCS device 
are at high risk that multiple organ failure will develop.(5) MCS devices have the potential to 
reverse the syndrome of severe heart failure, and to improve functional status, quality of life, 
and outcome in patients with severe cardiac dysfunction.(1, 6)
Tissue hypoperfusion is an important factor in the pathophysiology of multiple organ failure 
and has been associated with in-hospital death.(7, 8) Global hemodynamic parameters do not 
reflect differential patterns of regional organ blood flow or compromised tissue perfusion of 
the splanchnic bed associated with shock states. Therefore, optimization of tissue microcircula-
tion should be an objective of the treatment of critically ill patients.(9) However, it is largely 
unknown whether interventions that significantly increase cardiac output, including implan-
tation of a MCS device, do improve tissue capillary perfusion. Goal-directed manipulation of 
hemodynamics is the key to understanding the interventions required to reduce the morbidity 
and mortality associated with multiorgan and hepatorenal failure in patients with end-stage 
heart disease.
We hypothesized that MCS devices do have beneficial effects on perfusion in a microvascular 
bed away from the heart. Using a novel handheld videomicroscope applying Sidestream Dark 
Field (SDF) imaging, we investigated perfusion of the sublingual mucosa, as a prognosticating 
surrogate for splanchnic microperfusion, before and after implantation of a MCS device.
METhODS
Study design
This observational study was conducted at the Thoraxcenter, Erasmus University Medical 
Center, Rotterdam, the Netherlands. The Institutional Ethical Committee on Human Research 
approved the protocol. Written informed consent was obtained from each patient or, in case 
of patients who were sedated, from a relative authorized to consent on behalf of the patient.
Patients and devices
We included 10 consecutive patients with end-stage heart failure or cardiogenic shock, who 
received a MCS device between May 2008 and April 2009 in our center. Cardiogenic shock 
was defined as a cardiac index (CI) <2.2 L.min-1.m-2 and clinical signs of hypoperfusion (cold 
extremities, oliguria or altered mental state), not responsive to fluid resuscitation. The cardiac 
assist devices used were HeartMate II (Thoratec Corp, Pleasanton, CA, USA) in 7 patients, 
Centrimag (Levitronix, LLC, Walthan, MA, USA) in 2 patients, and TandemHeart (CardiacAssist 
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Inc, Pittsburgh, PA, USA) in 1 patient. Extracorporeal membrane oxygenation (ECMO/ECLS, 
Maquet Inc, Bridgewater, NJ, USA) was used in 2 patients.
hemodynamic monitoring
Patients were monitored with a pulmonary artery catheter (Becton Dickinson Criticath 
SP5107H, Sandy, UT, USA). The following parameters of systemic and pulmonary circulation 
were collected: central body temperature, heart rate, mean arterial pressure (MAP), central 
venous pressure, pulmonary capillary wedge pressure (PCWP), mean pulmonary artery pres-
sure (PAP), CI, systemic vascular resistance, lactate level, and mixed-venous oxygen saturation 
(SvO2). Cardiac power index (CPI) was calculated as MAP*CI/451.(10)
Microcirculatory assessment and analysis
The Microscan (MicroVision Medical, Amsterdam, The Netherlands) was used to obtain 
2-dimensional video images of sublingual microcirculatory blood flow. This technique has 
been described and validated previously.(7, 11-13) During each measurement, at least 3 
video sequences with duration of 20 seconds were obtained and analyzed. Quantification of 
these video files was performed using dedicated software (Automated Vascular Analysis 3.0, 
MicroVisionMedical).(11) After automated image stabilization and frame averaging, perfused 
capillary density (PCD) was calculated by measuring total length of perfused capillaries divided 
by image area. Capillaries were defined as the microvessels with a diameter less than 20 μm. 
Space-time diagrams were used to measure capillary red blood cell velocity (cRBCv) in 5 repre-
sentative capillaries per video sequence. The velocities measured in 5 capillaries were averaged. 
PCD and cRBCv values obtained from the 3 video sequences were averaged to produce single 
mean values for each measurement. Tissue perfusion index was calculated as PCD * cRBCv.(14)
Study protocol
Microcirculation and global hemodynamic parameters were measured at three subsequent 
time points. First, baseline measurements were performed at the intensive cardiac care unit 
or at the heart transplant ward before device implantation. Baseline measurements were 
performed twice within 15 minutes and the results for each variable were averaged to pro-
duce single baseline values (T0). The HeartMate II and ECMO devices were implanted at the 
operating room. The TandemHeart device was introduced in the catheterization laboratory. 
Measurements were repeated immediately after device implantation when the patient was 
admitted to the intensive care unit (T1) and 1 day after device implantation (T2). Cardiogenic 
shock patients were also investigated after weaning of the MCS device or at hospital discharge 
(T3). Postoperatively, all HeartMate II patients received temporary mechanical ventilation with 
inhaled nitric oxide to decrease right ventricular afterload. During the measurements, dosages 
of vasoactive agents were stable.
MCS improves tissue perfusion 207
Statistical analyses
Categoric variables are presented as the number with percentage. All measurements are pre-
sented as median with interquartile range (IQR, [25th–75th percentiles]). The Wilcoxon signed 
ranks test was used to establish differences in global hemodynamic and microcirculatory 
parameters between 2 subsequent time points. A value of p<0.05 was regarded as statistically 
significant.
rESULTS
Baseline characteristics
Baseline and clinical characteristics of the study population are presented in Table 1. Median 
age was 45 [38-52] years and 70% were male. Six patients had end-stage chronic heart failure 
and were on the waiting list for heart transplantation. These patients received a Heartmate 
II LVAD for progressive heart failure and as a bridge to cardiac transplantation. Four patients 
received a MCS device for cardiogenic shock: 3 had an acute myocardial infarction complicated 
by shock (1 received a TandemHeart, 1 received a HeartMate II, and 1 received ECMO). One 
patient had acute graft failure and cardiogenic shock after cardiac transplantation and received 
ECMO. Hemodynamic and microcirculatory responses to the different devices were similar.
Table 1. Baseline and clinical characteristics of the study population (N=10).
Characteristic No. (%) or median [IQR]
Age, years (median and IQR) 45 [38-52]
Gender, male 7 (70%)
CV risk factors: Hypertension
 Dyslipidemia
 Diabetes mellitus
 Current smoking
1 (10%)
4 (40%)
0 (0%)
1 (10%)
Etiology of heart failure: Ischemic cardiomyopathy
 Non-ischemic cardiomyopathy
 Acute graft failure post-HTx
5 (50%)
4 (40%)
1 (10%)
Baseline pharmacologic therapy: Any inotropic agent*
 Vasopressors†
 Vasodilators‡
7 (70%)
2 (20%)
5 (50%)
Mechanical ventilation 3 (30%)
NT-pro-BNP level, pmol/L (median and IQR) 814 [529-1474]
Type of device: Heartmate II LVAD
 Heartmate II LVAD + Levitronics RVAD
 TandemHeart
 ECMO
5 (50%)
2 (20%)
1 (10%)
2 (20%)
Abbreviations: IQR, interquartile range; CV, cardiovascular; HTx, heart transplantation; NT-pro-BNP, N-terminal portion of pro-B-type natriuretic 
peptide; LVAD, left ventricular assist device; RVAD, right ventricular assist device; ECMO, extracorporeal membrane oxygenation. * Dobutamine, 
dopamine, norepinephrine or enoximone. † Norepinephrine or dopamine at a dose >5 μg.kg-1.min-1. ‡ Nitroglycerin or enoximone.
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Macrohemodynamic parameters
Device implantation lowered PCWP (20 [17-23] mm Hg at T0 vs. 17 [16-19] mm Hg at T1, p=0.04, 
Table 2), and increased CI (1.8 [1.2-2.2] L.min-1.m-2 at T0 vs. 2.4 [2.0-3.1] L.min-1.m-2 at T1, p=0.007) 
as well as SvO2 (54 [46-61] % at T0 vs. 78 [67-85] % at T1, p=0.007). CPI significantly increased 
after MCS implantation (0.29 [0.21-0.34] at T0 vs. 0.48 [0.39-0.54] at T1, p=0.005). There was a 
significant decrease in central venous pressure at T2 relative to T1 (15 [13-18] mmHg at T1 vs. 
14 [12-15] mmHg at T2, p=0.04) and in lactate concentration (2.1 [1.4-5.1] mmol.L-1 at T1 vs. 1.5 
[0.9-2.1] mmol.L-1, p=0.009). The other parameters remained constant between T1 and T2.
Table 2. The effects of active mechanical circulatory support on global hemodynamics and sublingual microcirculation (N=10).
Baseline
(T0)
immediately after 
device implantation
(T1)
P-value
(T0 vs. 
T1)
One day after device 
implantation
(T2)
P-value
(T2 vs. 
T1)
Core 
temperature 
(°C)
37.3 [36.8-37.7] 36.7 [36.1-37.1] 0.02 37.1 [36.4-37.3] NS
hr (bpm) 97 [78-107] 97 [69-114] NS 95 [74-107] NS
MAP (mmhg) 77[71-82] 82 [71-94] NS 82 [71-90] NS
CvP (mmhg) 20 [14-23] 15 [13-18] NS 14 [12-15] 0.04
PCWP (mmhg) 20 [17-23] 17 [16-19] 0.04 17 [13-17] NS
MPAP (mmhg) 29 [23-30] 27 [25-33] NS 25 [20-29] NS
Ci (L.min-1.m-2) 1.8 [1.2-2.2] 2.4 [2.0-3.1] 0.007 2.4 [2.1-3.1] NS
Svr (dynes.sec.
cm-5)
1425 [1193-2306] 1077 [901-1347] NS 1185 [982-1273] NS
CPi (W.m-2) 0.29 [0.21-0.34] 0.48 [0.39-0.54] 0.005 0.46 [0.33-0.58] NS
Lactate 
(mmol.L-1)
1.7 [1.2-4.1] 2.1 [1.4-5.1] NS 1.5 [0.9-2.1] 0.009
SvO2 (%) 54 [46-61] 78 [67-85] 0.007 76 [74-83] NS
PCD (mm-1) 7.4 [6.3-7.9] 12.0 [10.3-14.2] 0.005 11.5 [10.2-12.6] NS
crBCv (μm.s-1) 80 [59-92] 179 [138-239] 0.005 239 [201-312] NS
TPi 573 [407-693] 1909 [1771-2835] 0.005 2731 [2125-3333] NS
All values are shown in median [25th-75th percentiles]. T0, before device implantation (averaged baseline values); T1, immediately after device 
implantation; T2, one day after device implantation. Abbreviations: HR, heart rate; MAP, mean arterial pressure; CVP, central venous pressure; 
PCWP, pulmonary capillary wedge pressure; MPAP, mean pulmonary artery pressure; CI, cardiac index; SVR, systemic vascular resistance; CPI, 
cardiac power index; SvO2, mixed-venous oxygen saturation; PCD, perfused capillary density; cRBCv, capillary red blood cell velocity; TPI, tissue 
perfusion index; NS, non-significant. Formulas: Cardiac power index = cardiac index * mean arterial pressure / 451; Tissue perfusion index = 
perfused capillary density * capillary red blood cell velocity.
Microcirculation
In general, MCS device implantation resulted in a non-pulsatile blood flow in sublingual 
microvessels. All devices consistently increased both sublingual perfused capillary density 
and cRBCv, which resulted in a better tissue perfusion index in all patients (573 [407-693] at T0 
vs. 1909 [1771-2835] at T1, p=0.005). No significant change in PCD or cRBCv was documented 
between T1 and T2. Individual patient data for the cardiac power index and microcirculatory 
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parameters are shown in Figure 1. This small study found no significant correlation between 
change in CI and change in tissue perfusion index.
Clinical outcome
Through April 2009, the 6 patients with end-stage heart failure who received a HeartMate II 
device were alive. Two of these patients underwent successful heart transplantation. Only 2 
patients admitted with cardiogenic shock survived: 1 was bridged with ECMO to urgent heart 
transplantion, and the other received a HeartMate II device and is still on the waiting list for 
heart transplantation. The patient with the TandemHeart device underwent percutaneous 
aortic valve replacement for concomitant severe aortic valve stenosis 4 days after hospital 
admission. Unfortunately, irreversible multiple organ failure developed in this patient and in 
the patient receiving ECMO for primary cardiac graft failure after weaning and removal of the 
devices. This occurred despite initial recovery of macrocirculatory parameters. Microvascular 
perfusion in these patients returned to baseline (shock) values after weaning and removal of 
the devices (Figure 2). Further treatment was stopped after multiple organ failure developed, 
and both patients died, at 15 days and 9 days after hospital admission. Retrospectively, the 
Figure 1. Evolution of macrocirculation and microcirculation before device implantation (T0), immediately after device implantation (T1), 
and 1 day after device implantation (T2) at the individual patient level for cardiac power index, (cardiac index * mean arterial pressure / 451), 
perfused capillary density, capillary red blood cell velocity, and tissue perfusion index (perfused capillary density * capillary red blood cell 
velocity). Abbreviation: ECMO, extracorporeal membrane oxygenation.
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patient with graft failure had an obstructed inferior caval vein anastomosis that might have 
contributed to the adverse outcome.
In the 7 HeartMate II patients, major adverse events included bleeding requiring re-
exploration in 2 patients. Right ventricular (RV) failure in 2 patients required initiation of right 
ventricular support (Levitronix Centrimag). The RVAD was successfully weaned and removed in 
both patients, at 6 and 7 days after surgery. Device-related infection developed in 3 patients, 
and all were successfully treated with antibiotics. No patients experienced device-related 
neurologic or thromboembolic events.
DiSCUSSiON
This study demonstrates that mechanical circulatory support improves microvascular tissue 
perfusion in a heterogeneous series of patients with severe heart failure or cardiogenic shock. 
Sublingual perfused capillary density and capillary red blood cell velocity increased in all 
patients, which resulted in a 3-fold increase in the tissue perfusion index immediately after 
cardiac assist device implantation (p=0.005).
Several recent case reports have described a relatively preserved microvascular blood flow 
in single patients with cardiogenic shock being treated with an Impella device (Abiomed, 
Danvers, MA, USA)(15), or ECMO.(16) We analyzed the microcirculation before and after MCS 
implantation, thus providing direct evidence for a beneficial effect of cardiac assist devices on 
tissue microcirculation. Although no apparent correlation existed between improvement in CI 
and the tissue perfusion index, we believe that a better hemodynamic profile due to MCS is the 
Figure 2. Correlation between microcirculation and clinical outcome in patients with cardiogenic shock. Patient 1: Cardiogenic shock (T0); 
stabilized with extracorporeal membrane oxygenation (T1-T2); patient survived after cardiac transplantation (T3). Patient 2: Cardiogenic 
shock (T0); stabilized with HeartMate II (T1-T3); patient discharged alive, HeartMate II is still in situ and the patient is still on the waiting list 
for cardiac transplantation (T3). Patient 3: Cardiogenic shock (T0); stabilized with TandemHeart (T1-T2); multiple organ failure developed 
after weaning of mechanical circulatory support (T3), and the patient died. Patient 4: Cardiogenic shock (T0); stabilized with ECMO (T1-T2); 
multiple organ failure developed after weaning of mechanical circulatory support (T3), and the patient died. T0, before device implantation; T1, 
immediately after device implantation; T2, 1 day after device implantation; T3, follow-up.
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main cause for improved perfusion of organs and tissues. Dissociation between changes in sys-
temic circulation and microcirculation is a well-known phenomenon that might be explained 
by local autoregulatory mechanisms. Nevertheless, improved organ perfusion may result in a 
lower incidence of multiple organ failure and improved functional status and short-term sur-
vival.(1,9,17,18) In an earlier study, we demonstrated no major effect of changing intra-aortic 
balloon pump (IABP) assist ratio on sublingual microcirculation. In that study, however, we did 
not perform microcirculation measurements before the IABP was introduced.(19) Nevertheless, 
it is interesting to observe the pronounced benefit on sublingual microcirculation induced by 
the more powerful MCS devices investigated in the current study.
In the patients with cardiogenic shock who did not survive, microvascular perfusion only 
temporarily improved but returned to baseline values after weaning and removal of the MCS 
devices. A recent microcirculation landmark study by De Backer et al(8) also demonstrated a 
correlation between impaired microcirculation and in-hospital death. These preliminary case 
observations should be confirmed and investigated more comprehensively in larger studies.
Limitations
Several limitations of this study should be acknowledged. First, we investigated a small, hetero-
geneous group of patients receiving different types of MCS devices. However, the effect of MCS 
on tissue perfusion was consistent. Second, factors other than MCS support, especially inhaled 
nitric oxide ventilation and administration of sedative and vasoactive pharmacologic agents, 
might have been confounders for improved microcirculatory perfusion after MCS implantation. 
However, effects were present in patients treated with or without inhaled nitric oxide. In addi-
tion, one would not expect that inhaled nitric oxide affects sublingual microvascular perfusion 
because nitric oxide-hemoglobin is immediately broken down in the circulation.
Clinical perspective and conclusions
In conclusion, MCS devices improve the hemodynamic profile and microvascular perfusion. We 
propose that future larger studies on outcomes of patients receiving MCS devices should also 
report the effects of MCS devices on tissue perfusion. Frequent real-time monitoring of micro-
circulation, followed by prompt interventions in case of tissue hypoperfusion, might prevent 
multiple organ failure before as well as during institution of MCS. Our findings suggest that 
improvement of tissue perfusion by MCS devices is a key factor responsible for improvement 
of functional status, quality of life, and outcome in patients with severe cardiac dysfunction.
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iNTrODUCTiON
In this thesis, we investigated the feasibility and relevance of monitoring of the microcirculation 
in patients with severe heart failure and cardiogenic shock. In this section, I will discuss our 
main findings, and consider implications of the findings with respect to clinical practice and 
future research.
MAiN fiNDiNGS
Thirty-day mortality rates among patients with cardiogenic shock remain very high, about 50%.
(1) However, in-hospital survivors of cardiogenic shock have a favorable prognosis. Singh et al. 
reported similar long-term annual survival rates for patients with ST-segment elevation myo-
cardial infarction (STEMI) complicated by shock relative to STEMI patients without shock.(2) 
Using the Rotterdam Intra-Aortic Balloon Pump (IABP) database, we found comparable results 
for patients treated in the Thoraxcenter (Chapter 4 and Chapter 5). In addition, we found a 
decrease in 30-day mortality of cardiogenic shock over time (52% within the time period 1990-
1994 vs. 36% within 2000-2004, p<0.05, Chapter 5). This improvement in short-term prognosis 
is probably due to the concomitant implementation of immediate reperfusion therapy, mainly 
primary percutaneous coronary intervention, in cardiogenic shock from acute myocardial 
infarction (AMI, Chapter 5). However, although revascularization in cardiogenic shock from AMI 
is a mainstay of therapy, cardiogenic shock patients are still at high risk of dying. Therefore, it has 
been investigated whether active temporary support of the circulation in patients with failing 
hearts would be beneficial. Chapter 6 reviews the results of the three available efficacy studies 
that compared IABP counterpulsation with the more powerful percutaneous left ventricular 
assist devices (LVADs) in the mechanical treatment of cardiogenic shock. We demonstrated 
that, although percutaneous LVADs are superior to IABPs with respect to improvement in 
hemodynamics, this does not translate into a better prognosis. Pooling the results from the 
available studies, there was no survival benefit of the use of LVADs.
A fascinating feature that has been increasingly well recognized is that almost half of the 
nonsurvivors of cardiogenic shock die with a normal cardiac index but with multi-organ failure.
(3) Many things are unknown about this observation and new approaches are needed urgently 
to better understand the pathogenesis of cardiogenic shock to come to better treatment.
Part C contains explorative studies in patients without cardiogenic shock, but at risk of 
developing multi-organ failure following on-pump cardiac surgery (Chapter 7 and 8). Measure-
ments were performed of sublingual as well as pleural microcirculation. In patients admitted to 
an intensive care unit, assessment of sublingual microcirculation is the easiest way to study the 
microcirculation. However, it is largely unknown whether microcirculatory changes in the sub-
lingual area are representative of hypoperfusion elsewhere, most importantly in the splanchnic 
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region. Several arguments suggest that this is indeed the case. First, the tongue shares a 
common embryogenic origin with the gut.(4) Second, indirect evidence comes from studies of 
sublingual tonometry which demonstrated a good correlation between PCO2 measurements 
obtained in the sublingual region and in the stomach.(5, 6) Finally, De Backer et al. demon-
strated in a small study that the proportion of perfused sublingual capillaries correlated with 
survival.(7) We found that patients with an impaired microcirculation, defined as a sublingual 
perfused capillary density (PCD) ≤ median, had more severe heart failure, as demonstrated by 
higher levels of N-terminal proB-type natriuretic peptide, as well as higher pulmonary capillary 
wedge pressure, lower cardiac power index and lower SvO2.
In addition, impaired sublingual perfused capillary density (PCD) was related to the develop-
ment of organ failure and was an independent predictor for 30-day mortality in a large cohort 
of patients with cardiogenic shock (Chapter 9). This chapter provides evidence that the micro-
circulation, measured sublingually and regarded as a surrogate of splanchnic perfusion, is an 
important factor contributing to the development of organ failure and adverse outcome. These 
findings raise the question whether an impaired PCD can be improved, and, if so, whether such 
a strategy will be associated with improved outcome. Chapter 9 demonstrates that patients 
who had an impaired PCD at baseline as well as after 24 hours were at a high risk to die, as 
opposed to patients in whom microcirculation was initially impaired, but recovered at 24 hours. 
The latter patients actually had a similar prognosis relative to patients who had a preserved 
PCD at both time points. These results indeed suggest that therapies directed at improving 
microcirculation as assessed by SDF-imaging-derived sublingual PCD might improve outcome 
in patients with cardiogenic shock.
Having studied descriptives of patients with cardiogenic shock and impaired microcircula-
tion, and the correlation with clinical outcome, we focused on intervention studies in order to 
investigate whether sublingual PCD could be changed by pharmacologic or mechanical treat-
ment. We investigated the effect of the vasodilator and nitric oxide donor nitroglycerin (NTG) 
at a low dose of 33 μg/min in patients with acute heart failure (Chapter 11) and found a median 
increase in sublingual PCD of 10%, although 30% of the patients did not respond. Interestingly, 
responders had a greater decrease in central venous pressure after NTG. In fact, non-responders 
might simply have received an insufficient dose of NTG. To better understand the response of 
the microcirculation in patients with heart failure, we performed an NTG dose-response study 
(Chapter 12), which provided direct evidence for improvement of tissue perfusion induced by 
NTG, which could be monitored with Sidestream Dark Field imaging. In addition, we inves-
tigated the effects of the inotropic agents dobutamine, enoximone, and norepinephrine on 
sublingual microcirculation (Chapter 13). Dobutamine and enoximone improved sublingual 
PCD, whereas norepinephrine diminished sublingual perfusion. Finally, we studied the effects 
of mechanical support of the failing heart in cardiogenic shock patients. Since no before-after 
study could be performed in patients receiving IABP counterpulsation, we switched the 
IABP assist ratio, in patients already treated with IABP, from 1:1 to 1:8 for a time period of 15 
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minutes (Chapter 14). We found only moderate effects on systemic and pulmonary circulation 
and no effect on microcirculation, which could be explained by autoregulatory mechanisms, 
which prevent decreases of microcirculatory blood flow in case of modest changes in global 
hemodynamics. In Chapter 15, we presented the results of the effects of mechanical circulatory 
support devices, including HeartMate II devices, on sublingual microcirculation in patients with 
end-stage chronic heart failure or cardiogenic shock. The effects were beneficial and consistent 
in all patients, but this study also demonstrated that in patients who died, improvement of 
microcirculation was only temporary, which underlines the importance of frequent monitoring 
of not only macro- but also microcirculation.(8)
CLiNiCAL iMPLiCATiONS
The studies described in this thesis potentially have direct implications for current clinical 
practice.
First of all, clinicians should be aware of the favorable long-term prognosis of in-hospital sur-
vivors of cardiogenic shock.(2) This means that great efforts must be made to stabilize patients 
with cardiogenic shock as much as possible, if necessary with mechanical support devices, to 
aid them through the acute, critical phase.
Second, most clinicians would still classify cardiogenic shock as an almost entirely macro-
circulatory disorder due to pump failure. The studies described in this thesis add significantly 
to the paucity of evidence on the clinical significance of microcirculatory impairment in this 
disease.
Third, the introduction of Sidestream Dark Field imaging has allowed to directly observing 
microcirculatory alterations of the sublingual tissue in patients with cardiogenic shock at the 
bedside. A problem is still that the video sequences, obtained with SDF imaging, have to be 
quantified off-line for research purposes. However, in clinical practice, it might be very well 
possible that a first impression of the quality of microvascular perfusion, comparable to echo-
cardiography, might be sufficient to tailor vaso-active therapy. In addition, a transition from 
semi-quantitative analysis of video frames towards a software-based analysis reduces analysis 
time substantially and might readably become available at the bedside in the future.(9-13)
Fourth, in order to reduce multi-organ failure in patients with cardiogenic shock, it is 
important to understand its etiology. This thesis demonstrates the predictive value of impaired 
functional capillary density on organ failure and worse outcome in patients with cardiogenic 
shock.
Fifth, we demonstrated the feasibility of serial monitoring of the microcirculation, which 
opens the door to a microcirculation-guided, individualized therapy to patients with cardio-
genic shock.
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DirECTiONS fOr fUTUrE rESEArCh
Although this thesis demonstrated the predictive value of impaired microcirculation on organ 
failure and patient outcome, it is difficult to prove causal relationships in observational stud-
ies. The pathogenesis of impaired microcirculation might involve multiple factors, including 
diminished cardiac output and systemic inflammation. However, as also demonstrated by the 
studies presented in this thesis, a correlation between diminished cardiac output and impaired 
microcirculation, if present, is far from straightforward. Several studies recently demonstrated 
the correlation between elevated markers of systemic inflammation, especially interleukin-6, 
on outcome in cardiogenic shock.(14-16) It would be interesting to investigate the correlation 
between these parameters of inflammation and impaired microcirculation. Finally, a logical 
next step in microcirculation research would be to perform a multi-center trial to test whether 
a therapy, guided by monitoring of microcirculation and directed at improving microcircula-
tion, added to current management, would improve outcome (i.e., measures of organ failure, 
length-of-stay in the hospital, and 30-day survival) in patients with cardiogenic shock.
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An adequate function of the microcirculation is absolutely essential in providing oxygen to all 
tissues and organs of the human body, especially in severe heart failure and cardiogenic shock. 
Untill recently, the microcirculation could not be directly measured at the bedside in patients. 
The aim of this thesis was to investigate whether sublingual microcirculation, regarded as a 
surrogate marker for splanchnic perfusion and measured with the novel Sidestream Dark Field 
(SDF) imaging technique, was a determinant of organ failure and outcome in patients with 
cardiogenic shock. We hypothesized that impaired sublingual perfusion correlated to organ 
failure and short-term mortality and that this parameter could be improved using pharmaco-
logic or mechanical therapy.
Part A of this thesis reviews the available literature on the microcirculation in critical 
diseases. In Part B, we presented the short- as well as long-term outcomes of patients with 
cardiogenic shock. These chapters have several important messages. First of all, 30-day prog-
nosis of patients with cardiogenic shock from acute myocardial infarction improved last years, 
due to early revascularization strategies. Nevertheless, short-term mortality rates remain very 
high, which underlines the malignancy of the disease. Interestingly, long-term prognosis of 
in-hospital survivors is rather favourable and similar to the long-term prognosis of patients 
admitted to the hospital with acute myocardial infarction without shock. Finally, sophisticated 
percutaneous left ventricular assist devices have better effects on hemodynamic parameters 
than conventional intra-aortic balloon pumping, but fail to increase short-term survival (Chap-
ter 6). New approaches are therefore needed urgently.
In Part C, we have investigated the feasibility of applying SDF imaging in patients undergo-
ing coronary artery bypass grafting and in patients with cardiogenic shock. In Chapter 7, we 
describe a modest impairment of sublingual microcirculation in patients undergoing coronary 
artery bypass grafting. Whether these microcirculatory changes contribute to and predict 
postoperative multiple organ failure should be investigated in a larger study. In Chapter 8, we 
describe the results of our efforts to visualize pulmonary alveoli and alveolar microvessels in 
patients undergoing cardiac surgery. The results obtained in infants were succesfull, however, 
in adults it was very hard to obtain high-quality images, presumably due to the thicker visceral 
pleura, as compared to children. In Chapter 9, we found that impaired sublingual microcircula-
tion was associated with organ failure, and was an independent predictor of 30-day mortality. 
Accordingly, we explained the tentative importance of monitoring of the microcirculation in 
cardiogenic shock (Chapter 10).
In Part D, we investigated whether several routinely applied pharmacological and mechani-
cal treatment options influence sublingual microcirculation and whether it was feasible to 
monitor these changes using Sidestream Dark Field imaging of the sublingual microcirculation. 
We found that nitroglycerin, administered at a low dose, improved microcirculation in most 
patients admitted to the Intensive Cardiac Care Unit with decompensated heart failure (Chap-
ter 11). However, a subgroup of patients did not respond to nitroglycerin. To further investigate 
the response of the microcirculation to nitroglycerin and to investigate the maximal reponse 
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of the microcirculation investigated with SDF imaging and quantified with dedicated software, 
we performed a nitroglycerin dose-response study in patients with severe heart failure or 
cardiogenic shock (Chapter 12). We found that nitroglycerin progressively improved sublingual 
perfused capillary density as well as central-peripheral temperature gradient in these patients. 
It was also possible to visalize the effects of several inotropic agents on the microcirculation 
in patients with cardiogenic shock (Chapter 13). Finally, we found that a temporary break in 
intra-aortic balloon pumping did not impair sublingual microcirculation (Chapter 14), but that 
institution of an active circulatory support device substantially improved microcirculation in 
patients with severe heart failure or cardiogenic shock (Chapter 15). In our opinion, Part D 
demonstrates the feasibility and value of the SDF measurements in patients with severe heart 
failure. Whether a microcirculation-based therapy will have a beneficial outcome on patients 
with severe heart failure and cardiogenic shock should be investigated in a future randomized 
controlled trial.
Chapter 18
Samenvatting
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Een goede functie van de microcirculatie is onontbeerlijk om alle organen en weeefsels van het 
menselijk lichaam van bloed en zuurstof te voorzien. Bij patiënten met ernstig hartfalen of car-
diogene shock (d.w.z.: verstoorde weefseldoorbloeding als gevolg van een falende hartfunctie) 
schiet de microcirculatie vaak tekort. Tot op heden kon de microcirculatie niet direct worden 
onderzocht. De introductie van de “Sidestream Dark Field (SDF) imaging” techniek heeft het 
mogelijk gemaakt om de allerkleinste bloedvaatjes (capillairen) onder de tong zichtbaar te 
maken. Het doel van dit proefschrift was om te onderzoeken of we door middel van microcircu-
latiemetingen, gemeten met SDF imaging onder de tong, kunnen bepalen of de doorbloeding 
in de kleine bloedvaten in het lichaam adequaat is. We onderzochten onder andere of een 
verstoorde microcirculatie samenhangt met het ontwikkelen van orgaanfalen en ziekenhuis-
sterfte bij patiënten met cardiogene shock. Verder hadden we de hypothese dat medicatie die 
actief op het hart en de bloedvaten werkt (“vaso-actieve medicatie”) alsmede mechanische 
ondersteuning van de hartspier met behulp van een pomp, de microcirculatie kunnnen beïn-
vloeden en dat we deze veranderingen zichtbaar kunnen maken met SDF imaging.
Deel A van dit proefschrift vatten de beschikbare literatuur over de microcirculatie bij ernstig 
zieke patiënten samen. In Deel B presenteren we de korte en lange termijn resultaten van op 
dit moment beschikbare behandelingen bij patiënten met cardiogene shock. Deze hoofdstuk-
ken bevatten enkele belangrijke boodschappen. Ten eerste, hoewel de korte termijn prognose 
van patiënten met een hartinfarct gecompliceerd door cardiogene shock slecht is, is deze de 
laatste jaren verbeterd, waarschijnlijk met name door implementatie van het routinematig 
toepassen van een spoed-dotterbehandeling. Desalniettemin is de kans om binnen 30 dagen 
na ziekenhuisopname te overlijden nog steeds 35-50%. Een interessante observatie is dat de 
lange termijn prognose van een patiënt die cardiogene shock heeft overleefd en levend het 
ziekenhuis verlaat, gunstig is. Dit gegeven suggereert dat er alles aan gedaan moet worden om 
de patiënt door de kritieke eerste 30 dagen heen te loodsen. Ten slotte worden in Hoofdstuk 6 
twee methoden van mechanische ondersteuning van het falende hart met elkaar vergeleken: 
de intra-aortale ballonpomp versus nieuwere, geavanceerde pompen die zelf flow genereren. 
We vonden dat ondersteuning van het hart middels de geavanceerde pompen leidt tot een 
grotere verbetering van hemodynamische parameters, maar niet tot een betere 30-daagse 
overleving van cardiogene shock patiënten. Nieuwe benaderingen in de behandeling van 
cardiogene shock patiënten zijn daarom dringend noodzakelijk.
In Deel C van het proefschrift worden de resultaten gepresenteerd van de studies die we 
hebben gedaan om meer inzicht te verkrijgen in de microcirculatie van patiënten die een 
kans hebben op het ontwikkelen van orgaanfalen, zoals patiënten die openhartoperaties 
ondergaan en patiënten met cardiogene shock. In Hoofdstuk 7 beschrijven we dat er sprake 
is van een voorbijgaande, milde verslechtering in microcirculatie bij een deel van de patiënten 
die gecirculeerd worden door de hartlongmachine. Of deze verslechtering in microcirculatie 
klinisch belangrijk is, en bijdraagt aan het postoperatief optreden van multipel orgaanfalen, 
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dient te worden onderzocht in een grotere studie. Verder is bij deze patiënten ook gekeken 
of we de microcirculatie van de longen alsmede longblaasjes zichtbaar konden maken met 
SDF imaging (Hoofdstuk 8). Dit lukte goed bij kinderen, omdat het longvlies (waaronder de 
longblaasjes zich bevinden) bij kinderen nog dun is. Deze bevindingen banen de weg voor 
nieuwe studies, waarin bijvoorbeeld de reactie van de longen op mechanische ventilatie direct 
bij mensen zou kunnen worden bestudeerd. Tot op heden waren deze studies slechts mogelijk 
bij proefdieren. In Hoofdstuk 9 beschrijven we een groep van 104 patiënten met cardiogene 
shock bij wie de microcirculatie is gemeten. We vonden dat een verstoorde microcirculatie 
geassocieerd was met het optreden van orgaanfalen, en dat deze verstoringen in microcircu-
latie 30-daagse mortaliteit konden voorspellen. Vervolgens legden we uit waarom monitoring 
van de microcirculatie dus belangrijk is bij de patiënt met cardiogene shock (Hoofdstuk 10).
Vervolgens is onderzocht wat de effecten zijn van farmacologische behandeling en van 
mechanische ondersteuning van cardiogene shock op de microcirculatie (Deel D). Van belang 
was met name of we deze veranderingen konden monitoren met behulp van SDF imaging. 
We vonden dat de microcirculatie verbeterde wanneer we patiënten met gedecompenseerd 
hartfalen een lage dosering, intraveneus toegediend, nitroglycerine gaven (Hoofdstuk 11). 
Bij een subgroep van deze patiënten vonden we echter geen effect. Om dit fenomeen beter 
te onderzoeken en om te bestuderen wat de maximale repons was van de microcirculatie 
op nitroglycerine, besloten we om een dose-response studie uit te voeren bij patiënten met 
ernstig hartfalen (Hoofdstuk 12). We vonden dat nitroglycerine geleidelijk microcirculatie 
verbeterde, wat bleek uit een toename van geperfundeerde capillaire dichtheid en een afname 
van de gradiënt tussen centrale en perifere lichaamstemperatuur. Het was ook mogelijk om 
de effecten van verschillende inotropica op de microcirculatie te bestuderen (Hoofdstuk 13). 
Tenslotte bestudeerden we de effecten van mechanische ondersteuning van de hartspier 
door middel van verschillende typen steunharten (Hoofdstuk 14 en 15). Naar onze mening 
demonstreert Deel D van het proefschrift de werkzaamheid van de techniek en de waarde van 
microcirculatiemetingen bij patiënten met ernstig hartfalen. Of de microcirculatie een nieuwe 
parameter is die een rol zou moeten spelen binnen de therapeutische benadering van de 
patiënt met ernstig hartfalen, zou in de nabije toekomst bij voorkeur getest moeten worden 
met behulp van een klinische, gerandomiseerde en gecontroleerde trial.
Part F
Epilogue

Chapter 19
Dankwoord

Dankwoord 237
Vier jaar geleden startte ik mijn oudste co-assistentschap op de afdeling Cardiologie in het 
Thoraxcentrum van het Erasmus MC. Onder de inspirerende begeleiding van remon Baak en 
Chris van der Lee raakte ik snel enthousiast voor dit bijzondere vakgebied. In de afgelopen 
jaren is er veel gebeurd. Ik wil een poging wagen om alle mensen te bedanken die het wer-
ken en promoveren mede hebben mogelijk gemaakt. Er bestaat een kans dat ik iemand ten 
onrechte niet noem, maar in dat geval is mijn dank voor de samenwerking niet minder.
Mijn co-promotor, Wim Lagrand, dank ik voor zijn initiatief om dit promotieonderzoek te starten. 
Je bent een goede clinicus en daarnaast ben je zeer geïnteresseerd in wetenschappelijk onderzoek 
binnen de acute Cardiologie. Ik heb het altijd jammer gevonden dat je Rotterdam verliet. Maar 
ook na je vertrek was je betrokken, je was aanwezig bij de vergaderingen op de 5e verdieping, en 
we hebben veelvuldig gebruik gemaakt van Skype (+headset!). Laten we dat blijven doen.
Peter Spronk, ik ben blij dat je mijn tweede co-promotor bent. Het is fantastisch dat we tij-
dens onze eerste vergadering in oktober 2006 het raamwerk voor dit boekje hebben gevormd. 
Maar weinig mensen weten hoe belangrijk je bent geweest om “de vaart erin te houden” en te 
“focussen”. Je inzicht in de literatuur heeft me vaak verrast en was erg leerzaam. Ik ben je erg 
dankbaar en zou het prachtig vinden om onze samenwerking te continueren.
Verder gaat mijn dank uit naar mijn promotor, Prof.Dr. Maarten Simoons. Prof. Simoons, dit 
boekje is een bewijs van uw gelijk dat er maar weinig ideeën zijn die echt onuitvoerbaar zijn. U 
leerde me schrijven en presenteren. Verder hebben uw aanmoedigingen om me niet te veel te 
laten afleiden mij zeer geholpen.
De overige leden van de kleine promotiecommissie, Prof.Dr. Jan Bakker, Dr. Aggie Balk, 
en Prof.Dr. Dirk Jan Duncker dank ik voor hun commentaar op de manuscripten en voor hun 
bereidheid om het proefschrift te beoordelen.
Ik dank Prof.Dr. D. Tibboel voor zijn aanwezigheid bij de verdediging. Dat geldt ook voor 
Prof.Dr. Can ince, die ik tevens dank voor zijn inspirerende ideeën en voor de dag Amsterdam/
Leeuwarden, nu 5 maanden geleden. Uw netwerk binnen de wereld van de microcirculatie is 
enorm en daar heb ik bewondering voor. I would like to thank Prof.Dr. Daniel de Backer, who 
is the associate editor of “Intensive Care Medicine” and should be regarded as an established 
investigator of the microcirculation, for his interest in the present thesis and his enthusiasm to 
take part in the jury.
Mijn paranimfen Jasper Brugts en Annemieke den Uil wil ik bedanken voor hun steun. 
Jasper, je bent belangrijk geweest. Ik heb veel geleerd van jouw onderzoekservaring, je kennis 
van statistiek, en van je ambitieuze houding. Onder het genot van een Swirl hebben we keer 
op keer toekomstplannen besproken en nieuwe strategieën verzonnen. Je bent er mede voor 
verantwoordelijk dat ik enthousiast ben geworden voor research. Ik wens je veel succes met het 
afronden van je eigen promotie.
Martin van der Ent bedank ik voor zijn belangrijk aandeel in de inclusie van patiënten. Jij 
hebt het praktische gedeelte van mijn onderzoek voor een groot gedeelte gefaciliteerd en 
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gaf me de vrijheid om volledig mijn gang te gaan met vasoactieve medicatie. Ik bewonder 
je daadkracht in de kliniek. Lucia Jewbali en Koen Nieman dank ik voor hun enthousiasme 
voor het microcirculatie onderzoek en voor alle hulp bij het includeren van patiënten. Lucia, 
ook bedankt voor de vele gesprekken die we hebben gehad en die me hielpen om door te 
gaan. Ik heb altijd erg gewaardeerd dat je die tijd voor me nam. Kadir Caliskan bedank ik voor 
zijn ideeën en zijn enthousiaste houding. Hartfalen is een interessant onderwerp, waarover in 
de toekomst nog wel meer te schrijven is! Joke en Nathalie, ook hartelijk bedankt voor de 
gezellige gesprekken tussen het werk door.
Ik bedank verpleegkundigen en overig personeel van de afdelingen OK, ICCU, IC-thorax, 
1200 en 800 voor de gezelligheid en hulp bij de vele (Swan-Ganz!) metingen.
ron van Domburg en Suzanne valk dank ik voor hun toestemming en medewerking om 
te schrijven op de IABP-database, waaruit verschillende hoofdstukken in dit boek zijn voortge-
komen.
Veel dank ben ik verschuldigd aan de patiënten die ik heb onderzocht en tevens aan 
familie van patiënten, die niet in staat waren tot het geven van toestemming. Onder moeilijke 
omstandigheden kregen ze mij aan het bed met de vraag of ik onder de tong mocht kijken.
Ik ben trots op Jin Ming Cheng. Jin, ik heb je, naast Ron, begeleid bij het schrijven van 
enkele artikelen. Ik vind het erg leuk dat je ons idee voor het schrijven van de meta-analyse zo 
enthousiast hebt uitgewerkt. Je hebt je enorm ingezet en dat is beloond geworden met arti-
kelen in mooie tijdschriften. Veel succes met je co-schappen. Daarna zien we je hopelijk terug.
I would like to thank my roommates harm feringa, radosav vidakovic, Jasper Brugts, 
Wael Galal, Jan-Peter van Kuijk, Willem-Jan flu, Amber Otten, Tuncay yetgin, and Olivier 
Witteveen. Dear friends, we had a great time together. What a gigantic amounts of coffee were 
required to produce the scientific output we had! I really enjoyed the nice moments with all 
of you and I wish you all the best. Eva Klijn, bedankt voor de microcirculatie discussies en de 
samenwerking bij de reviews. Ik wens je veel succes met je eigen promotie.
Medewerkers van MiT-groep, afdeling iCT en thoraxlaboratorium dank ik voor hun snelle 
en adequate steun tijdens de studies. Ik dank Maud van Nierop en Willeke van der Bent voor 
jullie hulp bij de praktische afronding van het proefschrift.
Ik dank mijn familie en vrienden voor alle gezellige en goede momenten. Ik bedank mijn 
ouders voor wat ze mij hebben meegegeven. Ik ben bevoorrecht. Ik dank jullie ook voor het 
aanhoren van de “promotieverhalen”.
Lieve Therése, dankjewel voor wie je voor me bent. Je klaagde nooit als ik je weer eens 
moest bellen met “het wordt wat later”. Ik hoop dat we altijd van elkaar zullen blijven houden. 
Lucas, je bent een van de mooiste geschenken die ik heb. Je enthousiasme als papa thuiskomst 
is een stimulans om dat ook op tijd te doen.
Tenslotte, maar vooral, dank ik God, Die me de kracht en de gezondheid gaf om dit proef-
schrift tot een goed einde te brengen. Ik geloof dat het dienen van deze Koning het leven zinvol 
maakt. Zijn Naam moet de eer ontvangen.
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